var title_f35_22_36192="Fluocinolone: Drug information";
var content_f35_22_36192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinolone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12624506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/18/29987?source=see_link\">",
"       Fluocinolone (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/9/23699?source=see_link\">",
"       Fluocinolone (otic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/28/25029?source=see_link\">",
"       Fluocinolone (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8458 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-E769C354BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36192=[""].join("\n");
var outline_f35_22_36192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/18/29987?source=related_link\">",
"      Fluocinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/9/23699?source=related_link\">",
"      Fluocinolone (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/28/25029?source=related_link\">",
"      Fluocinolone (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_22_36193="Preparation catheter sheath";
var content_f35_22_36193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Preparation of the catheter sheath",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pictures showing the correct preparation of the cathether sheath.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36193=[""].join("\n");
var outline_f35_22_36193=null;
var title_f35_22_36194="Patient information: Breast pumps (The Basics)";
var content_f35_22_36194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15828\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/30/8674\">",
"         The breast",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/43/17075\">",
"         Patient information: Breastfeeding (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/26/3491\">",
"         Patient information: Common breastfeeding problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/19/38194\">",
"         Patient information: Deciding to breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/13/7379\">",
"         Patient information: Health and nutrition for women who breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/27/4531\">",
"         Patient information: Weaning from breastfeeding (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/25/17813\">",
"         Patient information: Breast pumps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/19/1333\">",
"         Patient information: Breastfeeding guide (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/63/34805\">",
"         Patient information: Deciding to breastfeed (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Breast pumps (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/breast-pumps-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2044660\">",
"      <span class=\"h1\">",
"       What is a breast pump?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A breast pump is a device that can pump milk out of a woman&rsquo;s breasts. If a woman is going to be away from her baby when it is time to breastfeed, she can instead pump milk from her breasts using a pump. The breast milk can be collected, stored, and fed to her baby later.",
"     </p>",
"     <p>",
"      A woman can use a breast pump to start her milk flow or keep her milk supply up when she wants to breastfeed but can&rsquo;t because:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Her baby needs to stay in the hospital after birth because it was born too early or is sick",
"       </li>",
"       <li>",
"        She can&rsquo;t be with her baby all the time because of work, travel, or other reasons",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2044667\">",
"      <span class=\"h1\">",
"       Are there different types of breast pumps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The right breast pump for you will depend on why you need it and how often you plan to use it.",
"     </p>",
"     <p>",
"      The different types of breast pumps include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Electric pumps that are used in hospitals &mdash; These breast pumps are powerful and collect breast milk the fastest. They are often used by women whose babies need to stay in the hospital after birth. Women can also rent these types of pumps to use at home.",
"       </li>",
"       <li>",
"        Personal electric pumps &mdash; These breast pumps are smaller than hospital electric pumps. They can collect breast milk fast, but usually not as fast as hospital pumps. Personal pumps can come in a carrying case. They can be good for women who pump at work.",
"       </li>",
"       <li>",
"        Single-sided pumps &mdash; These breast pumps collect milk slower than hospital and personal electric pumps. They can be powered by hand, batteries, or electricity. They can be good for women who need to pump breast milk only once in a while.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2044674\">",
"      <span class=\"h1\">",
"       How do I use a breast pump?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each breast pump will have its own directions. But for all breast pumps, it&rsquo;s important to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands with soap and water before pumping. You do not have to wash your breasts or nipples.",
"       </li>",
"       <li>",
"        Make sure that the pump pieces and the containers for storing breast milk are clean.",
"       </li>",
"       <li>",
"        Make sure that the cone-shaped pieces that fit over the breasts are the right size. Your nipples should not rub against the tunnel part of these pieces.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Before a breast pump can collect your breast milk, your breasts need to &ldquo;let down&rdquo; the milk. Let-down is when the milk flows from the milk glands into the milk ducts (",
"      <a class=\"graphic graphic_figure graphicRef72583 \" href=\"mobipreview.htm?8/30/8674\">",
"       figure 1",
"      </a>",
"      ). Usually, let-down happens soon after you start pumping. But if it doesn&rsquo;t, you can try the following things:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Massage your breasts gently before you pump",
"       </li>",
"       <li>",
"        Put a warm wet cloth on your breasts before you pump",
"       </li>",
"       <li>",
"        Pump in a dark and quiet room",
"       </li>",
"       <li>",
"        Look at a picture of your baby when you start pumping",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2044681\">",
"      <span class=\"h1\">",
"       How should I store pumped breast milk?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can store pumped breast milk in different places and for different amounts of time. Breast milk can be stored:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        At room temperature for up to 4 hours",
"       </li>",
"       <li>",
"        In the refrigerator for up to 3 days",
"       </li>",
"       <li>",
"        In the freezer for up to 3 months",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You can store breast milk in clean glass or plastic bottles, or in plastic bags. It can be helpful to store breast milk in small amounts. You should also write the date that the milk was pumped on the container. That way, you can use the oldest milk first.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2044688\">",
"      <span class=\"h1\">",
"       How do I warm up stored breast milk?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Make sure to warm up breast milk from the freezer or refrigerator slowly. Do not thaw or warm up breast milk by putting it in the microwave. Instead, fill a pot or container with warm water and put the bottle in it. Do not let the whole bottle go under water.",
"     </p>",
"     <p>",
"      Be sure to test the temperature of the milk before you feed it to your baby. The milk should be a little bit warm or at room temperature.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2044695\">",
"      <span class=\"h1\">",
"       How do I pump at work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Talk with the people you work with about when and where you can pump. By law, your work needs to give you breaks so that you can pump. Your work also needs to give you a private place where you can pump.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2044702\">",
"      <span class=\"h1\">",
"       What if I have questions?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have any questions about breast pumps, ask your doctor or nurse. Some women also find it helpful to work with a breastfeeding expert called a &ldquo;lactation consultant.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2044814\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/43/17075?source=see_link\">",
"       Patient information: Breastfeeding (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3491?source=see_link\">",
"       Patient information: Common breastfeeding problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=see_link\">",
"       Patient information: Health and nutrition for women who breastfeed (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/19/38194?source=see_link\">",
"       Patient information: Deciding to breastfeed (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/27/4531?source=see_link\">",
"       Patient information: Weaning from breastfeeding (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"       Patient information: Breastfeeding guide (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/63/34805?source=see_link\">",
"       Patient information: Deciding to breastfeed (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/25/17813?source=see_link\">",
"       Patient information: Breast pumps (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/22/36194?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15828 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36194=[""].join("\n");
var outline_f35_22_36194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2044660\">",
"      What is a breast pump?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2044667\">",
"      Are there different types of breast pumps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2044674\">",
"      How do I use a breast pump?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2044681\">",
"      How should I store pumped breast milk?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2044688\">",
"      How do I warm up stored breast milk?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2044695\">",
"      How do I pump at work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2044702\">",
"      What if I have questions?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2044814\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15828\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/30/8674\">",
"      The breast",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/25/17813?source=related_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/43/17075?source=related_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=related_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3491?source=related_link\">",
"      Patient information: Common breastfeeding problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/19/38194?source=related_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=related_link\">",
"      Patient information: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/27/4531?source=related_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_22_36195="Trichorrhexis nodosa";
var content_f35_22_36195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Trichorrhexis nodosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Broom-like fraying of the hair shaft is seen in trichorrhexis nodosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36195=[""].join("\n");
var outline_f35_22_36195=null;
var title_f35_22_36196="Tension pneumothorax";
var content_f35_22_36196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Tension pneumothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 455px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36196=[""].join("\n");
var outline_f35_22_36196=null;
var title_f35_22_36197="Linagliptin and Metformin: Patient drug information";
var content_f35_22_36197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Linagliptin and Metformin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/37/27222?source=see_link\">",
"     see \"Linagliptin and Metformin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13813137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Jentadueto&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13818103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have more acid in their blood. Metformin may cause this. It may happen in people whose liver or kidneys do not work the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13818105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13818104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3652902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to linagliptin, metformin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, very bad kidney disease, or type 1 diabetes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having an x-ray with dye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13818109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug for 2 days after you have an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you are having surgery, if you have had a heart attack, bad infection, or stroke, or if you are 80 years of age or older and have not had your kidney function tested.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatic disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13818110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much acid in the blood (lactic acidosis) may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13818111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13818107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13818108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13818112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13818113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83367 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36197=[""].join("\n");
var outline_f35_22_36197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813137\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818103\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818105\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818104\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818109\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818110\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818111\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818107\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818108\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818112\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13818113\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/37/27222?source=related_link\">",
"      Linagliptin and Metformin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_22_36198="Isosorbide dinitrate: Drug information";
var content_f35_22_36198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isosorbide dinitrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/50/24356?source=see_link\">",
"    see \"Isosorbide dinitrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dilatrate&reg;-SR;",
"     </li>",
"     <li>",
"      IsoDitrate&reg; ER;",
"     </li>",
"     <li>",
"      Isordil&reg; Titradose&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ISDN;",
"     </li>",
"     <li>",
"      Isosorbide;",
"     </li>",
"     <li>",
"      Novo-Sorbide;",
"     </li>",
"     <li>",
"      PMS-Isosorbide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F185031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release: Initial: 5-20 mg 2-3 times/day; Maintenance: 10-40 mg 2-3 times/day",
"     <b>",
"      or",
"     </b>",
"     5-80 mg 2-3 times/day (Anderson, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Sustained release: 40-160 mg/day has been used in clinical trials (a nitrate free interval of at least 18 hours is recommended; however, a clinically efficacious dosage interval has not been clearly established)",
"     <b>",
"      or",
"     </b>",
"     40 mg 1-2 times/day (Anderson, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Sublingual:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prophylactic use: 2.5-5 mg administered 15 minutes prior to activities which may provoke an anginal episode",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment of acute anginal episode (use only if patient has failed sublingual nitroglycerin): 2.5-5 mg every 5-10 minutes for maximum of 3 doses in 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure (unlabeled use; Cohn, 1991; HFSA, 2010; Hunt, 2009):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release (",
"     <b>",
"      Note:",
"     </b>",
"     Use in combination with hydralazine):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial dose: 20 mg 3-4 times per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Target dose: 160 mg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophageal spastic disorders (unlabeled use; Goyal, 1998):",
"     </b>",
"     <i>",
"      Oral, sublingual:",
"     </i>",
"     Immediate release: 10-30 mg before meals",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly patients should be given lowest recommended adult daily doses initially and titrate upward.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F184990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sustained release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilatrate&reg;-SR: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg, 20 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isordil&reg; Titradose&trade;: 5 mg, 40 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual: 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IsoDitrate&reg; ER: 40 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F184967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May consider administration of first dose in physician office; observe for maximal cardiovascular dynamic effects and adverse effects (orthostatic hypotension, headache). Do not administer around the clock; allow nitrate-free interval &ge;14 hours (immediate release products) and &gt;18 hours (sustained release products). Do not crush sublingual tablets or extended release formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release products: When prescribed twice daily, consider administering at 8 AM and 1 PM. For 3 times/day dosing, consider 8 AM, 1 PM , and  6 PM.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sustained release products: Consider once daily in morning or twice-daily dosing at 8 AM and between 1-2 PM.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of angina pectoris",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to slower onset of action, not the drug of choice to abort an acute anginal episode.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F185028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with heart failure (HF) who do not tolerate an ACE inhibitor or an angiotensin receptor blocker (ARB); African-American (self-identified) patients with HF remaining symptomatic despite optimal standard therapy; esophageal spastic disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Isordil&reg; may be confused with Inderal&reg;, Isuprel&reg;, Plendil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F185029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Crescendo angina (uncommon), hypotension, orthostatic hypotension, rebound hypertension (uncommon), syncope (uncommon)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (most common), lightheadedness (related to blood pressure changes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia (rare, overdose)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isosorbide dinitrate or any component of the formulation; hypersensitivity to organic nitrates; concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, or vardenafil)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/bradycardia: Severe hypotension can occur; paradoxical bradycardia and increased angina pectoris can accompany hypotension. Postural hypotension can also occur. Use with caution in volume depletion and moderate hypotension, and use with extreme caution with inferior wall MI and suspected right ventricular infarctions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intracranial pressure increased: Nitrates may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM): Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (Gersh, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PDE-5 inhibitors: Avoid concurrent use with PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil). When nitrate administration becomes medically necessary, may administer nitrates only if 24 hours have elapsed after use of sildenafil or vardenafil (48 hours after tadalafil use) (Trujillo, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release formulations: Avoid use in acute MI or acute HF; cannot easily reverse effects if adverse events develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sublingual tablets: Per the manufacturer labeling, use of isosorbide dinitrate sublingual tablets to treat acute anginal attacks is recommended only in patients unresponsive to sublingual nitroglycerin; however, onset of action is significantly slower and duration of activity longer than sublingual nitroglycerin. Currently, clinical practice guidelines do not recommend use during an acute anginal episode.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: Appropriate dosing intervals are needed to minimize tolerance development. Tolerance can only be overcome by short periods of nitrate absence from the body. Dose escalation does not overcome this effect. When used for HF in combination with hydralazine, tolerance is less of a concern (Gogia, 1995).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F185026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of myocardial ischemia was reported for users of this combination in a meta-analysis.  Management: Consider alternatives to this combination when possible.  Rosiglitazone prescribing information states that the combination of rosiglitazone and a nitrate is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F184979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Caution with ethanol (may increase risk of hypotension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may cause hypotension).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12584821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased fetal mortality has been observed in animal studies using isosorbide dinitrate at doses much higher than those used in humans. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F184972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Dilatrate-SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $300.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Isosorbide Dinitrate Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $7.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Isosorbide Dinitrate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $84.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Isordil Titradose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $121.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $268.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Isosorbide Dinitrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $98.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $108.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $119.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $125.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F184962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Angibid SR (KP);",
"     </li>",
"     <li>",
"      Angitrit (SG, TH);",
"     </li>",
"     <li>",
"      Angsobide (MY);",
"     </li>",
"     <li>",
"      Cardonit (HU);",
"     </li>",
"     <li>",
"      Cardopax (DK);",
"     </li>",
"     <li>",
"      Carsodil (KP);",
"     </li>",
"     <li>",
"      Carvasin (IT);",
"     </li>",
"     <li>",
"      Cedocard (AT, BE, GB, ID, IE, LU, NL);",
"     </li>",
"     <li>",
"      Cedocard Retard (AT, ID, NL);",
"     </li>",
"     <li>",
"      Coronex (NZ);",
"     </li>",
"     <li>",
"      Diconpin (DE);",
"     </li>",
"     <li>",
"      Flindix (PT);",
"     </li>",
"     <li>",
"      Gasrobid (ID);",
"     </li>",
"     <li>",
"      Hartsorb (TH);",
"     </li>",
"     <li>",
"      Huma-Sorbide (HU);",
"     </li>",
"     <li>",
"      Imtack (IE);",
"     </li>",
"     <li>",
"      ISDN (DE);",
"     </li>",
"     <li>",
"      ISDN AL (HU);",
"     </li>",
"     <li>",
"      ISDN-Q (HU);",
"     </li>",
"     <li>",
"      ISDN-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Iso Mack (CH, HU);",
"     </li>",
"     <li>",
"      Iso Mack Retard (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Iso-Lacer (ES);",
"     </li>",
"     <li>",
"      Iso-Puren (DE);",
"     </li>",
"     <li>",
"      Isobide (TW);",
"     </li>",
"     <li>",
"      Isobinate (TH);",
"     </li>",
"     <li>",
"      Isocard (LU);",
"     </li>",
"     <li>",
"      Isocard Retard (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Isocord (BR, CO);",
"     </li>",
"     <li>",
"      Isoday 40 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Isodinit (LU);",
"     </li>",
"     <li>",
"      Isoket (AR, BG, CH, CL, CZ, DE, EE, HK, HU, ID, IE, IL, LU, MY, PH, PL, RU, SG, UY, VE);",
"     </li>",
"     <li>",
"      Isoket Retard (CH, CZ, DE, GB, HK, IN, KP);",
"     </li>",
"     <li>",
"      Isoket Spray (KP);",
"     </li>",
"     <li>",
"      Isomack (AT, HU, LU);",
"     </li>",
"     <li>",
"      Isomack Spray (KP);",
"     </li>",
"     <li>",
"      Isorbid (MX);",
"     </li>",
"     <li>",
"      Isorbide (PE);",
"     </li>",
"     <li>",
"      Isordil (AE, AR, AU, BH, BR, CY, EG, HN, ID, IE, IL, IN, IQ, IR, JO, KW, LB, LU, LY, NL, OM, PH, PK, PY, QA, SA, SY, TR, YE, ZA);",
"     </li>",
"     <li>",
"      Isorem (TH);",
"     </li>",
"     <li>",
"      Isotonax (LU);",
"     </li>",
"     <li>",
"      Langoran (FR);",
"     </li>",
"     <li>",
"      Langoran LP (FR);",
"     </li>",
"     <li>",
"      Maycor (DE);",
"     </li>",
"     <li>",
"      Maycor Retard (ES);",
"     </li>",
"     <li>",
"      Nitrol R (JP);",
"     </li>",
"     <li>",
"      Nitrosid (FI);",
"     </li>",
"     <li>",
"      Nitrosid Retard (FI);",
"     </li>",
"     <li>",
"      Nitrosorbide (BF, BJ, CI, ET, GH, GM, GN, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Nitrosorbon (DE, PH);",
"     </li>",
"     <li>",
"      Pensodril (GR);",
"     </li>",
"     <li>",
"      Risordan (FR, GR);",
"     </li>",
"     <li>",
"      Risordan LP (FR);",
"     </li>",
"     <li>",
"      Soni-Slo (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Sorbangil (NO, SE);",
"     </li>",
"     <li>",
"      Sorbidilat (CH);",
"     </li>",
"     <li>",
"      Sorbidin (AU);",
"     </li>",
"     <li>",
"      Sorbitrate (IN, LU);",
"     </li>",
"     <li>",
"      Sorbonit (HN, HU, PL);",
"     </li>",
"     <li>",
"      TD Spray Iso Mack (HU, LU);",
"     </li>",
"     <li>",
"      Tinidil (HR);",
"     </li>",
"     <li>",
"      Trindil (PH);",
"     </li>",
"     <li>",
"      Vascardin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, ID, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulation of intracellular cyclic-GMP results in vascular smooth muscle relaxation of both arterial and venous vasculature with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload. Additionally, coronary artery dilation improves collateral flow to ischemic regions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Sublingual tablet: ~3 minutes; Oral tablet and capsule (includes extended-release formulations): ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Sublingual tablet: 1-2 hours; Oral tablet and capsule (includes extended-release formulations): Up to 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2-4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to conjugated metabolites, including isosorbide 5-mononitrate (active) and 2-mononitrate (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Sublingual tablet: 40% to 50%; Oral immediate release formulations: Highly variable (10% to 90%); increases with chronic therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: ~1 hour; Metabolites (5-mononitrate: 5 hours; 2-mononitrate: 2 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636. Available at  file://www.circulationaha.org/cgi/content/full/110/5/588",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;ACC/AHA Expert Consensus Document. Use of Sildenafil (Viagra) in Patients With Cardiovascular Disease. American College of Cardiology/American Heart Association,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):273-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/9935041/pubmed\" id=\"9935041\" target=\"_blank\">",
"        9935041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN, Archibald DG, Ziesche S, et al, \"Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1986, 314(24):1547-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/3520315/pubmed\" id=\"3520315\" target=\"_blank\">",
"        3520315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN, Johnson G, Ziesche S, et al, \"A Comparison of Enalapril With Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 325(5):303-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/2057035/pubmed\" id=\"2057035\" target=\"_blank\">",
"        2057035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gogia H, Mehra A, Parikh S, et al, &ldquo;Prevention of Tolerance to Hemodynamic Effects of Nitrates With Concomitant Use of Hydralazine in Patients With Chronic Heart Failure,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1995, 26(7):1575-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/7594088/pubmed\" id=\"7594088\" target=\"_blank\">",
"        7594088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goyal RK, \"Diseases of the Esophagus,\"",
"      <i>",
"       Harrison&rsquo;s Principles of Internal Medicine",
"      </i>",
"      , 14th ed, Fauci AS, Braunwald E, Isselbacher KJ, et al, eds, New York, NY: McGraw-Hill, 1998, 1592.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parker JO, Fanell B, Lahey KA, et al, &ldquo;Effect of Intervals Between Doses on the Development to Tolerance to Isosorbide Dinitrate,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1987, 316(23):1440-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/3574424/pubmed\" id=\"3574424\" target=\"_blank\">",
"        3574424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor AL, Ziesche S, Yancy C, et al, \"Combination of Isosorbide Dinitrate and Hydralazine in Blacks With Heart Failure,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(20):2049-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/15533851/pubmed\" id=\"15533851\" target=\"_blank\">",
"        15533851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trujillo TC and Dobesh PP, &ldquo;Traditional Management of Chronic Stable Angina,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2007, 27(12):1677-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36198/abstract-text/18041888/pubmed\" id=\"18041888\" target=\"_blank\">",
"        18041888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8580 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36198=[""].join("\n");
var outline_f35_22_36198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185031\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184988\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184989\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184990\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160049\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184964\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184949\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184967\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184965\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185028\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185039\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185029\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184970\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184953\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185026\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184958\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184979\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184960\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584821\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184993\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184972\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184962\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184973\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184952\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184969\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8580\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8580|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/50/24356?source=related_link\">",
"      Isosorbide dinitrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_22_36199="Amlodipine: Pediatric drug information";
var content_f35_22_36199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amlodipine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"    see \"Amlodipine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/13/4309?source=see_link\">",
"    see \"Amlodipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norvasc&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accel-Amlodipine;",
"     </li>",
"     <li>",
"      Amlodipine-Odan;",
"     </li>",
"     <li>",
"      Apo-Amlodipine&reg;;",
"     </li>",
"     <li>",
"      CO Amlodipine;",
"     </li>",
"     <li>",
"      Dom-Amlodipine;",
"     </li>",
"     <li>",
"      GD-Amlodipine;",
"     </li>",
"     <li>",
"      JAMP-Amlodipine;",
"     </li>",
"     <li>",
"      Manda-Amlodipine;",
"     </li>",
"     <li>",
"      Mint-Amlodipine;",
"     </li>",
"     <li>",
"      Mylan-Amlodipine;",
"     </li>",
"     <li>",
"      Norvasc&reg;;",
"     </li>",
"     <li>",
"      PHL-Amlodipine;",
"     </li>",
"     <li>",
"      PMS-Amlodipine;",
"     </li>",
"     <li>",
"      Q-Amlodipine;",
"     </li>",
"     <li>",
"      RAN&trade;-Amlodipine;",
"     </li>",
"     <li>",
"      ratio-Amlodipine;",
"     </li>",
"     <li>",
"      Riva-Amlodipine;",
"     </li>",
"     <li>",
"      Sandoz Amlodipine;",
"     </li>",
"     <li>",
"      Septa-Amlodipine;",
"     </li>",
"     <li>",
"      Teva-Amlodipine;",
"     </li>",
"     <li>",
"      ZYM-Amlodipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianginal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker, Dihydropyridine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"      see \"Amlodipine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Hypertension:",
"     <b>",
"      Note:",
"     </b>",
"     For a summary of other pediatric studies see Additional Information",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-5 years: Limited information exists in the literature. One population pharmacokinetic study found that children &lt;6 years of age had weight-adjusted clearance and V",
"     <sub>",
"      d",
"     </sub>",
"     of amlodipine that were significantly greater than children &ge;6 years of age. This may suggest the need for higher mg/kg/day doses in younger children (&lt;6 years of age); however, the study included only a small number of younger children (n=11) (Flynn, 2006). One retrospective pediatric study (n=55) that included only eight patients 1-6 years of age used initial doses of 0.05-0.1 mg/kg/day; doses were titrated upwards as needed; mean required dose was significantly higher in patients 1-6 years of age (0.3 &plusmn; 0.16 mg/kg/day) compared to older children (6-12 years: 0.16 &plusmn; 0.12 mg/kg/day; 12-20 years: 0.14 &plusmn; 0.1 mg/kg/day) (Flynn, 2000a). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-17 years: Manufacturer recommendations: 2.5-5 mg once daily; doses &gt;5 mg daily have not been fully studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Limited data exists in the literature. In the only randomized, placebo-controlled trial of amlodipine in children (n=268; mean age: 12.1 years; range: 6-16 years), a significant reduction in systolic blood pressure (compared to placebo) was observed in both the 2.5 mg once daily and the 5 mg once daily amlodipine groups. The authors recommend an initial dose of 0.06 mg/kg/day with a maximum dose of 0.34 mg/kg/day (not to exceed 10 mg/day) (Flynn, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypertension: Initial: 2.5-5 mg once daily; use initial dose of 2.5 mg once daily in patients who are small or fragile, and when adding amlodipine to other antihypertensive therapy; in general, titrate dose over 7-14 days to fully assess effects; usual dose: 5 mg once daily; maximum dose: 10 mg once daily; usual dosage range (JNC 7): 2.5-10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Angina or CAD: 5-10 mg once daily; use lower dose for patients with hepatic impairment; most patients with CAD require 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Not needed; patients may receive the usual initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adults: Angina: Initial: 5 mg once daily; Hypertension: Initial: 2.5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norvasc&reg;: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food; use caution if administered with grapefruit juice",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); dispense in tightly-closed, light-resistant container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension (FDA approved in ages &ge;6 years and adults); chronic stable angina (FDA approved in adults); vasospastic (Prinzmetal's) angina (FDA approved in adults); angiographically documented CAD [to decrease risk of hospitalization (due to angina) and coronary revascularization procedure] (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AmLODIPine may be confused with aMILoride",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norvasc&reg; may be confused with Navane&reg;, Norvir&reg;, Vascor&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Norvasc [U.S., Canada, and multiple international markets] may be confused with Vascor brand name for imidapril [Philippines] and simvastatin [Malaysia, Singapore, and Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F134049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing (more common in females), palpitations, peripheral edema (more common in females)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Male sexual dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute interstitial nephritis, allergic reactions, angioedema, anorexia, arrhythmia, arthrosis, atrial fibrillation, bradycardia, cholestasis, conjunctivitis, depersonalization, depression, diarrhea, diplopia, dysphagia, epistaxis, erythema multiforme, exfoliative dermatitis, eye pain, female sexual dysfunction, gingival hyperplasia, gynecomastia, hepatitis, hot flushes, hyperglycemia, hypoesthesia, insomnia, jaundice, leukocytoclastic vasculitis, leukopenia, micturition disorder, micturition frequency, myalgia, nocturia, nonthrombocytopenic purpura, orthostatic hypotension, pain, pancreatitis, paresthesia, peripheral ischemia, peripheral neuropathy, phototoxicity, purpura, rash erythematous, rash maculopapular, rigors, Stevens-Johnson syndrome, syncope, tachycardia, thirst, thrombocytopenia, transaminases increased, tremor, vasculitis, ventricular tachycardia, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amlodipine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce the dose in patients with hepatic impairment; titrate dose slowly in patients with severe hepatic impairment. Symptomatic hypotension may occur; use with caution in patients with severe aortic stenosis; acute hypotension may rarely occur",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May increase frequency, duration, and severity of angina or precipitate acute MI during initiation of therapy or dosage increase (particularly in patients with severe obstructive coronary artery disease)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F134037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2A6 (weak), CYP2B6 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect the bioavailability of amlodipine. Grapefruit juice increased amlodipine peak serum concentrations by 15% and AUC by 16% in one single dose study (Josefsson, 1996); however, repeated daily ingestion of grapefruit juice did",
"     <b>",
"      not",
"     </b>",
"     affect amlodipine pharmacokinetics in another single-dose amlodipine study (Vincent, 2000); multiple dose amlodipine-grapefruit juice interaction studies are needed. Avoid natural licorice (causes sodium and water retention and increases potassium loss)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxic effects have been demonstrated in animal studies. No well-controlled studies have been conducted in pregnant women. Use in pregnancy only when clearly needed and when the benefits outweigh the potential hazard to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, liver enzymes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ions from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antihypertensive effects: Duration: &ge;24 hours with chronic daily dosing",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distribution into breast milk is unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mean V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;6 years: Similar to adults on a mg per kg basis;",
"     <b>",
"      Note:",
"     </b>",
"     Weight-adjusted V",
"     <sub>",
"      d",
"     </sub>",
"     in younger children (&lt;6 years of age) may be greater than in older children (Flynn, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 21 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver with 90% metabolized to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 64% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Terminal: 30-50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentrations: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 10% of parent drug and 60% of metabolites are excreted in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: May be decreased in patients with hepatic insufficiency or moderate to severe heart failure; weight-adjusted clearance in children &gt;6 years of age is similar to adults;",
"     <b>",
"      Note:",
"     </b>",
"     Weight-adjusted clearance in younger children (&lt;6 years of age) may be greater than in older children (Flynn, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/13/4309?source=see_link\">",
"      see \"Amlodipine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not discontinue abruptly; report unrelieved headache, vomiting, palpitations, peripheral or facial swelling, weight gain, or respiratory changes; may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10215864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Summary of additional pediatric studies:",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In one prospective study, 21 hypertensive children (mean age: 13.1 years; range: 6-17 years) received the following initial daily doses of amlodipine based on weight groups: Children &lt;50 kg: 0.05 mg/kg/day; children 50-70 kg: 2.5 mg daily; children &gt;70 kg: 5 mg daily; mean initial dose: 0.07 &plusmn; 0.04 mg/kg/day; doses were increased by 25% to 50% (rounded to the nearest 2.5 mg) every 5-7 days to a maximum of 0.5 mg/kg/day, as needed to control blood pressure; the mean required dose was almost twice as high for children &lt;13 years of age (0.29 &plusmn; 0.13 mg/kg/day) compared to children &ge;13 years of age (0.16 &plusmn; 0.11 mg/kg/day) (Tallian, 1999).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In a small randomized crossover trial, amlodipine was compared to nifedipine or felodipine in 11 hypertensive children (mean age: 16 years; range: 9-17 years); amlodipine was administered once daily as a liquid preparation (tablets dissolved in water immediately prior to administration); an initial daily dose of 0.1 mg/kg/day (maximum: 5 mg daily) was increased by 50% to 100% after 1 week to a maximum of 10 mg/day, as needed for blood pressure control; mean initial dose: 0.09 &plusmn; 0.01 mg/kg/day; mean required dose: 0.12 mg/kg/day (Rogan, 2000). A third prospective study used fixed mg doses, rather than dosing on a mg/kg basis (Pfammatter, 1998).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A prospective study in 43 pediatric outpatients with chronic kidney disease (median age:  9 years; range: 1-19 years) used the following initial daily doses of amlodipine based on weight groups: Children 10-30 kg: 2.5 mg once daily; children &ge;31 kg: 5 mg once daily. Doses were increased if needed to a maximum of 0.5 mg/kg/day (20 mg/day). Younger patients required significantly higher mg/kg/day doses of amlodipine compared to older children. This relationship was not observed when the dose was expressed as mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day. The authors recommend a dose of 7-10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     given once daily (von Vigier, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Five retrospective studies used a variety of initial amlodipine doses ranging from 0.05-0.13 mg/kg/day; mean required dose after dosage titration (for all aged pediatric patients) ranged from 0.15-0.23 mg/kg/day (Andersen, 2006; Flynn, 2000a; Khattak, 1998; Parker 2002; Silverstein, 1999). Two of these studies noted a relationship between dose and age, with younger patients requiring higher mg/kg/day doses. Several retrospective studies used twice daily dosing in younger children, but it is unknown whether this reflects altered pharmacokinetics or physician prescribing habits. One population pharmacokinetic study suggests there is no justification for twice-daily dosing of amlodipine children (Flynn, 2006). Further pediatric studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F133977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of simple syrup and 1% methylcellulose or a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg;. Crush fifty 5 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     250 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 250 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 56 days at room temperature or 91 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Hipple TF, \"Stability of Amlodipine Besylate in Two Liquid Dosage Forms,\"",
"     <i>",
"      J Am Pharm Assoc (Wash)",
"     </i>",
"     , 1999, 39(3):375-7.",
"     <span class=\"pubmed-id\">",
"      10363465",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andersen J, Groshong T, and Tobias JD, \"Preliminary Experience With Amlodipine in the Pediatric Population,\"",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2006, 13(3):198-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/16772760/pubmed\" id=\"16772760\" target=\"_blank\">",
"        16772760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT and Pasko DA, &ldquo;Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2000, 15(3-4):302-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/11149130/pubmed\" id=\"11149130\" target=\"_blank\">",
"        11149130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT, Nahata MC, Mahan JD Jr, et al, \"Population Pharmacokinetics of Amlodipine in Hypertensive Children and Adolescents,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2006, 46(8):905-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/16855075/pubmed\" id=\"16855075\" target=\"_blank\">",
"        16855075",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT, Newburger JW, Daniels SR, et al, \"A Randomized, Placebo-Controlled Trial of Amlodipine in Children With Hypertension,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2004, 145(3):353-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/15343191/pubmed\" id=\"15343191\" target=\"_blank\">",
"        15343191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT, Smoyer WE, and Bunchman TE, &ldquo;Treatment of Hypertensive Children With Amlodipine,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000a, 13(10):1061-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/11041159/pubmed\" id=\"11041159\" target=\"_blank\">",
"        11041159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Josefsson M, Zackrisson AL, and Ahlner J, &ldquo;Effect of Grapefruit Juice on the Pharmacokinetics of Amlodipine in Healthy Volunteers,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1996, 51(2):189-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/8911887 /pubmed\" id=\"8911887 \" target=\"_blank\">",
"        8911887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khattak S, Rogan JW, Saunders EF, et al, &ldquo;Efficacy of Amlodipine in Pediatric Bone Marrow Transplant Patients,&rdquo;",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1998, 37(1):31-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/9475697/pubmed\" id=\"9475697\" target=\"_blank\">",
"        9475697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meredith PA and Elliott HL, \"Clinical Pharmacokinetics of Amlodipine,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1992, 22(1):22-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/1532771/pubmed\" id=\"1532771\" target=\"_blank\">",
"        1532771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parker ML, Robinson RF, and Nahata MC, &ldquo;Amlodipine Therapy in Pediatric Patients With Hypertension,&rdquo;",
"      <i>",
"       J Am Pharm Assoc",
"      </i>",
"      , 2002, 42(1):114-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/11833502/pubmed\" id=\"11833502\" target=\"_blank\">",
"        11833502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfammatter JP, Clericetti-Affolter C, Truttmann AC, et al, &ldquo;Amlodipine Once-Daily in Systemic Hypertension,&rdquo;",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1998, 157(8):618-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/9727842/pubmed\" id=\"9727842\" target=\"_blank\">",
"        9727842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rogan JW, Lyszkiewicz DA, Blowey D, et al, &ldquo;A Randomized Prospective Crossover Trial of Amlodipine in Pediatric Hypertension,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2000, 14(12):1083-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/11045391/pubmed\" id=\"11045391\" target=\"_blank\">",
"        11045391",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein DM, Palmer J, Baluarte HJ, et al, &ldquo;Use of Calcium-Channel Blockers in Pediatric Renal Transplant Recipients,&rdquo;",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 1999, 3(4):288-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/10562973/pubmed\" id=\"10562973\" target=\"_blank\">",
"        10562973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tallian KB, Nahata MC, Turman MA, et al, &ldquo;Efficacy of Amlodipine in Pediatric Patients With Hypertension,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 1999, 13(4):304-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/10454779/pubmed\" id=\"10454779\" target=\"_blank\">",
"        10454779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vincent J, Harris SI, Foulds G, et al, &ldquo;Lack of Effect of Grapefruit Juice on the Pharmacokinetics and Pharmacodynamics of Amlodipine,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2000, 50(5):455-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/11069440/pubmed\" id=\"11069440\" target=\"_blank\">",
"        11069440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Vigier RO, Franscini LM, Bianda ND, et al, \"Antihypertensive Efficacy of Amlodipine in Children With Chronic Kidney Diseases,\"",
"      <i>",
"       J Hum Hypertens",
"      </i>",
"      , 2001, 15(6):387-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/22/36199/abstract-text/11439313/pubmed\" id=\"11439313\" target=\"_blank\">",
"        11439313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12603 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36199=[""].join("\n");
var outline_f35_22_36199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051019\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051012\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133971\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133957\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051023\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051015\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051022\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134051\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134049\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051028\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051011\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051010\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134037\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133966\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051030\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133968\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133982\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051018\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051009\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051026\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051027\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051017\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10215864\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133977\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12603\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12603|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=related_link\">",
"      Amlodipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/13/4309?source=related_link\">",
"      Amlodipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_22_36200="Prevention of varicella-zoster virus infection: Herpes zoster";
var content_f35_22_36200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of varicella-zoster virus infection: Herpes zoster",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36200/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36200/contributors\">",
"     Mary A Albrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36200/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36200/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/22/36200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease.",
"   </p>",
"   <p>",
"    Primary infection with VZV results in varicella, known as chickenpox, characterized by vesicular lesions in different stages of development on the face, trunk, and extremities. Herpes zoster, also known as shingles, results from reactivation of endogenous latent VZV infection within the sensory ganglia. This clinical form of the disease is characterized by a painful, unilateral vesicular eruption, which usually occurs in a restricted dermatomal distribution.",
"   </p>",
"   <p>",
"    Vaccines are available for prevention of both infections. This topic will address issues of infectivity and the efficacy of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    for prevention of reactivation disease. The prevention of varicella (chickenpox) infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical manifestations and treatment of VZV infection, as well as treatment chickenpox, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISSUES OF INFECTIVITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542988\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with herpes zoster should be counseled about the risk of viral transmission to others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, varicella-zoster virus (VZV) is much less transmissible from a person presenting with herpes zoster than from a person presenting with varicella. VZV is transmitted from person to person by direct contact or by aerosolization of virus from skin lesions.",
"   </p>",
"   <p>",
"    Persons are not infectious before vesicles appear and are no longer infectious when the lesions have re-epithelized. Individuals who have not had varicella, and are exposed to a patient with herpes zoster, are at risk for developing primary varicella. &nbsp;",
"   </p>",
"   <p>",
"    Patients should be counseled to keep the rash covered, if feasible, and to wash their hands often to prevent the spread of virus to others. Until the rash has crusted, patients should be advised to avoid contact with pregnant women who have never had chickenpox or the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , premature or low birth weight infants, and immunocompromised individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Airborne transmission of VZV from localized zoster has been documented in several reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. A small outbreak of varicella occurred in a long-term care facility after one of the nursing home residents developed herpes zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/6\">",
"     6",
"    </a>",
"    ]. Clinical specimens were collected from three case patients with varicella; viral analysis demonstrated a unique mosaic genotype strain that was present in all three varicella patients. Although environmental sampling for VZV DNA demonstrated widespread contamination, airborne transmission was still suspected since VZV is known to easily desiccate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VZV has also been detected in saliva. In a study of 54 patients with zoster who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , VZV DNA was identified in saliva in all patients on the first day of treatment and resolved in 82 percent of patients by day 15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, infectious VZV was isolated from one of two patients whose saliva was cultivated in tissue culture. Whether saliva is a vehicle of transmission, however, is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542995\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact precautions are not currently recommended for cases of localized zoster within the community setting but are instituted for hospitalized patients who can keep lesions covered with clothing or dressings. However, in the outbreak noted above, the lesions of the index patient with herpes zoster were covered with gauze and clothing, raising concerns about the most appropriate precautions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/8\">",
"     8",
"    </a>",
"    ]. This and other studies also reinforce the importance of vaccination of healthcare workers and persons who are potentially exposed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hospitalized patients with disseminated zoster should be placed in strict isolation since airborne spread of infection is possible. Isolation is also prudent for immunocompromised patients with localized zoster, since these patients are at risk for subsequent dissemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF CELL-MEDIATED IMMUNITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4543175\">",
"    <span class=\"h2\">",
"     Immunity and risk of reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decline in cell-mediated immunity to VZV is observed in the elderly population and immunosuppressed hosts and is regarded as the major precipitant for inducing VZV reactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately 30 to 40 percent of persons over the age of 55 years do not have any detectable VZV-specific T cell responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/9\">",
"     9",
"    </a>",
"    ]. Zoster immunization is associated with a boost in VZV-specific T cell immune responses, which is the probable mechanism explaining the vaccine&rsquo;s efficacy in preventing or attenuating disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among those who develop herpes zoster, in vitro data suggest that robust VZV cell-mediated immunity, at the onset of rash, is correlated with reduced severity of disease and less risk of postherpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/10\">",
"     10",
"    </a>",
"    ]. Immunocompromised patients who lack adequate VZV-specific cellular immune responses are at risk for prolonged episodes of reactivation and disseminated disease, which can be fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4543182\">",
"    <span class=\"h2\">",
"     Boosting of T-cell specific immunity to VZV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell-mediated immune responses improve with periodic subclinical VZV reactivation, which may limit virus replication and spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. Environmental boosting of T-cell responses has also been documented among VZV-immune healthy adults who have household exposure to children with primary varicella and may decrease the risk of developing zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the possibility of community exposure to VZV is declining with universal varicella immunization. Thus, it is possible that the absence of environmental boosting may lead to accelerated declines in VZV-specific T-cell immune responses; whether this will lead to an earlier age of onset of zoster reactivation in the general population is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H213071756\">",
"    <span class=\"h2\">",
"     Depression and cell-mediated immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two-year longitudinal cohort study that included 92 community-dwelling adults &ge;60 years of age who were enrolled in the Shingles Prevention Study evaluated the influence of depression on cell-mediated immune responses to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/15\">",
"     15",
"    </a>",
"    ]. Depressed individuals who were not treated with antidepressant medications had lower levels of VZV-specific cell-mediated immune responses following administration of the zoster vaccine than nondepressed individuals or depressed individuals receiving antidepressants, even when antidepressant medications failed to reduce depressive symptom severity. Further study is necessary to determine whether the reduction in VZV-specific cell-mediated immunity in patients with untreated depression increases the risk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of herpes zoster",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduces the efficacy of the zoster vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL TRIAL DATA ON ZOSTER VACCINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adults &ge;60 years of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Shingles Prevention Study (SPS), a placebo-controlled clinical trial of 38,546 adults 60 years of age or older was conducted to determine if the use of a live attenuated",
"    <span class=\"nowrap\">",
"     Oka/Merck",
"    </span>",
"    VZV vaccine (\"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    \") would decrease the incidence and severity of herpes zoster and postherpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/14\">",
"     14",
"    </a>",
"    ]. All participants had a history of infection or had resided in the United States for 30 years; serologic testing for varicella was not performed. More than 95 percent of the subjects completed three years of surveillance with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmed herpes zoster occurred in 957 (2.5 percent); immunization reduced the incidence of herpes zoster by 51 percent compared with placebo (1.6 versus 3.3 percent, respectively).",
"     </li>",
"     <li>",
"      In those who did develop herpes zoster, the median duration of pain and discomfort was modestly reduced in the vaccine group than in the placebo group (21 versus 24 days, respectively).",
"     </li>",
"     <li>",
"      The incidence of postherpetic neuralgia was reduced by 67 percent in the vaccine group (0.1 versus 0.4 percent overall [0.46 versus 1.38 cases per 1000 person-years]). The magnitude of benefit was greater in patients &ge;70 years of age (0.2 versus 0.6 percent overall [0.71 versus 2.13 cases per 1000 person-years]). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link\">",
"       \"Postherpetic neuralgia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An immunology substudy of 1395 patients demonstrated increases in VZV-specific antibody and cell-mediated immunity at six weeks after vaccination compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/11\">",
"       11",
"      </a>",
"      ]. Increases in CMI persisted during the three years of follow-up, although the magnitude of these T-cell responses declined over time.",
"     </li>",
"     <li>",
"      A follow-up study, the Short-Term Persistence Sub-Study (STPS), re-enrolled 7320 vaccine recipients and 6950 placebo recipients and followed them through year 7 after vaccination; a 15-month gap in surveillance occurred between completion of the SPS and commencement of the STPS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/16\">",
"       16",
"      </a>",
"      ]. In the STPS as compared to the SPS, there were no statistically significant differences in vaccine efficacy for herpes zoster burden of illness, vaccine efficacy for the incidence of post-herpetic neuralgia, or vaccine efficacy for the incidence of herpes zoster. Vaccine efficacy for the incidence of herpes zoster and for the burden of herpes zoster illness remained statistically significant through year 5.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis evaluated the efficacy of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    in eight randomized trials that included 52,269 individuals 60 years of age or older, the majority of whom came from the SPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/17\">",
"     17",
"    </a>",
"    ]. A similar reduction in herpes zoster was observed as was seen in the SPS. For herpes zoster incidence, a greater benefit was observed in individuals aged 60 to 69 years (RR 0.36, 95% CI 0.30-0.45) than in participants aged 70 years and over (RR 0.63, 95% CI 0.53-0.75).",
"   </p>",
"   <p>",
"    A post-licensure observational study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     herpes zoster vaccine",
"    </a>",
"    effectiveness was performed among immunocompetent patients enrolled in a large health plan in California; 75,761 patients were vaccinated and 227,283 patients were unvaccinated during a two-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/18\">",
"     18",
"    </a>",
"    ]. A total of 5434 cases of herpes zoster were identified; in an adjusted analysis, vaccination was associated with a significantly reduced risk of herpes zoster (hazard ratio, 0.45; 95% CI 0.42-0.48). This risk reduction occurred in all age strata (60 to &gt;80 years of age) and among individuals with chronic diseases (eg, diabetes, liver disease, coronary artery disease). The risk of ophthalmic herpes zoster and hospitalization was also reduced by approximately two-thirds among vaccine recipients. These retrospective data complement the findings of the original clinical trial noted above and reinforce the potential to reduce significant morbidity with immunization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7023178\">",
"    <span class=\"h2\">",
"     Adults 50 to 59 years of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Zostavax Efficacy and Safety Trial (ZEST), 22,439 patients aged 50 to 59 years of age from the United States and Europe were randomly assigned to vaccine or placebo and followed for a mean of 15 months for the development of zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/19\">",
"     19",
"    </a>",
"    ]. The majority of the patients were women (62 percent) and most of the study participants were white (94 percent). Herpes zoster infection was determined by testing lesions for varicella zoster virus DNA by polymerase chain reaction. The following results were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"       Zoster vaccine",
"      </a>",
"      reduced the incidence of herpes zoster (30 cases in the vaccine group with an incidence rate 2 per 1000 person-years versus 99 cases in the placebo group with an incidence rate 6.6 per 1000 person-years)",
"     </li>",
"     <li>",
"      Vaccine efficacy for preventing herpes zoster was 70 percent (95% CI, 54.1-80.6)",
"     </li>",
"     <li>",
"      The VZV antibody response at six weeks postvaccination was higher in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"       zoster vaccine",
"      </a>",
"      group",
"     </li>",
"     <li>",
"      The proportion of subjects reporting clinical adverse events was higher in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"       zoster vaccine",
"      </a>",
"      group; side effects were mainly injection site reactions and headache. One recipient of zoster vaccine developed an anaphylactic reaction on the day of vaccination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR USE OF ZOSTER VACCINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542488\">",
"    <span class=\"h2\">",
"     General recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    (Zostavax; Merck Pharmaceuticals) has been approved for use in the United States, Europe, and Australia. The United States Advisory Committee on Immunization Practices (ACIP) voted to recommend herpes zoster vaccination for all people aged 60 years and older in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2011, the Food and Drug Administration (FDA) approved the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    among persons 50 to 59 years of age based on preliminary efficacy data from a randomized clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/19\">",
"     19",
"    </a>",
"    ]. In June 2011 the Advisory Committee on Immunization Practices declined to recommend zoster vaccine in this age group, citing concerns regarding shortfalls of zoster vaccine for general use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7023178\">",
"     'Adults 50 to 59 years of age'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     Zoster vaccine",
"    </a>",
"    is NOT indicated for the treatment of zoster or post-herpetic neuralgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4543250\">",
"    <span class=\"h2\">",
"     Formulation and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    is a live-attenuated vaccine, which is administered as a one-time subcutaneous injection. The vaccine contains 18,700 to 60,000 plaque-forming units of virus, considerably more than the approximately 1350 plaque-forming units found in the",
"    <span class=\"nowrap\">",
"     Oka/Merck",
"    </span>",
"    VZV vaccine for prevention of varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumovax and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    should not be given simultaneously, because the administration of Pneumovax reduces the immunogenicity of zoster vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542627\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not necessary to elucidate whether the patient has a history of varicella prior to vaccine administration. Serologic testing for past exposure to VZV prior to immunization is also not required since it was not utilized in the large clinical trials described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/20,24,25\">",
"     20,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reader is referred elsewhere for details on the sensitivity and specificity of serologic testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/77?source=see_link\">",
"     \"Diagnosis of varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542495\">",
"    <span class=\"h2\">",
"     Use in patients with prior zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention and the ACIP recommend a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    for adults aged &gt;60 years, regardless of whether the patient has reported a prior episode of herpes zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is unclear if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    offers any clear benefit among those with a recent history of herpes zoster. One retrospective study of 1036 vaccinated and 5180 unvaccinated persons &gt;60 years of age with a history of zoster within the past four years found that the incidence of recurrent disease was low; only 29 well-documented cases were discovered on chart review during the 4.5 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/28\">",
"     28",
"    </a>",
"    ]. The low number of events precluded any definitive analysis of vaccine efficacy in prevention of zoster recurrence, though there was a trend toward lower rates among vaccinated patients. The scarcity of cases among persons with recent zoster may be related to endogenous boosting of VZV-specific T cells during reactivation disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542502\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     Zoster vaccine",
"    </a>",
"    is NOT advised for use in pregnant women or in individuals with a history of an anaphylactic reaction to gelatin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     Zoster vaccine",
"    </a>",
"    is also NOT advised in patients with primary or acquired immunodeficiencies (including leukemia, lymphoma, or other malignancies affecting the bone marrow or lymphatic system), AIDS, and patients on immunosuppressive therapies, since it is a live attenuated vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/30\">",
"     30",
"    </a>",
"    ]. The use of zoster vaccine in the patient who is going to initiate immunosuppressive therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H4542909\">",
"     'Vaccination before immunosuppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4543280\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cost-effective analyses of immunization for herpes zoster are currently hampered by the unknown duration of vaccine protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     herpes zoster vaccine",
"    </a>",
"    is generally well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/29,33\">",
"     29,33",
"    </a>",
"    ]. In a randomized placebo-controlled trial with enrollment from 1998 to 2001 (n = 38,546 immunocompetent adults), the most common side effect after administration of herpes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    was pain at the injection site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/33\">",
"     33",
"    </a>",
"    ]. There were no documented episodes of disseminated vesicular rash linked to the vaccine virus. Long-term follow-up through 2004 showed that rates of hospitalization or death did not differ between vaccine and placebo recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/33\">",
"     33",
"    </a>",
"    ]. In a 2012 meta-analysis, vaccine-related systemic adverse effects were more frequent in the vaccinated group (RR 1.29, 95% CI 1.05-1.57) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/17\">",
"     17",
"    </a>",
"    ]. Side effects were more frequent in individuals from 60 to 69 years than in those &ge;70 years of age.",
"   </p>",
"   <p>",
"    Two cases of acute retinal necrosis (ARN) following herpes zoster vaccination have been reported; the patients developed loss of vision six days and two months following vaccination, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/34\">",
"     34",
"    </a>",
"    ]. VZV was detected from the vitreous or aqueous by polymerase chain reaction in both patients. Since it is not known whether the viruses that caused ARN were identical to the vaccine strain, it is not clear whether the episodes of ARN were caused by vaccination. Both patients were over 75 years of age and one was immunocompromised, having undergone renal transplantation. As noted above, herpes zoster vaccination is contraindicated in immunocompromised patients because it is a live virus vaccine. (See",
"    <a class=\"local\" href=\"#H4542502\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All clinically significant events should be reported to the Vaccine Adverse Events Reporting System (VAERS) at",
"    <a class=\"external\" href=\"file://www.vaers.hhs.gov/\">",
"     file://www.vaers.hhs.gov",
"    </a>",
"    or by telephone (800-822-7967).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542575\">",
"    <span class=\"h2\">",
"     Transmission of vaccine virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials, transmission of the vaccine virus has not been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/35\">",
"     35",
"    </a>",
"    ]. According to the package insert, post-marketing experience suggests that transmission of vaccine virus may occur rarely from vaccine recipients to susceptible contacts who may develop a varicella-like rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542811\">",
"    <span class=\"h2\">",
"     Barriers to use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     Herpes zoster vaccine",
"    </a>",
"    is the most expensive vaccine routinely recommended for older adults. Early uptake of the herpes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    has been low, at 2 to 7 percent from 2007 and 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/36\">",
"     36",
"    </a>",
"    ]. A national survey conducted in 2008 among general internists and family medicine physicians found that the most frequently reported barrier to vaccination was a financial one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/37\">",
"     37",
"    </a>",
"    ]. Only 45 percent of respondents knew that herpes zoster vaccine is reimbursed through Medicare Part D. Coverage by other Medicare programs should be checked on a state-by-state basis.",
"   </p>",
"   <p>",
"    Clinicians should also be aware that the CDC has posted a notice regarding backorders and significant lag time to availability of the vaccine, which will probably continue through 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION OF ZOSTER IN IMMUNOSUPPRESSED HOSTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542909\">",
"    <span class=\"h2\">",
"     Vaccination before immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for zoster and its associated morbidity and mortality is much greater among persons who are immunosuppressed. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    is not recommended in patients who are immunosuppressed.",
"   </p>",
"   <p>",
"    A review of vaccination status for zoster and other vaccines should be a key component of the medical assessment for immunocompetent patients aged &gt;60 years who might be anticipating initiation of immunosuppressive treatments or who have diseases that might lead to immunodeficiency. Whenever feasible, it is optimal to vaccinate patients prior to the initiation of planned immunosuppression. Patients who do not have a history of zoster vaccination should receive one dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    while their immunity is intact. Zoster vaccine should be administered at least 14 days before the initiation of immunosuppressive therapy, although some experts advise administration a full month prior, if feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542928\">",
"    <span class=\"h2\">",
"     Prevention of zoster reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes zoster reactivation disease occurs in 30 percent of allogeneic hematopoietic cell transplant recipients with a prior history of varicella. These immunosuppressed patients are not candidates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    . Prophylaxis strategies with antiviral therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4542935\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical trial sponsored by the National Institutes of Health (Clinical trial number NCT00851786) is evaluating the safety and efficacy of two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    among HIV-infected patients in 34 sites around the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients must have a CD4 count of 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and viral suppression on ART to enroll [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23747684\">",
"    <span class=\"h2\">",
"     Patients with rheumatic and inflammatory bowel diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rheumatoid arthritis, Crohn disease, and other immune-mediated diseases are at increased risk of herpes zoster; this observation has been attributed to the treatments that these patients are often taking (eg, immune-modulating biologic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or disease-modifying antirheumatic drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and corticosteroids) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/41\">",
"     41",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     Zoster vaccine",
"    </a>",
"    should be avoided in this population based on concerns that patients may develop varicella from the live attenuated vaccine strain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/20,42\">",
"     20,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis was performed among 463,541 US Medicare beneficiaries diagnosed with rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, or inflammatory bowel disease who were 60 years of age or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/43\">",
"     43",
"    </a>",
"    ]. Over a median duration of two years of follow-up, 18,683 patients (4 percent) received the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    and 7780 contributed person-time within 42 days after vaccination with the following outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 2032 cases of herpes zoster occurred in patients while unvaccinated; the risk of herpes zoster was higher among patients exposed to corticosteroids.",
"     </li>",
"     <li>",
"      Among 633 patients exposed to biologics (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ), no cases of varicella or herpes zoster occurred within the 42 days following vaccination.",
"     </li>",
"     <li>",
"      Among all vaccinated patients, only one case of varicella was identified within the 42 day risk window while 11 cases of herpes zoster were reported.",
"     </li>",
"     <li>",
"      During the more than 42 days after vaccination, lower rates of herpes zoster were observed among those who were vaccinated compared with the unvaccinated patients (HR 0.61; 95% CI, 0.52-0.71). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that immunization with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    may be safe and protective among patients with rheumatic diseases or inflammatory bowel disease. Limitations of the study include ascertainment of herpes zoster through administrative claims, potential misclassification of medication exposure, loss to follow-up and potential bias through vaccination of healthier patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H213071710\">",
"    <span class=\"h1\">",
"     INACTIVATED VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been interest in developing an inactivated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    , especially for use in immunocompromised hosts who cannot receive live virus vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/35\">",
"     35",
"    </a>",
"    ]. In a phase",
"    <span class=\"nowrap\">",
"     I/II,",
"    </span>",
"    open-label randomized trial that included young adults (18 to 30 years) and older adults (50 to 70 years), an adjuvanted recombinant glycoprotein E subunit vaccine was well tolerated and more immunogenic than the live attenuated VZV vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36200/abstract/44\">",
"     44",
"    </a>",
"    ]. Further study is necessary to establish the efficacy of inactivated zoster vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     VARICELLA VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the licensure of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , concerns were raised that immunization might lead to an increased risk of vaccine-associated herpes zoster, particularly in immunocompromised children, and that widespread varicella immunization in childhood may increase the incidence of herpes zoster in the general population due to decreased circulation of wild-type virus and a decline in T-cell immunity. These concerns have not been born out clinically to date. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\", section on 'Impact of varicella vaccine on incidence of herpes zoster'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in children and adults (including healthcare workers) is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"       \"Patient information: Vaccines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/0/14338?source=see_link\">",
"       \"Patient information: Shingles (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13507?source=see_link\">",
"       \"Patient information: Shingles (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease. Primary infection with VZV results in varicella, characterized by vesicular lesions in different stages of development on the face, trunk and extremities. Herpes zoster is related to reactivation of VZV infection and is characterized by a painful, unilateral vesicular eruption in a restricted dermatomal distribution. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals who have not had varicella and are exposed to a patient with herpes zoster are at risk for developing primary varicella and not herpes zoster. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Issues of infectivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A decline in specific cell-mediated immune responses to VZV is observed in elderly and immunocompromised patients, which is the major precipitant for VZV reactivation. Immunocompromised patients who lack adequate VZV-specific cellular immune responses are at risk for episodes of reactivation and disseminated disease, which can be fatal. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Importance of cell-mediated immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical trials have demonstrated that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"       zoster vaccine",
"      </a>",
"      reduces the incidence of zoster and post-herpetic neuralgia in immunocompetent hosts. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical trial data on zoster vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend zoster vaccination in individuals who are 60 years of age or older to decrease the risk of zoster and postherpetic neuralgia. (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Preliminary data also suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"       zoster vaccine",
"      </a>",
"      is effective in reducing the incidence of zoster and preventing post-herpetic neuralgia in persons 50 to 59 years of age.",
"     </li>",
"     <li>",
"      Serologic testing for past exposure is not required prior to immunization. (See",
"      <a class=\"local\" href=\"#H4542627\">",
"       'Serologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"       Zoster vaccine",
"      </a>",
"      is not advised for use in patients with primary or acquired immunodeficiencies, pregnant women, or in those with a history of an anaphylactic reaction to gelatin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4542502\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/1\">",
"      Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/shingles/about/transmission.html (Accessed on June 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/3\">",
"      Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 1988; 158:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/4\">",
"      Yoshikawa T, Ihira M, Suzuki K, et al. Rapid contamination of the environments with varicella-zoster virus DNA from a patient with herpes zoster. J Med Virol 2001; 63:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/5\">",
"      Viner K, Perella D, Lopez A, et al. Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings. J Infect Dis 2012; 205:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/6\">",
"      Lopez AS, Burnett-Hartman A, Nambiar R, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008; 197:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/7\">",
"      Mehta SK, Tyring SK, Gilden DH, et al. Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis 2008; 197:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/8\">",
"      Breuer J. Herpes zoster: new insights provide an important wake-up call for management of nosocomial transmission. J Infect Dis 2008; 197:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/9\">",
"      Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis 2010; 201:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/10\">",
"      Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/11\">",
"      Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/12\">",
"      Ljungman P, L&ouml;nnqvist B, Gahrton G, et al. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986; 153:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/13\">",
"      Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/14\">",
"      Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/15\">",
"      Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis 2013; 56:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/16\">",
"      Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/17\">",
"      Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2012; 10:CD008858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/18\">",
"      Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/19\">",
"      Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/20\">",
"      Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011; 60:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/22\">",
"      Gilden DH. Varicella-zoster virus vaccine--grown-ups need it, too. N Engl J Med 2005; 352:2344.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi.pdf (Accessed on December 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/24\">",
"      Mitka M. FDA approves shingles vaccine: herpes zoster vaccine targets older adults. JAMA 2006; 296:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/25\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007-September 2008. Ann Intern Med 2007; 147:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/26\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009*. Ann Intern Med 2009; 150:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/27\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2010. Ann Intern Med 2010; 152:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/28\">",
"      Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012; 206:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/29\">",
"      Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther 2006; 48:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/30\">",
"      Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/31\">",
"      Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/32\">",
"      Koplan JP, Harpaz R. Shingles vaccine: effective and costly or cost-effective? Ann Intern Med 2006; 145:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/33\">",
"      Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010; 152:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/34\">",
"      Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK. Acute retinal necrosis after herpes zoster vaccination. Arch Ophthalmol 2011; 129:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/35\">",
"      Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010; 51:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/36\">",
"      Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/37\">",
"      Hurley LP, Lindley MC, Harpaz R, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med 2010; 152:555.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccines/vac-gen/shortages/default.htm#5 (Accessed on December 13, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/PDF/rr/rr5705.pdf (Accessed on April 05, 2011).",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00851786 (Accessed on April 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/41\">",
"      Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/42\">",
"      Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/43\">",
"      Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36200/abstract/44\">",
"      Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8343 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36200=[""].join("\n");
var outline_f35_22_36200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISSUES OF INFECTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542988\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542995\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMPORTANCE OF CELL-MEDIATED IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4543175\">",
"      Immunity and risk of reactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4543182\">",
"      Boosting of T-cell specific immunity to VZV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H213071756\">",
"      Depression and cell-mediated immunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL TRIAL DATA ON ZOSTER VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adults &ge;60 years of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7023178\">",
"      Adults 50 to 59 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RECOMMENDATIONS FOR USE OF ZOSTER VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542488\">",
"      General recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4543250\">",
"      Formulation and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542627\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542495\">",
"      Use in patients with prior zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542502\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4543280\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542575\">",
"      Transmission of vaccine virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542811\">",
"      Barriers to use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION OF ZOSTER IN IMMUNOSUPPRESSED HOSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542909\">",
"      Vaccination before immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542928\">",
"      Prevention of zoster reactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4542935\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23747684\">",
"      Patients with rheumatic and inflammatory bowel diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213071710\">",
"      INACTIVATED VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VARICELLA VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/77?source=related_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13507?source=related_link\">",
"      Patient information: Shingles (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/0/14338?source=related_link\">",
"      Patient information: Shingles (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=related_link\">",
"      Prevention and control of varicella in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_22_36201="Immunology of the maternal-fetal interface";
var content_f35_22_36201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunology of the maternal-fetal interface",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36201/contributors\">",
"     Vikki M Abrahams, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36201/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36201/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36201/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36201/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/22/36201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnant women, local adaptation of the maternal immune system allows for successful coexistence between the mother and the semi-allograft that is the",
"    <span class=\"nowrap\">",
"     fetus/placenta",
"    </span>",
"    expressing both maternal (self) and paternal (nonself) genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Cytotoxic adaptive immune responses are diminished, bypassed, or even abrogated, while regulatory adaptive immunity is enhanced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. By contrast, innate (natural) immunity remains intact, serving two purposes: 1. to continue to provide host defense against infection; and 2. to interact with fetal tissues to promote successful placentation and pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/2,6-9\">",
"     2,6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An introduction to the immunology of pregnancy and the maternal-fetal interface is presented here. Basic immunologic concepts are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFENSE MECHANISMS OF THE PLACENTA AND EXTRAPLACENTAL MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta and fetal membranes are directly exposed to maternal blood and tissues. Thus, unique features of the cells that comprise this interface must underlie the remarkable ability of the genetically distinct fetal tissue to inhabit the maternal host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fetal trophoblast cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal trophoblast cells are the specific cell layer that protects the embryo from those components of the maternal immune system dedicated to destroying foreign tissues. The inner cell mass and resultant embryo are secluded and protected beneath a layer of trophoblastic cells throughout pregnancy.",
"   </p>",
"   <p>",
"    Trophoblast cells are derived from the external trophectoderm layer of the blastocyst and develop into the placenta. Precursor trophoblast cells choose one of three developmental pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They may remain quiescent in the villi as a pool of cells for future needs (villous cytotrophoblast cells).",
"     </li>",
"     <li>",
"      They may proliferate and",
"      <span class=\"nowrap\">",
"       migrate/invade",
"      </span>",
"      into the decidua, ultimately forming the chorion membrane (extravillous cytotrophoblast cells). Extravillous trophoblast cells may also invade into the maternal spiral arteries, replacing the endothelial layer (endovascular trophoblast).",
"     </li>",
"     <li>",
"      They may merge into the developing syncytiotrophoblast cell layer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43175?source=see_link\">",
"     \"Fetal membranes: Anatomy and biochemistry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These subpopulations are variably exposed to maternal hematopoietic elements in the decidua (extravillous cytotrophoblast cells, chorion membrane cytotrophoblasts, and endovascular trophoblasts) and in maternal blood flowing over the fetal surface of the placenta (syncytiotrophoblasts). Certain trophoblast cells (villous cytotrophoblast cells) are only rarely exposed to maternal blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Placental membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta and its attached membranes have the ability to protect themselves from maternal immune cell attack. The mechanisms utilized vary with the state of differentiation and anatomic location of the trophoblast cells. This cell type, which protects the embryo itself as well as certain components of the extraembryonic membranes that are derived from the inner cell mass, such as the amnion membrane, relies upon multiple strategies to avoid maternal immune cells and antibody-mediated cell destruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Specific protective mechanisms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Altered HLA expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary cellular immune response that develops against transplanted tissue is directed against the major histocompatibility complex (MHC) proteins on donor tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/10\">",
"     10",
"    </a>",
"    ]. In humans, the MHC proteins are called human leukocyte antigens (HLA). The proteins derived from HLA genes are not expressed codominantly on trophoblast cell membranes, unlike other cell types. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HLA class I &mdash; Strict regulation of the expression of specific HLA class I molecules in subpopulations of trophoblasts is believed to protect the fetus against maternal immune cells programmed to attack cells expressing foreign (paternal) HLA class I antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. The extravillous trophoblasts migrating into the decidua express none of the HLA-A, B class Ia antigens that are primary stimulators of graft rejection and instead display a unique pattern of HLA class Ib molecules, with HLA-E, -F and &ndash;G predominating. The genes encoding HLA-G and HLA&ndash;E antigens have few alleles in comparison to HLA-A and HLA-B. HLA-G and -E may dampen the immune response by interacting with leukocyte inhibitory receptors (LIRs) on uterine natural killer (NK) cells and macrophages and with the T cell receptor on CD8+ cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/1,11-15\">",
"       1,11-15",
"      </a>",
"      ]. The consequences of these interactions include activation of pathways in NK cells and macrophages that interfere with the killer functions of these cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. One HLA class Ia antigen, HLA-C, is expressed on extravillous trophoblast, and may have important interactions with leukocytes in some mothers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The",
"      <span class=\"nowrap\">",
"       Fas/Fas",
"      </span>",
"      ligand pathway for killing of activated T cells via apoptosis, which was first identified for other soluble HLA class I molecules, has also been documented for a soluble isoform of HLA-G [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. Antigen presenting cells expressing either a soluble or membrane-bound form of HLA-G repress T cell alloproliferation via this pathway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/21\">",
"       21",
"      </a>",
"      ]. Soluble HLA-G, now termed HLA-G5, has been identified in maternal serum, is biochemically unique among the HLA-G isoforms, and is associated with desirable immune suppression in both pregnancy and graft transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/22-25\">",
"       22-25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In contrast to migrating extravillous cells, syncytiotrophoblast forming the outermost layer of the placental villi that is exposed to maternal blood, does not express membrane-bound HLA class I antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/26\">",
"       26",
"      </a>",
"      ]. Syncytiotrophoblast in term placentas lacks HLA class IA mRNA (HLA-A, -B, and -C) and membrane bound protein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/1,11-15\">",
"       1,11-15",
"      </a>",
"      ]. However, there is evidence for HLA class IB (HLA-E, -F, and -G) HLA-G5 mRNA and antigens in this continuous cell layer both early and late in pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/11-13,23,27,28\">",
"       11-13,23,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HLA class II &mdash;The genes that encode potentially dangerous, paternally-derived foreign HLA class II HLA-D region molecules are entirely repressed in trophoblast cells; none of the trophoblast subpopulations express HLA class II antigens either in vivo or in vitro. Control over transcription of class II genes may be exerted by a trophoblast-specific repressor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      B7 family &mdash; Members of the B7 family of costimulatory molecules that have both lymphocyte stimulatory and inhibitory functions are expressed on trophoblast cells in human placentas. The B7H1 protein, which has lymphocyte inhibitory properties, is uniquely expressed on syncytiotrophoblast and therefore positioned to interfere with activation of lymphocytes circulating in maternal blood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IDO &mdash; Trophoblast cells produce indoleamine 2,3-dioxygenase (IDO), which depletes tryptophan by promoting its catabolism. This is believed to inactivate T cells since they require tryptophan. Strong evidence supporting the importance of this potential mechanism remains to be acquired for human trophoblast. Although IDO is clearly important to survival of the mouse embryo, studies in",
"      <span class=\"nowrap\">",
"       IDO-/-knockout",
"      </span>",
"      mice have failed to reveal any impact on pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TNF superfamily &mdash; Apoptosis-inducing members of the tumor necrosis factor (TNF) supergene family may also have important roles in protecting the placenta and its membranes by inducing apoptosis in potentially cytotoxic T cells. The ligands identified in",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      on human trophoblasts include TNFalpha, Fas ligand (FasL), and TNF-related apoptosis-inducing ligand (TRAIL) as well as a number of less well-characterized TNF superfamily members [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. Some of these latter ligands, which include B cell activating factor (BAFF), may positively influence pregnancy host defenses by supporting maternal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fetal antibody production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/36\">",
"       36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These molecules, which are expressed in both membrane and soluble forms, can kill activated immune cells that bind to the trophoblast by transducing an apoptotic signal via specific receptors on activated leukocytes. FasL may be of particular importance, since FasL prevents immune cell attack by interacting with leukocyte receptors (eg, Fas) in other organs such as the eye and the testis. Studies have shown that the trophoblast secretes active FasL via exosomes and microvesicles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Placental-derived microparticles, such as microvesicles and exosomes that contain an array of placental proteins, mRNA, and microRNAs, are thought to play a role in regulating the maternal immune system during pregnancy. Their release is increased and altered under certain pathologic conditions, and as such they may be involved in the pathogenesis of pregnancy complications such as preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all immunologists studying reproduction agree that maternal immunity is solely antagonistic to trophoblast tissue; alternative views have been expressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], some of which are described below. Evidence of the opposite hypothesis, ie, that trophoblasts have offensive mechanisms for killing maternal lymphocytes, is also lacking. It is clear, however, that the placenta is normally protected from the killing functions of maternal cells. This protection may result from synthesis of soluble receptors (TNFalpha), display of non-functional receptors (Fas), and expression of decoy receptors (TRAIL DcR1, DcR2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/34,35,44,45\">",
"     34,35,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Soluble immunomodulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal immune modulation during pregnancy is also conferred by the synthesis of immunosuppressive molecules. As examples, the human placenta produces progesterone, prostaglandin E2, and antiinflammatory cytokines, such as interleukin-10 (IL-10) and IL-4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/1,14,15,46,47\">",
"     1,14,15,46,47",
"    </a>",
"    ]. Progesterone may drive placental production of these antiinflammatory cytokines in placental cells just as it does in lymphocytes; for example, IL-10 appears to stimulate production of HLA-G [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/48\">",
"     48",
"    </a>",
"    ], and this pathway may be important in a common problem of pregnancy, preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/49\">",
"     49",
"    </a>",
"    ]. Studies using",
"    <span class=\"nowrap\">",
"     IL-10-/-knockout",
"    </span>",
"    mice have highlighted the potentially important protective role for this cytokine in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/50\">",
"     50",
"    </a>",
"    ]. Soluble thymic stromal lymphopoietin (TSLP) may also play a role. TSLP secreted by trophoblast cells stimulates decidual dendritic cells (dDCs) to produce IL-10 and CCL-17 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/51\">",
"     51",
"    </a>",
"    ]. These activated dDCs induce Th2 differentiation of decidual T cells. Lower levels of TSLP are seen in miscarriage than in normal pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Complement proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trophoblast cells express high levels of the following complement regulatory proteins: CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF), and CD59 (membrane inhibitor of reactive lysis, MIRL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Complement regulatory proteins are critically important for protecting the extraembryonic tissues from maternal anti-paternal cytotoxic antibodies, since complement activation leads to opsonization and destruction of the immunologic target (the fetal cells). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mothers routinely produce high titers of antibodies to paternally-derived HLA and unique trophoblast antigens, such as the unique placental isoform of alkaline phosphatase. Antibody induction of complement mediated lysis is prevented by high expression of CD46 and DAF in various subpopulations of trophoblast cells.",
"   </p>",
"   <p>",
"    Evidence supporting a role for complement proteins in placental immune privilege is provided by genetic deletion experiments. In mice, the absence of the complement regulatory protein derived from Crry gene leads to placental disruption due to complement deposition in the placenta and lysis of cells at the implantation site, followed by a massive inflammatory reaction and fetal demise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMMUNE ADAPTATION AND THE PREGNANT UTERUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dramatic changes take place in the uterus during pregnancy that also help contribute to immune acceptance of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cross-talk with the",
"    <span class=\"nowrap\">",
"     fetus/placenta.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differences in lymphocyte populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    first histologically apparent maternal immunologic adjustment to the embryo is a dramatic change in the relative proportions of leukocyte subpopulations in the uterus. T and B cells become scarce and the uterine natural killer (NK) cell population shifts from endometrial (uterine) NK cells to decidual NK cells. Invading fetal trophoblasts become admixed with decidual NK cells, macrophages, and dendritic cells that account for approximately 70, 20, and 2 percent respectively, of all cells in the decidua [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decidual macrophages may help to prevent some uterine infections in pregnant women. However, some studies suggest trophoblast-macrophage cross-talk is more important for promoting normal placentation. Decidual macrophages produce immunosuppressive factors, can limit inflammatory responses at the maternal-fetal interface, and may facilitate vascular remodeling and tissue homeostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/8,58-60\">",
"     8,58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, the major roles of decidual NK cells may also be unique to pregnancy. Decidual NK cells have decreased cytotoxicity, and instead appear to play a role in trophoblast attraction and invasion, decidual and placental angiogenesis and possibly fetal vasculogenesis, and vascular modifications in the uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/60-71\">",
"     60-71",
"    </a>",
"    ]. Alterations in decidual NK cell numbers and activation status may play a role in pregnancy complications such as immunologic infertility and recurrent spontaneous abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Consequently, there have been efforts targeting NK cells in an attempt to cure infertility and miscarriage. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of decidual dendritic cells is less clear, although mouse studies have demonstrated these cells are critical for successful implantation and may also be involved in remodeling of the maternal vasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/5,77,78\">",
"     5,77,78",
"    </a>",
"    ]. An alternative view is that dendritic cells may be trapped in the decidua to prevent the exposure of peripheral T cells to fetal antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gamma-delta T cells and a population of double negative T lymphocytes",
"    <span class=\"nowrap\">",
"     (CD4-/CD8-)",
"    </span>",
"    have been reported in pregnant uteri [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Their roles are unclear, although immunosuppressive gamma-delta T cells may play a role in regulating the maternal immune system to protect the maternal-fetal interface from aggressive immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regulatory T cells (Treg) are also present in the decidua of normal pregnant women and their presence and expansion during pregnancy is thought to be triggered in both alloantigen-dependent and &ndash;independent manners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/4,83\">",
"     4,83",
"    </a>",
"    ]. These fetal-specific Tregs persist after delivery and rapidly reaccumulate during subsequent pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/84\">",
"     84",
"    </a>",
"    ]. In a mouse model, increased numbers of Tregs are seen in response to an antigenic fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/85\">",
"     85",
"    </a>",
"    ]. Selective killing of these Tregs results in fewer antigenic offspring. There are decreased numbers of peripheral blood and decidual Treg cells in women with preeclampsia compared with normal pregnancy subjects. These findings suggest that Treg cells play a role in maternal tolerance to the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Preeclampsia is also associated with persistence of decidual basalis macrophages and recruitment of dendritic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Soluble immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine immune regulation is also provided by the induction of immunosuppressive molecules that permeate the uterine environment. These principally include progesterone, prostaglandins, and some cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone, the dominant hormone of pregnancy, is initially produced by the corpus luteum; subsequently, the placenta is responsible for almost all progesterone synthesis.",
"   </p>",
"   <p>",
"    High concentrations of progesterone can suppress the maternal immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/90\">",
"     90",
"    </a>",
"    ]. As an example, progesterone alters the",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    balance and inhibits production of TNF-alpha in both mouse and human macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Prostaglandin E2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandin E2 (PGE2) is produced by resident macrophages and decidual cells. Lymphocytes proliferate poorly in the presence of this compound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;High levels of T helper-2 (Th2)-type cytokines are typical of mouse pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], but are less definitive in pregnant women. Nonetheless, many still consider human pregnancy to be a Th2 antiinflammatory condition, and that a shift towards Th1 cytokines will lead to abortion or pregnancy complications. As an example, elevated levels of interleukin-6 (IL-6) in cervicovaginal and amniotic fluid, but not plasma, was associated with spontaneous preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/95\">",
"     95",
"    </a>",
"    ]. While disruption in cytokine profiles during pregnancy may be detrimental, it is important to appreciate that pregnancy is both proinflammatory and antiinflammatory, depending upon the stage of gestation, rather than focusing on the",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    terminology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/2,83,96\">",
"     2,83,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MATERNAL SYSTEMIC IMMUNE RESPONSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current consensus is that there is little or no generalized depression of maternal immune responses in pregnancy. However, selective suppression or modulation may occur. Although multiparous women are excellent sources of antibodies to paternal HLA, maternal B lymphocytes specific for paternal HLA are partially deleted during pregnancy. In addition, T lymphocytes specific for paternal HLA are difficult to demonstrate. Results in transgenic mice suggest that pregnancy selectively depresses maternal T cells that recognize paternal H-2 class I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are at least two mechanisms for overcoming most immune reactions: one is active suppression and the other is enhanced tolerance. Enhanced tolerance has been clearly demonstrated in normal pregnancy. Regulatory T cells, which are critical mediators of tolerance, become more numerous in pregnancy in response to the introduction of fetal (paternal) antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/98-101\">",
"     98-101",
"    </a>",
"    ]. These regulatory T cells produce IL-10, which appears to play a role in maintaining pregnancy. In animals, IL-10 blockade increased the rate of abortions, although successful pregnancy was still possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     IMMUNE FACTORS IN EARLY PREGNANCY TERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 50 percent of potential pregnancies are lost prior to or during implantation, based upon the identification of chorionic gonadotropin (hCG) in women. Whether any of these losses can be accurately attributed to an immunologic cause (ie, based on maternal recognition and rejection of normal embryos expressing paternal antigens) is unclear. In contrast, recurrent embryonic losses due to genetic and endocrine abnormalities are well documented, as are miscarriages due to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Implantation and maternal immunorejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Programming the uterus for semiallogeneic pregnancy may occur with the introduction of semen, as demonstrated in the mouse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/105\">",
"     105",
"    </a>",
"    ]. Subsequently, assuming that the implanted blastocyst is intact and fully competent to develop into a fetus, the embryo should be entirely protected by trophoblasts via the proposed mechanisms previously described. However, in some women in whom the blastocyst is genetically abnormal, exposed paternally-derived antigens may be detected, resulting in a graft rejection response. A secondary immune response would be expected to cause early rejection in cases of recurrent spontaneous abortion.",
"   </p>",
"   <p>",
"    Alternatively, some mothers with recurrent spontaneous abortions may lack essential components of the networks that provide immunologic protection to the embryos, such as appropriate expression of complement regulatory proteins, apoptosis-inducing TNF superfamily members, and HLA-G or HLA-E. These and other aspects of infertility, such as the impact of endocrine disrupters, such as herbicides and industrial chemicals, are not well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interruption of pregnancy, by a variety of mechanisms, is most common during the periimplantation period. Infection of the decidua, placenta, and membranes appears to be one cause of early pregnancy loss and preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. Infection at the maternal-fetal interface may directly activate the trophoblast to generate either a proinflammatory or proapoptotic response that in turn may lead to a disruption in the normal distribution, phenotype, and function of the decidual immune cells. Similarly, infection may impact the function of gestational tissues and cell types. The pathways leading from infection to preterm labor are not completely understood, although there is increasingly evidence to suggest that innate immune receptors, such as Toll-like receptors and Nod-like receptors, may play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/2,110,111\">",
"     2,110,111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recurrent pregnancy loss and leukocyte immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization of potential mothers with paternal or third-party leukocytes to improve reproductive success was, in the past, a popular method of putatively improving live birth rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/112\">",
"     112",
"    </a>",
"    ]. This strategy developed because homozygosity within couples, particularly at some HLA loci, is associated with modestly reduced fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Thus, leukocyte immunization was thought to introduce a needed measure of immune recognition and stimulation. However, a multicenter study showed conclusively that leukocyte immunization was",
"    <strong>",
"     not",
"    </strong>",
"    effective and strongly suggested that reproductive outcomes might be worsened rather than improved by this intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/115\">",
"     115",
"    </a>",
"    ]. In addition, a randomized clinical trial of intravenous immunoglobulin treatment in women with repeated unexplained in vitro fertilization failure found no improvement in the live birth rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10931824\">",
"    <span class=\"h2\">",
"     Placental immune effects in antiphospholipid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) are at high risk for recurrent spontaneous miscarriage and late pregnancy complications, such as preeclampsia, preterm labor, and IUGR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/117\">",
"     117",
"    </a>",
"    ]. In vivo animal studies have shown that aPL target the trophoblast and decidua and trigger elevated local and systemic tumor necrosis factor alpha (TNFa) levels, elevated tissue factor expression and complement C3 deposition within the decidua, and a neutrophilic infiltration in the decidua [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/118-123\">",
"     118-123",
"    </a>",
"    ]. Blocking the complement pathway or tissue factor prevents aPL-mediated pregnancy failure and the associated inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/118,120,121\">",
"     118,120,121",
"    </a>",
"    ], suggesting that pregnancy failure in APS patients is a result of inflammation rather than thrombosis at the maternal-fetal interface. Studies using human first trimester trophoblast have demonstrated that aPL trigger an inflammatory response via the Toll-like receptor 4",
"    <span class=\"nowrap\">",
"     (TLR4)/MyD88",
"    </span>",
"    signaling pathway. In addition, aPL inhibit the trophoblast&rsquo;s constitutive IL-6 production and migration independent of the",
"    <span class=\"nowrap\">",
"     TLR4/MyD88",
"    </span>",
"    pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/124,125\">",
"     124,125",
"    </a>",
"    ] and alter the cell's angiogenic factor production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/126\">",
"     126",
"    </a>",
"    ]. Thus, aPL may directly alter trophoblast function and induce placental inflammation through innate immune pathways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FETAL IMMUNE SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contributions of the fetal immune system to maternal-fetal immunologic interactions are not well understood. Some evidence suggests that the fetal immune system is unable to mount an anti-maternal immune response until mid to late pregnancy. As an example, placental macrophages do not express HLA class II antigens until the second trimester; therefore they are incapable of acting as fully effective antigen presenting cells until this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/127\">",
"     127",
"    </a>",
"    ]. In contrast, another study showed that fetal T cells were highly responsive to stimulation but were biased towards developing into regulatory T cells, which are important in tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Immunoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin G (IgG) is transferred transplacentally from the mother to the fetus during the third trimester, although other classes of immunoglobulins are not under normal circumstances. Maternal IgG antibodies are usually beneficial to the infant, but certain maternal antibodies may result in disease in the newborn infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/129\">",
"     129",
"    </a>",
"    ]. Transplacental immunoglobulin transfer is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41544?source=see_link&amp;anchor=H2#H2\">",
"     \"Transient hypogammaglobulinemia of infancy\", section on 'Immunoglobulin levels in infancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41256?source=see_link&amp;anchor=H26#H26\">",
"     \"Placental development and physiology\", section on 'Immunoglobulin G transfer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although much is now known of the immunologic conditions that lead to successful pregnancy, much remains to be learned. Promising areas of research include the involvement of HLA-G in angiogenesis and autoimmune disorders, and the effect of complement activation on dysregulation of angiogenesis leading to intrauterine fetal growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/130-132\">",
"     130-132",
"    </a>",
"    ]. Utilization of new genomics and proteomics techniques may assist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/133\">",
"     133",
"    </a>",
"    ]. Manipulation of innate immune processes may also provide new avenues for therapeutics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36201/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of immune rejection of the fetus requires local immunologic adaptations within the mother, resulting in a state in which cytotoxic adaptive immune responses are diminished, bypassed, or even abrogated, while regulatory adaptive immunity is enhanced. In contrast, innate (natural) immunity remains intact, serving two purposes: 1. to continue to provide host defense against infection and 2. to interact with fetal tissues to promote successful placentation and pregnancy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Trophoblast cells protect the embryo itself and certain components of the extraembryonic membranes. Multiple strategies are used by these cells to avoid maternal immune cells and antibody-mediated cell destruction, including altered HLA expression, synthesis of immunosuppressive molecules, and expression of high levels of complement regulatory proteins that protect the extraembryonic tissues from maternal anti-paternal cytotoxic antibodies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Defense mechanisms of the placenta and extraplacental membranes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine changes during pregnancy also help contribute to maternal immune adaptation, including alterations in the relative proportions, phenotype, and functions of leukocyte subpopulations, induction of immunosuppressive molecules (progesterone, prostaglandins), and changes in cytokine profiles across gestation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Immune adaptation and the pregnant uterus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Loss of potential pregnancies prior to or during implantation is common. Causes include genetic and endocrine abnormalities and autoantibodies, such as antiphospholipid antibodies. It is unclear if any of these losses can be accurately attributed to infection. However, insults such as infection and antiphospholipid antibodies can alter normal placental function and mechanisms of immune tolerance, and can disrupt the normal trophoblast-maternal immune system crosstalk, resulting in adverse pregnancy outcomes such as preterm labor and preeclampsia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Immune factors in early pregnancy termination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/1\">",
"      Hunt JS. Stranger in a strange land. Immunol Rev 2006; 213:36.",
"     </a>",
"    </li>",
"    <li>",
"     Mor G, Abrahams VM. The immunology of pregnancy. In: Creasy and Resnik's maternal-fetal medicine: Principles and practice, 6th ed, Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore TR (Eds), Elsevier, 2009. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/3\">",
"      Robertson SA. Immune regulation of conception and embryo implantation-all about quality control? J Reprod Immunol 2010; 85:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/4\">",
"      Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update 2009; 15:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/5\">",
"      Leber A, Teles A, Zenclussen AC. Regulatory T cells and their role in pregnancy. Am J Reprod Immunol 2010; 63:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/6\">",
"      Barrientos G, Tirado-Gonz&aacute;lez I, Klapp BF, et al. The impact of dendritic cells on angiogenic responses at the fetal-maternal interface. J Reprod Immunol 2009; 83:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/7\">",
"      Dekel N, Gnainsky Y, Granot I, Mor G. Inflammation and implantation. Am J Reprod Immunol 2010; 63:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/8\">",
"      Nagamatsu T, Schust DJ. The contribution of macrophages to normal and pathological pregnancies. Am J Reprod Immunol 2010; 63:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/9\">",
"      Zhang J, Chen Z, Smith GN, Croy BA. Natural killer cell-triggered vascular transformation: maternal care before birth? Cell Mol Immunol 2011; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/10\">",
"      Tilburgs T, Scherjon SA, Claas FH. Major histocompatibility complex (MHC)-mediated immune regulation of decidual leukocytes at the fetal-maternal interface. J Reprod Immunol 2010; 85:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/11\">",
"      Le Bouteiller P, Mallet V. HLA-G and pregnancy. Rev Reprod 1997; 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/12\">",
"      Hunt JS, Orr HT. HLA and maternal-fetal recognition. FASEB J 1992; 6:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/13\">",
"      Hunt JS, Langat DK, McIntire RH, Morales PJ. The role of HLA-G in human pregnancy. Reprod Biol Endocrinol 2006; 4 Suppl 1:S10.",
"     </a>",
"    </li>",
"    <li>",
"     Petroff MG, Hunt JS. Immunity at the maternal-fetal interface. In: Mucosal immunology, 3rd ed, Mestecky J, Lamm ME, Strober W, et al (Eds), Academic Press, New York 2005. p.1735.",
"    </li>",
"    <li>",
"     Hunt JS, McIntire RH, Petroff MG. Immunobiology of human pregnancy. In: Knobil and Neill's physiology of reproduction, 3rd ed, Neill JD (Ed), Elsevier/Academic Press, St. Louis 2006. Vol 2, p.2759.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/16\">",
"      Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/17\">",
"      Shakhawat A, Shaikly V, Elzatma E, et al. Interaction between HLA-G and monocyte/macrophages in human pregnancy. J Reprod Immunol 2010; 85:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/18\">",
"      Zavazava N, Kr&ouml;nke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 1996; 2:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/19\">",
"      Zavazava N. Soluble HLA class I molecules: biological significance and clinical implications. Mol Med Today 1998; 4:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/20\">",
"      Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000; 164:6100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/21\">",
"      Naji A, Durrbach A, Carosella ED, Rouas-Freiss N. Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. Hum Immunol 2007; 68:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/22\">",
"      Hunt JS, Jadhav L, Chu W, et al. Soluble HLA-G circulates in maternal blood during pregnancy. Am J Obstet Gynecol 2000; 183:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/23\">",
"      Morales PJ, Pace JL, Platt JS, et al. Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells. Immunology 2007; 122:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/24\">",
"      Pfeiffer KA, Rebmann V, P&auml;ssler M, et al. Soluble HLA levels in early pregnancy after in vitro fertilization. Hum Immunol 2000; 61:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/25\">",
"      Lila N, Carpentier A, Amrein C, et al. Implication of HLA-G molecule in heart-graft acceptance. Lancet 2000; 355:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/26\">",
"      Hunt JS, Fishback JL, Andrews GK, Wood GW. Expression of class I HLA genes by trophoblast cells. Analysis by in situ hybridization. J Immunol 1988; 140:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/27\">",
"      Hunt JS, Fishback JL, Chumbley G, Loke YW. Identification of class I MHC mRNA in human first trimester trophoblast cells by in situ hybridization. J Immunol 1990; 144:4420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/28\">",
"      Chu W, Fant ME, Geraghty DE, Hunt JS. Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-gamma-activated macrophages but not placental fibroblasts. Hum Immunol 1998; 59:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/29\">",
"      Murphy SP, Tomasi TB. Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression. Mol Reprod Dev 1998; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/30\">",
"      Petroff MG, Chen L, Phillips TA, et al. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod 2003; 68:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/31\">",
"      Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/32\">",
"      Hunt JS, Chen HL, Miller L. Tumor necrosis factors: pivotal components of pregnancy? Biol Reprod 1996; 54:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/33\">",
"      Runic R, Lockwood CJ, Ma Y, et al. Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endocrinol Metab 1996; 81:3119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/34\">",
"      Phillips TA, Ni J, Pan G, et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J Immunol 1999; 162:6053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/35\">",
"      Phillips TA, Ni J, Hunt JS. Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines. Placenta 2001; 22:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/36\">",
"      Phillips TA, Ni J, Hunt JS. Cell-specific expression of B lymphocyte (APRIL, BLyS)- and Th2 (CD30L/CD153)-promoting tumor necrosis factor superfamily ligands in human placentas. J Leukoc Biol 2003; 74:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/37\">",
"      Abrahams VM, Straszewski-Chavez SL, Guller S, Mor G. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. Mol Hum Reprod 2004; 10:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/38\">",
"      Fr&auml;ngsmyr L, Baranov V, Nagaeva O, et al. Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol Hum Reprod 2005; 11:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/39\">",
"      Mincheva-Nilsson L, Baranov V. The role of placental exosomes in reproduction. Am J Reprod Immunol 2010; 63:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/40\">",
"      Redman CW, Sargent IL. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 2008; 29 Suppl A:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/41\">",
"      Holder BS, Tower CL, Forbes K, et al. Immune cell activation by trophoblast-derived microvesicles is mediated by syncytin 1. Immunology 2012; 136:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/42\">",
"      Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/43\">",
"      Mor G, Romero R, Aldo PB, Abrahams VM. Is the trophoblast an immune regulator? The role of Toll-like receptors during pregnancy. Crit Rev Immunol 2005; 25:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/44\">",
"      Austgulen R, Johnsen H, Kj&oslash;llesdal AM, et al. Soluble receptors for tumor necrosis factor: occurrence in association with normal delivery at term. Obstet Gynecol 1993; 82:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/45\">",
"      Payne SG, Smith SC, Davidge ST, et al. Death receptor Fas/Apo-1/CD95 expressed by human placental cytotrophoblasts does not mediate apoptosis. Biol Reprod 1999; 60:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/46\">",
"      Denison FC, Kelly RW, Calder AA, Riley SC. Cytokine secretion by human fetal membranes, decidua and placenta at term. Hum Reprod 1998; 13:3560.",
"     </a>",
"    </li>",
"    <li>",
"     Hunt JS. Cytokine networks in the human placenta. In: Cytokines in human reproduction, Hill JA (Ed), Wiley-Liss, New York 1999. p.203.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/48\">",
"      Moreau P, Adrian-Cabestre F, Menier C, et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999; 11:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/49\">",
"      Hennessy A, Pilmore HL, Simmons LA, Painter DM. A deficiency of placental IL-10 in preeclampsia. J Immunol 1999; 163:3491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/50\">",
"      Thaxton JE, Sharma S. Interleukin-10: a multi-faceted agent of pregnancy. Am J Reprod Immunol 2010; 63:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/51\">",
"      Guo PF, Du MR, Wu HX, et al. Thymic stromal lymphopoietin from trophoblasts induces dendritic cell-mediated regulatory TH2 bias in the decidua during early gestation in humans. Blood 2010; 116:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/52\">",
"      Hsi BL, Hunt JS, Atkinson JP. Differential expression of complement regulatory proteins on subpopulations of human trophoblast cells. J Reprod Immunol 1991; 19:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/53\">",
"      Holmes CH, Simpson KL, Okada H, et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 1992; 22:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/54\">",
"      Xu C, Mao D, Holers VM, et al. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000; 287:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/55\">",
"      Bulmer JN, Pace D, Ritson A. Immunoregulatory cells in human decidua: morphology, immunohistochemistry and function. Reprod Nutr Dev 1988; 28:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/56\">",
"      Gardner L, Moffett A. Dendritic cells in the human decidua. Biol Reprod 2003; 69:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/57\">",
"      King A, Wellings V, Gardner L, Loke YW. Immunocytochemical characterization of the unusual large granular lymphocytes in human endometrium throughout the menstrual cycle. Hum Immunol 1989; 24:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/58\">",
"      Abrahams VM, Kim YM, Straszewski SL, et al. Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol 2004; 51:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/59\">",
"      Fest S, Aldo PB, Abrahams VM, et al. Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol 2007; 57:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/60\">",
"      Harris LK. Review: Trophoblast-vascular cell interactions in early pregnancy: how to remodel a vessel. Placenta 2010; 31 Suppl:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/61\">",
"      Croy BA, Luross JA, Guimond MJ, Hunt JS. Uterine natural killer cells: insights into lineage relationships and functions from studies of pregnancies in mutant and transgenic mice. Nat Immun 1997; 15:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/62\">",
"      Parr EL, Chen HL, Parr MB, Hunt JS. Synthesis and granular localization of tumor necrosis factor-alpha in activated NK cells in the pregnant mouse uterus. J Reprod Immunol 1995; 28:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/63\">",
"      Stallmach T, Ehrenstein T, Isenmann S, et al. The role of perforin-expression by granular metrial gland cells in pregnancy. Eur J Immunol 1995; 25:3342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/64\">",
"      Allen MP, Nilsen-Hamilton M. Granzymes D, E, F, and G are regulated through pregnancy and by IL-2 and IL-15 in granulated metrial gland cells. J Immunol 1998; 161:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/65\">",
"      Hunt JS, Miller L, Vassmer D, Croy BA. Expression of the inducible nitric oxide synthase gene in mouse uterine leukocytes and potential relationships with uterine function during pregnancy. Biol Reprod 1997; 57:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/66\">",
"      Le Bouteiller P, Tabiasco J. Killers become builders during pregnancy. Nat Med 2006; 12:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/67\">",
"      Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/68\">",
"      Tabiasco J, Rabot M, Aguerre-Girr M, et al. Human decidual NK cells: unique phenotype and functional properties -- a review. Placenta 2006; 27 Suppl A:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/69\">",
"      Karimi K, Blois SM, Arck PC. The upside of natural killers. Nat Med 2008; 14:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/70\">",
"      Yagel S. The developmental role of natural killer cells at the fetal-maternal interface. Am J Obstet Gynecol 2009; 201:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/71\">",
"      Lash GE, Robson SC, Bulmer JN. Review: Functional role of uterine natural killer (uNK) cells in human early pregnancy decidua. Placenta 2010; 31 Suppl:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/72\">",
"      Hiby SE, Walker JJ, O'shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/73\">",
"      Hiby SE, Regan L, Lo W, et al. Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage. Hum Reprod 2008; 23:972.",
"     </a>",
"    </li>",
"    <li>",
"     Management of high-risk pregnancy. In: Queenan's High-risk obstetrics, 6th ed, Queenan JT, Spong CY, Lockwood CJ (Eds), Blackwell Publishing Ltd., Malden, MA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/75\">",
"      Moffett A, Regan L, Braude P. Natural killer cells, miscarriage, and infertility. BMJ 2004; 329:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/76\">",
"      De Carolis C, Perricone C, Perricone R. NK cells, autoantibodies, and immunologic infertility: a complex interplay. Clin Rev Allergy Immunol 2010; 39:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/77\">",
"      Krey G, Frank P, Shaikly V, et al. In vivo dendritic cell depletion reduces breeding efficiency, affecting implantation and early placental development in mice. J Mol Med (Berl) 2008; 86:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/78\">",
"      Plaks V, Birnberg T, Berkutzki T, et al. Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/79\">",
"      Collins MK, Tay CS, Erlebacher A. Dendritic cell entrapment within the pregnant uterus inhibits immune surveillance of the maternal/fetal interface in mice. J Clin Invest 2009; 119:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/80\">",
"      Heyborne KD, Cranfill RL, Carding SR, et al. Characterization of gamma delta T lymphocytes at the maternal-fetal interface. J Immunol 1992; 149:2872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/81\">",
"      Ito K, Karasawa M, Kawano T, et al. Involvement of decidual Valpha14 NKT cells in abortion. Proc Natl Acad Sci U S A 2000; 97:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/82\">",
"      Mincheva-Nilsson L. Pregnancy and gamma/delta T cells: taking on the hard questions. Reprod Biol Endocrinol 2003; 1:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/83\">",
"      Mj&ouml;sberg J, Berg G, Jenmalm MC, Ernerudh J. FOXP3+ regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. Biol Reprod 2010; 82:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/84\">",
"      Rowe JH, Ertelt JM, Xin L, Way SS. Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/85\">",
"      Kahn DA, Baltimore D. Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. Proc Natl Acad Sci U S A 2010; 107:9299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/86\">",
"      Sasaki Y, Darmochwal-Kolarz D, Suzuki D, et al. Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia. Clin Exp Immunol 2007; 149:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/87\">",
"      Williams Z. Inducing tolerance to pregnancy. N Engl J Med 2012; 367:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/88\">",
"      Huang SJ, Chen CP, Schatz F, et al. Pre-eclampsia is associated with dendritic cell recruitment into the uterine decidua. J Pathol 2008; 214:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/89\">",
"      Lockwood CJ, Matta P, Krikun G, et al. Regulation of monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha and interleukin-1beta in first trimester human decidual cells: implications for preeclampsia. Am J Pathol 2006; 168:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/90\">",
"      Szekeres-Bartho J, Halasz M, Palkovics T. Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol 2009; 83:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/91\">",
"      Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol 1996; 31:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/92\">",
"      Miller L, Hunt JS. Regulation of TNF-alpha production in activated mouse macrophages by progesterone. J Immunol 1998; 160:5098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/93\">",
"      Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/94\">",
"      Lin H, Mosmann TR, Guilbert L, et al. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 1993; 151:4562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/95\">",
"      Wei SQ, Fraser W, Luo ZC. Inflammatory cytokines and spontaneous preterm birth in asymptomatic women: a systematic review. Obstet Gynecol 2010; 116:393.",
"     </a>",
"    </li>",
"    <li>",
"     Mor G. Pregnancy reconceived: what keeps a mother's immune system from treating her baby as foreign tissue? A new theory resolves the paradox. Nat Hist 2007; 116:36. file://findarticles.com/p/articles/mi_m1134/is_4_116/ai_n19187208/ (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/97\">",
"      Tafuri A, Alferink J, M&ouml;ller P, et al. T cell awareness of paternal alloantigens during pregnancy. Science 1995; 270:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/98\">",
"      Somerset DA, Zheng Y, Kilby MD, et al. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004; 112:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/99\">",
"      Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004; 5:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/100\">",
"      Zenclussen AC, Gerlof K, Zenclussen ML, et al. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 2005; 166:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/101\">",
"      Schumacher A, Wafula PO, Bertoja AZ, et al. Mechanisms of action of regulatory T cells specific for paternal antigens during pregnancy. Obstet Gynecol 2007; 110:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/102\">",
"      Chaouat G, Assal Meliani A, Martal J, et al. IL-10 prevents naturally occurring fetal loss in the CBA x DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol 1995; 154:4261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/103\">",
"      Svensson L, Arvola M, S&auml;llstr&ouml;m MA, et al. The Th2 cytokines IL-4 and IL-10 are not crucial for the completion of allogeneic pregnancy in mice. J Reprod Immunol 2001; 51:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/104\">",
"      Christiansen OB, Nielsen HS, Kolte AM. Future directions of failed implantation and recurrent miscarriage research. Reprod Biomed Online 2006; 13:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/105\">",
"      Robertson SA, O'Leary S, Armstrong DT. Influence of semen on inflammatory modulators of embryo implantation. Soc Reprod Fertil Suppl 2006; 62:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/106\">",
"      Chalubinski M, Kowalski ML. Endocrine disrupters--potential modulators of the immune system and allergic response. Allergy 2006; 61:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/107\">",
"      Martius J, Eschenbach DA. The role of bacterial vaginosis as a cause of amniotic fluid infection, chorioamnionitis and prematurity--a review. Arch Gynecol Obstet 1990; 247:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/108\">",
"      Gibbs RS, Romero R, Hillier SL, et al. A review of premature birth and subclinical infection. Am J Obstet Gynecol 1992; 166:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/109\">",
"      Cardenas I, Means RE, Aldo P, et al. Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. J Immunol 2010; 185:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/110\">",
"      Abrahams VM. Pattern recognition at the maternal-fetal interface. Immunol Invest 2008; 37:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/111\">",
"      Abrahams VM. The role of the Nod-like receptor family in trophoblast innate immune responses. J Reprod Immunol 2011; 88:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/112\">",
"      Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet 1985; 1:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/113\">",
"      Ober C, Hyslop T, Hauck WW. Inbreeding effects on fertility in humans: evidence for reproductive compensation. Am J Hum Genet 1999; 64:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/114\">",
"      Ober C, Hyslop T, Elias S, et al. Human leukocyte antigen matching and fetal loss: results of a 10 year prospective study. Hum Reprod 1998; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/115\">",
"      Ober C, Karrison T, Odem RR, et al. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet 1999; 354:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/116\">",
"      Stephenson MD, Fluker MR. Treatment of repeated unexplained in vitro fertilization failure with intravenous immunoglobulin: a randomized, placebo-controlled Canadian trial. Fertil Steril 2000; 74:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/117\">",
"      Cervera R, Balasch J. Autoimmunity and recurrent pregnancy losses. Clin Rev Allergy Immunol 2010; 39:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/118\">",
"      Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/119\">",
"      Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/120\">",
"      Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/121\">",
"      Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/122\">",
"      Tincani A, Cavazzana I, Ziglioli T, et al. Complement activation and pregnancy failure. Clin Rev Allergy Immunol 2010; 39:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/123\">",
"      Girardi G. Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome. Clin Rev Allergy Immunol 2010; 39:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/124\">",
"      Mulla MJ, Brosens JJ, Chamley LW, et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol 2009; 62:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/125\">",
"      Mulla MJ, Myrtolli K, Brosens JJ, et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity. Am J Reprod Immunol 2010; 63:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/126\">",
"      Carroll TY, Mulla MJ, Han CS, et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol 2011; 66:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/127\">",
"      Hunt JS, Robertson SA. Uterine macrophages and environmental programming for pregnancy success. J Reprod Immunol 1996; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/128\">",
"      Mold JE, Micha&euml;lsson J, Burt TD, et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 2008; 322:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/129\">",
"      Hoftman AC, Hernandez MI, Lee KW, Stiehm ER. Newborn illnesses caused by transplacental antibodies. Adv Pediatr 2008; 55:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/130\">",
"      Fons P, Chabot S, Cartwright JE, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006; 108:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/131\">",
"      Nicolae D, Cox NJ, Lester LA, et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet 2005; 76:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/132\">",
"      Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/133\">",
"      Buhimschi CS, Weiner CP, Buhimschi IA. Proteomics, part II: the emerging role of proteomics over genomics in spontaneous preterm labor/birth. Obstet Gynecol Surv 2006; 61:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36201/abstract/134\">",
"      Abrahams VM. Antagonizing toll-like receptors to prevent preterm labor. Reprod Sci 2008; 15:108.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3966 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36201=[""].join("\n");
var outline_f35_22_36201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFENSE MECHANISMS OF THE PLACENTA AND EXTRAPLACENTAL MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fetal trophoblast cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Placental membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Specific protective mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Altered HLA expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Soluble immunomodulators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Complement proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMMUNE ADAPTATION AND THE PREGNANT UTERUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differences in lymphocyte populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Soluble immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Progesterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Prostaglandin E2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MATERNAL SYSTEMIC IMMUNE RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      IMMUNE FACTORS IN EARLY PREGNANCY TERMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Implantation and maternal immunorejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recurrent pregnancy loss and leukocyte immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10931824\">",
"      Placental immune effects in antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FETAL IMMUNE SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26679?source=related_link\">",
"      Evaluation of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43175?source=related_link\">",
"      Fetal membranes: Anatomy and biochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41256?source=related_link\">",
"      Placental development and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41544?source=related_link\">",
"      Transient hypogammaglobulinemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_22_36202="Risk factors for dementia";
var content_f35_22_36202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for dementia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36202/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36202/contributors\">",
"     Marie-Florence Shadlen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36202/contributors\">",
"     Eric B Larson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36202/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36202/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/22/36202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/22/36202/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/22/36202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dementia is a disorder that is characterized by impairment of memory and at least one other cognitive domain (aphasia, apraxia, agnosia, executive function). These must represent a decline from previous level of function and be severe enough to interfere with daily function and independence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the risk factors associated with dementia. The diagnosis, prevention, and treatment of dementia and the risk factors, treatment, and prevention of vascular dementia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link\">",
"     \"Prevention of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10104?source=see_link\">",
"     \"Treatment and prevention of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age remains the strongest risk factor for dementia, particularly for Alzheimer disease (AD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In a community-based study, for example, the estimated annual incidence of AD was 0.6 percent for individuals ages 65 to 69 years, 1.0 percent for those 70 to 74 years, 2.0 percent for those 75 to 79 years, 3.3 percent for those 80 to 84 years, and 8.4 percent for those 85 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/4\">",
"     4",
"    </a>",
"    ]. In a meta-analysis of 23 studies from around the world, AD increased exponentially with age up until the age of 90 years with no signs of leveling off [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/5\">",
"     5",
"    </a>",
"    ]. Dementia is estimated to be present in one-half to two-thirds of nursing home residents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies estimating dementia incidence in the very old have been limited by low numbers in this age group. A number of studies have found that dementia incidence continues to increase with age after 85 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/3,7-10\">",
"     3,7-10",
"    </a>",
"    ]. These cumulative increases in incidence rates result in the prevalence of dementia approaching or exceeding 50 percent in individuals over 90 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/3,7,10,11\">",
"     3,7,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While relatively uncommon, AD and other neurodegenerative dementias also occur in younger patients and account for an appreciable proportion of dementias in these patients. The reported incidence of AD in one study from England was 4.2 cases per 100,000 person years among individuals aged 45-64 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/12\">",
"     12",
"    </a>",
"    ], while the overall incidence of early onset dementia in this and another study was 11 to 13 cases per 100,000 for adults younger than 64 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Among 235 individuals aged 17 to 45 years diagnosed with dementia in Rochester, Minnesota, neurodegenerative disease accounted for 31 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FAMILY HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family history is a risk factor for the development of Alzheimer disease (AD); patients with a first-degree relative with dementia have a 10 to 30 percent increased risk of developing the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/15\">",
"     15",
"    </a>",
"    ]. First-degree relatives of African Americans with AD appear to have a higher cumulative risk of dementia than relatives of whites. This was illustrated in an epidemiologic study of 17,639 first-degree biological relatives of 2339 white probands and 2281 first-degree biological relatives of 255 African American probands with AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/16\">",
"     16",
"    </a>",
"    ]. The cumulative risk of the disorder in the African American and white relatives was 43.7 and 26.9 percent, respectively (relative risk 1.6; 95% CI 1.4-1.9) (",
"    <a class=\"graphic graphic_figure graphicRef55394 \" href=\"mobipreview.htm?28/38/29294\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One study found that the increased risk in first-degree relatives was lower if the patient developed AD late in life (age 85 or older) and similar to the risk in a control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/17\">",
"     17",
"    </a>",
"    ]. Additionally, the excess risk of AD in relatives of patients with early-onset disease was highest when the relatives were younger and diminished as the relatives aged: the hazard rate ratio of developing AD in relatives of a patient with early-onset disease was 19.7 when the relative was aged 50 to 54 but decreased to 1.2 by ages 90 to 94. Studies in asymptomatic family members of patients with familial AD have found an increased prevalence of certain biomarkers and abnormal activation patterns on functional neuroimaging; the specificity and prognostic value of these findings await further study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/18\">",
"     18",
"    </a>",
"    ]. These findings may have implications for counseling family members of patients with AD.",
"   </p>",
"   <p>",
"    Nearly all of the autosomal dominant familial forms of AD are related to mutations in one of three different genes: the amyloid precursor protein gene, the presenilin 1 gene, or the presenilin 2 gene. These mutations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42153?source=see_link&amp;anchor=H4#H4\">",
"     \"Genetic factors in the amyloid diseases\", section on 'Alzheimer amyloid precursor protein'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42153?source=see_link&amp;anchor=H22#H22\">",
"     \"Genetic factors in the amyloid diseases\", section on 'Presenilins and autosomal dominant early-onset AD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic risk factors for dementia are best studied in Alzheimer disease (AD). AD is highly heritable, even in so-called sporadic cases. The genetic basis for AD is best understood in the early-onset form, which accounts for less than one percent of cases and typically follows an autosomal dominant inheritance pattern related to mutations in genes that alter amyloid-beta (A&beta;) protein production, aggregation, or clearance. The genetic basis of late-onset AD is more complex, with susceptibility likely conferred by a variety of more common but less penetrant genetic factors such as apolipoprotein E (",
"    <em>",
"     APOE",
"    </em>",
"    ) alleles, interacting with environmental and epigenetic influences. The genetic basis of AD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32089?source=see_link\">",
"     \"Genetics of Alzheimer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MILD COGNITIVE IMPAIRMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies indicate that mild cognitive impairment may be a precursor state to dementia. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=see_link\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ATHEROSCLEROSIS RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular risk factors have been linked to all incident dementia as well as to Alzheimer disease (AD) and vascular dementia individually. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms linking vascular risk factors to AD are unclear, but they suggest a pathogenic role for vascular disease in AD. The strongest degrees of association between these risk factors and late life cognitive decline have been found in studies that identify the risk factor in midlife rather than late life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypercholesterolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercholesterolemia may increase the risk of dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/23\">",
"     23",
"    </a>",
"    ], and vascular dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], but not all studies have confirmed this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Some have even shown a lower risk of dementia with high cholesterol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/32\">",
"     32",
"    </a>",
"    ]. These discrepancies probably have their origin in study methodology, for example, whether all dementias or just a subset of dementias were included and, importantly, the timing of the hypercholesterolemia diagnosis (midlife versus late life). Some longitudinal studies indicate that, as with body mass index, serum cholesterol levels may decrease in the early stages of dementia, limiting the ability to see an effect of hypercholesterolemia on dementia risk when the measurements are made later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/22,33\">",
"     22,33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Obesity and body mass index'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The effect of hypercholesterolemia on dementia risk may be modified by ApoE status. An interaction is plausible because ApoE is involved in cholesterol uptake and transport in the brain. Some, but not all, studies suggest that the association of cholesterol and dementia is stronger in those without ApoE epsilon 4 and may be absent in those who carry the epsilon 4 allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. It is speculated that cholesterol may increase the risk of AD by enhancing the formation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deposition of Abeta, or that it may affect nonamyloid factors such as cerebrovascular risk, local inflammation, or tau metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the use of the cholesterol lowering HMG-CoA reductase inhibitors (statins) to prevent AD is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link\">",
"     \"Prevention of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective, large, population-based cohort studies have found that diabetes is associated with an increased risk of cognitive decline and dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/20,21,30,37-48\">",
"     20,21,30,37-48",
"    </a>",
"    ]. A systematic review of these studies found that diabetes is associated with a 50 to 100 percent increase in risk of AD and of dementia overall, and a 100 to 150 percent increased risk of vascular dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/49\">",
"     49",
"    </a>",
"    ]. Limitations in the clinical diagnostic criteria that classify dementia etiology preclude firm conclusions regarding a differential effect on dementia subtype in these studies. While some clinicopathologic studies suggest that diabetes is associated with cerebrovascular but not Alzheimer pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/47,50,51\">",
"     47,50,51",
"    </a>",
"    ], one study linked elevated glucose levels with hippocampal atrophy, a finding associated with AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear that treating diabetes reduces the risk of dementia. Patients treated with insulin actually had the highest incidence of dementia in a large prospective cohort study, although this was also probably a marker for more severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/37\">",
"     37",
"    </a>",
"    ]. In a study that randomly assigned 156 older patients with diabetes to two different oral antidiabetic agents, higher postprandial plasma glucose excursions (less tight diabetes control) were associated with greater declines in cognitive performance measures over one year of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/53\">",
"     53",
"    </a>",
"    ]. An inverse correlation has been noted between some cognitive measures and hemoglobin A1c levels, also suggesting that worse glycemic control may be associated with greater cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/54\">",
"     54",
"    </a>",
"    ]. In contrast, one study associated a history of severe hypoglycemic episodes with dementia risk among a cohort of patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/55\">",
"     55",
"    </a>",
"    ], suggesting some caution is appropriate in pursuing tight glycemic control in older adults. Cognitive outcomes, as measured by the Digit Symbol Substitution Test, were not different among patients randomized to intensive glycemic control versus usual care in a study subset of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial when assessed at 40 months into the trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which diabetes may increase dementia risk is uncertain; it does not appear to be mediated entirely through vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. An area of active research is investigating direct effects of hyperinsulinemia and insulin resistance in the brain, as well as a possible relationship between insulin and beta amyloid metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/49,59-66\">",
"     49,59-66",
"    </a>",
"    ]. One study has shown that increased peripheral insulin levels are associated with reduced brain atrophy and cognitive impairment in patients with early AD, suggesting a role for insulin signaling in the pathophysiology of AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/67\">",
"     67",
"    </a>",
"    ]. Other studies are investigating a pathogenic role for the accumulation of advanced glycation end products within brain tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the relationship between blood pressure and dementia risk is not yet entirely clear, most longitudinal studies have found that the risk of dementia and cognitive impairment is associated with either high blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/20,21,44,69-75\">",
"     20,21,44,69-75",
"    </a>",
"    ] or with low blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. However, other studies have found no association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/30,78,79\">",
"     30,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These discrepancies may be due to the fact that hypertension can be associated with certain subtypes of dementia and not others, that the relationship between hypertension and dementia is not monotonic, that the association between dementia and hypertension may be age specific, and that there may be a delay from exposure to clinical manifestation. These points are illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective longitudinal study of 9704 women found that hypertension was associated strongly with cognitive decline in the setting of an incident stroke, and only weakly associated in women who were stroke-free (OR 4.07 (95% CI 1.37-12.1) and 1.13 (95% CI 1.04-1.22), respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of longitudinal, population-based studies have suggested that the relationship between blood pressure and cognitive decline is complex and not linear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/80-83\">",
"       80-83",
"      </a>",
"      ]. In two of these studies, there was a U-shaped association between baseline blood pressure at baseline and subsequently measured cognitive performance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/80\">",
"       80",
"      </a>",
"      ]. In another study, the risk of AD appeared to be related to changes in blood pressure over time as well as the use of antihypertensive treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analysis of data from the Rotterdam study showed that a high diastolic pressure five years before MRI in patients with untreated hypertension was associated with hippocampal atrophy, whereas a low diastolic pressure at the time of MRI in patients with treated hypertension was associated with amygdala and hippocampal atrophy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/84\">",
"       84",
"      </a>",
"      ]. These findings suggest that vascular disease may contribute to atrophy of structures linked with Alzheimer pathology.",
"     </li>",
"     <li>",
"      In a prospective follow-up study of 2505 Japanese-American men, elevated systolic blood pressure in midlife (mean 58 years) was associated with incident dementia 20 years later (HR=1.77) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While most studies of blood pressure and cognition have examined the middle aged or elderly, young adults may also be susceptible to the deleterious effects of hypertension on cognition. In a 20-year longitudinal study of 529 adults comprising two age groups (18 to 46 and 47 to 83 years), higher levels of baseline systolic, diastolic, and mean blood pressure in both younger and older age groups were significantly associated with decline in one neuropsychological measure of cognitive ability, the",
"      <span class=\"nowrap\">",
"       visualization/fluid",
"      </span>",
"      abilities composite score [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/85\">",
"       85",
"      </a>",
"      ]. This result suggests that young adults are as vulnerable as the elderly to blood pressure-related decline in at least one aspect of cognitive function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that hypertension increases the risk of dementia by increasing the risk of stroke and multi-infarct dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    .) However, other pathophysiologic mechanisms may play a role. One longitudinal, positron emission tomography (PET) study found that hypertensive individuals demonstrated progressive changes in regional cerebral blood flow compared to healthy controls that correlated with the duration of hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the impact of smoking on the risk of dementia are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/89\">",
"     89",
"    </a>",
"    ]. Several prospective studies have suggested that smoking in middle aged and elderly people is associated with an increased risk of dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/20,21,89-92\">",
"     20,21,89-92",
"    </a>",
"    ], but at least one study found no association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/93\">",
"     93",
"    </a>",
"    ]. Another report suggested that nicotine may have a protective effect on AD by reducing senile plaque formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/94\">",
"     94",
"    </a>",
"    ]. The results of one pathologic study appeared to associate current smoking with dementia via free radical injury and microvascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 19 studies with at least 12 months of follow-up concluded that elderly smokers have increased risk of Alzheimer disease, vascular dementia and any dementia, with relative risks of 1.27 (95% CI 1.02-1.60) to 1.79 (95% CI 1.43-2.23) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/96\">",
"     96",
"    </a>",
"    ]. Current smoking was also associated with greater yearly declines in Mini-Mental State examination scores.",
"   </p>",
"   <p>",
"    Effect modification by ApoE e4 may explain, at least in part, the conflicting results. In two population-based cohorts, smoking was associated with either memory decline or AD in patients without, but not with, the ApoE e4 allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. One possible explanation may be that because the ApoE e4 risk factor is such a strong risk factor for AD, an association between AD and smoking cannot be seen in its presence. Also, ApoE e4 carriers with AD have fewer nicotinic receptor-binding sites than noncarriers, suggesting that there may be a direct biological modification of the effect of smoking associated with ApoE e4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11254288\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome is a cluster of cardiovascular risk factors, which include obesity, hypertension, insulin resistance, and dyslipidemia. The metabolic syndrome has been linked to cardiovascular disease and overall mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there is some evidence linking the metabolic syndrome and dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/101-107\">",
"     101-107",
"    </a>",
"    ], the data are as yet inconclusive.",
"   </p>",
"   <p>",
"    In a population-based study involving 980 older participants (69 to 78 years), the prevalence of AD was significantly higher in patients with metabolic syndrome (OR 2.5; 95% CI 1.3-4.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/105\">",
"     105",
"    </a>",
"    ]. The association remained significant even after patients with diabetes were excluded. One case-control study also found an association between the metabolic syndrome and AD (OR 3.2; 95% CI 1.2-8.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/101\">",
"     101",
"    </a>",
"    ]. Longitudinal cohort studies have had mixed results. In the longitudinal Three-City study, the metabolic syndrome was associated with cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/106\">",
"     106",
"    </a>",
"    ]. In the Honolulu-Asia aging study, the metabolic syndrome was weakly associated with incident vascular dementia but not AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/102\">",
"     102",
"    </a>",
"    ]. Other longitudinal studies of the metabolic syndrome and cognitive decline in older subjects have found either no association or increased cognitive decline only in people who also had increased markers of inflammation such as serum C-reactive protein and interleukin-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. In a study of 6401 individuals, both obesity and metabolic abnormalities were risk factors for cognitive decline, which was most pronounced in those with both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total atherosclerotic risk factor burden and other systemic or cerebrovascular manifestations of atherosclerosis may also identify individuals at risk of dementia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to the individual associations of risk factors with dementia (discussed above), the clustering of risk factors may be important. In one longitudinal cohort study, the risk of probable AD increased with the number of risk factors (diabetes, hypertension, heart disease, and smoking) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/110\">",
"       110",
"      </a>",
"      ]. Hazard ratios for one, two, and three or more risk factors were 1.8 (95%CI 1.1-3.0), 2.8 (95%CI 1.7-4.7), and 3.4 (95% CI 1.8-6.3) in a model adjusting for age, sex, APOE-e4, and other confounders. Another study found that the total Framingham Stroke Risk Profile score was associated with incident cognitive impairment among 1907 patients 45 years and older followed for four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atrial fibrillation appears to be associated with incident dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/112-114\">",
"       112-114",
"      </a>",
"      ]. A meta-analysis of eight observational studies yielded a hazard ratio of 1.4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Carotid atherosclerosis (visualized plaque and intimal medial thickness) has been linked with incident dementia and cognitive decline in a number of observational studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/115-117\">",
"       115-117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retinal microvascular signs and retinopathy have also been linked to poor cognitive function and dementia in a number of studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/118-122\">",
"       118-122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atherosclerosis affecting the intracranial arteries was associated with dementia in an autopsy study of 200 older patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/123\">",
"       123",
"      </a>",
"      ]. No association was found between dementia and atherosclerosis affecting the aorta or coronary arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LIFESTYLE AND ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence suggests that three components of lifestyle - social, mental, and physical activity - are inversely associated with the risk for dementia and Alzheimer disease (AD). Nearly all of the data on these issues comes from observational studies, where methodological issues may obscure the exact relationship between activity level and dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/124,125\">",
"     124,125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples of potential confounders, subjects in observational studies who have higher cognitive activity may have had higher premorbid intellectual function. Given the same degree of Alzheimer pathology, they may still have sufficient remaining cognitive skills to prevent the diagnosis of a dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/126\">",
"     126",
"    </a>",
"    ]. Another potential confounder is that early dementia may manifest with decreased initiative, interest, and mood, which in turn may lead to limited mental and physical activity and reduced social interaction. Comorbid health conditions may also confound a possible relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/127\">",
"     127",
"    </a>",
"    ]. A study of male twins suggested that genetic factors appeared to explain the observed relationship between higher cognitive performance and occupations requiring higher intellectual demands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With these caveats in mind, a systematic review published in 2004 analyzed the results of 15 longitudinal observational studies that addressed the impact of lifestyle with cognition or dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/129\">",
"     129",
"    </a>",
"    ]. All of the studies adjusted for cognitive ability at baseline to account for the possibility that undiagnosed early dementia could cause decreased activity and interaction. All but one study had at least three years of follow-up, although even three years may be insufficient to exclude the possibility of early undiagnosed cognitive decline. Fourteen of the studies were done in Europe or North America, and one was from China.",
"   </p>",
"   <p>",
"    None of the 15 studies were totally free of methodological problems, but the findings were judged to be internally valid. The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/129\">",
"     129",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher risk of cognitive decline or lower cognitive performance was observed in five of seven studies of social networks and six of seven studies of nonphysical activity",
"     </li>",
"     <li>",
"      Physical activity, including both exercise and daily activity, was related to cognition in six of seven studies",
"     </li>",
"     <li>",
"      An association between social network and dementia was reported in three of six studies; two studies showed an association with marital status",
"     </li>",
"     <li>",
"      An association between mental activity and dementia was seen in six of seven studies, and confirmed for AD in four studies",
"     </li>",
"     <li>",
"      An association between physical activity and both dementia and AD was reported in six of nine studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Published reports subsequent to this systematic review continue to support these findings, including several population-based longitudinal studies that have found that social, cognitive, and physical activity are inversely associated with the risk for dementia, AD,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/130-148\">",
"     130-148",
"    </a>",
"    ]. One study found that in 69 older adults (55 to 88 years), higher levels of physical exercise (self-reported) over the prior decade were associated with reduced beta-amyloid uptake on positron emission tomography studies (a marker for AD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lifestyle and activity levels are clearly modifiable and may present options for decreasing the risk of cognitive decline and dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of dementia\", section on 'Lifestyle and activity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26138?source=see_link&amp;anchor=H20#H20\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Potential mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible mechanisms by which lifestyle might affect the risk of dementia are speculative, but three biologically plausible hypotheses have emerged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cognitive reserve hypothesis suggests that mental activity, learning, and social interaction prevent or reduce cognitive deficits by activating brain plasticity and enhancing synaptogenesis and perhaps neurogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/150\">",
"       150",
"      </a>",
"      ]. Physical activity may enhance vascular and non neuronal brain components that support neurons. The cognitive reserve hypothesis is supported by the apparent effect of education (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Role of education and cognitive reserve'",
"      </a>",
"      below) on the risk of dementia.",
"     </li>",
"     <li>",
"      The vascular hypothesis suggests that social, mental, and physical activity prevents or reduces dementia and AD through reduction of cardiovascular disease and stroke. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The stress hypothesis suggests that active individuals have more positive emotional states and reduced stress, leading to a lower susceptibility to AD. Increased stress may result in dampening of negative feedback control of the adrenocortical axis via downregulation of hippocampal corticosteroid receptors, resulting in high cortisol levels, hippocampal atrophy, and impaired cognition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Role of education and cognitive reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher levels of education have been associated with a reduced risk of AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/151-153\">",
"     151-153",
"    </a>",
"    ]. Advanced education is believed to represent a higher cognitive reserve that decreases the impact of AD pathology on cognitive function, rather than providing a protective effect against the accumulation of AD pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/153-155\">",
"     153-155",
"    </a>",
"    ]. The following observations provide support for this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of 997 cognitively normal older adults, low &beta;-amyloid",
"      <span class=\"nowrap\">",
"       42/40",
"      </span>",
"      levels (a potential biomarker for Alzheimer disease) were associated with greater cognitive decline over nine years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/156\">",
"       156",
"      </a>",
"      ]. This effect was modified by higher educational status, such that individuals with lower educational level experienced the greatest degree of cognitive decline.",
"     </li>",
"     <li>",
"      In a prospective, neuropathologic study in 130 older men, years of formal education were associated with higher cognitive status in relation to the plaque burden [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/157\">",
"       157",
"      </a>",
"      ]. In addition, the presence of highly developed cognitive systems, specifically perceptual speed and working memory, appeared to ameliorate the effects of Alzheimer pathology on overall cognitive status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/158\">",
"       158",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of three large autopsy datasets found that, among individuals meeting neuropathologic criteria for AD, those with higher education levels were less likely to have had a premortem clinical dementia diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/159\">",
"       159",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neuroimaging studies using different PET scanning techniques have found that among patients with AD or amnestic mild cognitive impairment, evidence of more severe brain pathology is found in patients with higher levels of education despite similar cognitive scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/160-163\">",
"       160-163",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 270 patients with AD found that with greater levels of cerebral atrophy, cognition was higher for individuals who had a larger head circumference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/164\">",
"       164",
"      </a>",
"      ]. Assuming that head circumference, brain size and cognition are related, this finding also suggests that cognitive reserve may protect against the clinical manifestations of AD.",
"     </li>",
"     <li>",
"      A few studies have found that cognitive activities in late life appeared to delay the onset of dementia, independent of educational level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/165,166\">",
"       165,166",
"      </a>",
"      ]. However, this finding may signify that participation in late life cognitive activities is a better marker of cognitive reserve than the educational level attained earlier in life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One neuropathologic study found that individuals who had normal premortem cognitive function despite significant AD pathology at autopsy also had significant hypertrophy of neurons in the CA1 region of the hippocampus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/167\">",
"     167",
"    </a>",
"    ]. These individuals also had higher language ability scores measure earlier in life. These and similar observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/168\">",
"     168",
"    </a>",
"    ] suggest that a capacity for neuronal plasticity (perhaps through synaptic reorganization) may underlie the apparent protective mechanism that higher education and baseline cognition may play in the prevention of clinically apparent AD.",
"   </p>",
"   <p>",
"    However, once AD develops, patients with higher education or occupational levels appear to experience a somewhat more rapid cognitive decline, at least in part because they are assumed to have accumulated a greater degree of AD pathology by the time dementia is apparent, compared with those with less education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/169-171\">",
"     169-171",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weaker risk factors for dementia include a history of head trauma associated with loss of consciousness (particularly in patients with the ApoE epsilon 4 allele) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/172,173\">",
"     172,173",
"    </a>",
"    ], and low educational attainment.",
"   </p>",
"   <p>",
"    Alzheimer disease (AD) is more common in women; approximately 16 percent of women surviving to an average life expectancy will develop AD compared with 6 percent of men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on alcohol use and risk of dementia are mixed. Alcohol abuse is associated with cognitive dysfunction and dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40328?source=see_link\">",
"     \"Overview of the chronic neurologic complications of alcohol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there is some evidence that light to moderate drinking may be protective, this is largely based on observational studies and the findings have been inconsistent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of the risks and benefits of alcohol consumption\", section on 'Dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of even a moderate reduction in glomerular filtration rate, defined as a serum creatinine concentration &ge;1.5 (133",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in men and &ge;1.3 (115",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in women, is associated with an accelerated rate of cognitive decline as well as an increased risk of dementia among older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/175,176\">",
"     175,176",
"    </a>",
"    ]. Among such individuals in good to excellent health, renal impairment is associated with vascular dementia, not AD. A faster rate of GFR decline has also been associated with more significant cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/177\">",
"     177",
"    </a>",
"    ] These observations are consistent with the increasing data showing an increase in risk of coronary heart disease in patients with mild to moderate chronic kidney disease, which has resulted in chronic kidney disease being considered a manifestation of vascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Obesity and body mass index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators have had somewhat conflicting results in studying the relationship between weight or body mass index (BMI) and the risk of dementia; some found an association between obesity and dementia and others between low weight or BMI and dementia. The apparently opposing results are probably explained by the time interval between the assessment of BMI or weight and the assessment of dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/178-180\">",
"     178-180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies finding an association between obesity and incident AD usually measured BMI or adiposity in mid rather than late life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/107,178,181-187\">",
"     107,178,181-187",
"    </a>",
"    ]. Findings of larger cohort studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 27-year follow-up study of 10,276 health care plan participants, obesity was associated with an increased risk of dementia, HR=1.74 (95% CI 1.34-2.26), as was being overweight, HR=1.35 (95% CI 1.14-1.60) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/181\">",
"       181",
"      </a>",
"      ]. The magnitude of the relationship was similar when obesity was approximated by skinfold measurements. This relationship was maintained after controlling for hyperlipidemia and diabetes.",
"     </li>",
"     <li>",
"      Among 7402 men aged 47 to 55 years in 1970 to 1973, elevated BMI greater than 20 was associated with a linear increased risk of a hospital or death certificate diagnosis of dementia during 20 to 30 years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/183\">",
"       183",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased BMI has also been linked to lower baseline cognitive function and increased five-year cognitive decline in a population-based study of 2223 healthy non-demented individuals aged 32 to 62 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/188\">",
"       188",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, in other studies, weight loss in late life appeared to more closely precede the diagnosis of AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/178,186,189-195\">",
"     178,186,189-195",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Honolulu-Asia Aging study, weight loss in late life in 1890 Japanese American men was associated with the subsequent development of dementia; decline in weight had accelerated by the time of diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/189\">",
"       189",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Religious Order Study, evaluations in 832 elderly clergy found that both lower and declining BMI was associated with incident AD after adjusting for chronic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/190\">",
"       190",
"      </a>",
"      ]. Cognitive decline increased by 8 percent for each unit less of BMI at baseline and declined an additional 40 percent per year in patients who lost one unit BMI compared with those with stable BMI. The association remained significant after early incident cases (within the first four years) were excluded. Postmortem examinations in 298 individuals in this cohort found that low BMI was associated with a higher degree of AD pathology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/196\">",
"       196",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, while a lower BMI was associated with incident dementia in a cohort study of 3646 older French patients (OR = 1.48), the association disappeared when patients who developed early dementia were excluded from the analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/191\">",
"       191",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, it appears that obesity or increased weight in midlife is a risk factor for dementia in later life. This might reflect that obesity has an effect of accelerated aging as suggested by one investigation looking at changes on brain magnetic resonance spectroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/197\">",
"     197",
"    </a>",
"    ]. Low BMI in later life is associated with the subsequent development of dementia, probably because weight loss is an early manifestation of the disease rather than a true risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/198\">",
"     198",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H417059\">",
"    <span class=\"h2\">",
"     Homocysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amino acid homocysteine may be an independent risk factor for cognitive decline and dementia, but the evidence is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/199-208\">",
"     199-208",
"    </a>",
"    ]. The potential mechanisms whereby homocysteine might mediate cognitive decline and dementia include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/202\">",
"     202",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neurotoxicity induced by activation of N-methl-D-aspartate (NMDA) receptors",
"     </li>",
"     <li>",
"      Promotion of apoptosis",
"     </li>",
"     <li>",
"      Vascular injury from promotion of atherogenesis and proliferation of smooth muscle cells",
"     </li>",
"     <li>",
"      Platelet activation",
"     </li>",
"     <li>",
"      Increased burden of ischemic strokes and white matter lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Homocysteine is recognized as a risk factor for stroke and heart disease, and it could potentially play a role in vascular dementia through its association with large [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/209\">",
"     209",
"    </a>",
"    ] and small vessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/210\">",
"     210",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some studies suggest that the association between abnormal homocysteine levels as well as other changes in serum vitamin concentrations reflects early weight loss as a manifestation of early dementia rather than its cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/211\">",
"     211",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Obesity and body mass index'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Moreover, homocysteine-lowering therapy using supplementation with vitamins B12 and B6 has not been shown to improve cognitive function or prevent cognitive decline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of dementia\", section on 'Vitamins B6, B12, and folate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H416938\">",
"    <span class=\"h2\">",
"     Dietary fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that a diet high in saturated or transunsaturated fat or low in nonhydrogenated unsaturated fats, may be associated with an increased risk of developing AD or cognitive decline. However, the evidence is conflicting. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of dementia\", section on 'Diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of estrogens and hormonal replacement therapy in cognition remains unsettled. Estrogen was previously felt to be a protective factor based upon descriptive epidemiologic studies and possible protective effects in laboratory models of aging. However, the Women's Health Initiative Memory Study (WHIMS) found that estrogens provided no benefit, but rather were associated with an increased risk of dementia in a low-risk group. Thus, estrogens cannot be recommended as preventive therapy based on current evidence. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link\">",
"     \"Estrogen and cognitive function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Gait and other functional impairments",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some studies have associated gait and other functional impairments with incident dementia, these may represent early signs of dementia, rather than risk factors.",
"   </p>",
"   <p>",
"    Gait impairment may also be a risk factor for dementia, particularly non-Alzheimer dementia. This was illustrated in a prospective study of 422 community dwelling patients older than age 75 years who did not have dementia at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/212\">",
"     212",
"    </a>",
"    ]. Neurologic gait abnormalities were present in 85 patients at study entry. During a median 6.6 years of follow-up there were 125 newly diagnosed cases of dementia. Patients with gait abnormalities had a greater risk of developing any dementia compared with patients without gait abnormalities (hazard ratio 1.96, 95% CI 1.30-2.96). The risk was increased for non-Alzheimer (hazard ratio 3.51, 95% CI 1.98-6.24) but not Alzheimer dementia.",
"   </p>",
"   <p>",
"    Two studies suggest that hearing loss may presage dementia. A prospective study of 639 individuals found that hearing loss was a risk factor for all-cause dementia and AD over a median of 12 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/213\">",
"     213",
"    </a>",
"    ]. A greater severity of baseline hearing loss was associated with higher rates of dementia. In another prospective study, 274 normal volunteers were followed for up to four years after complete audiometric assessment. A finding of severe central auditory dysfunction (based on a test of dichotic sentence identification) was associated with incident dementia (HR 9.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/214\">",
"     214",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418326\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that vitamin D deficiency is associated with cognitive impairment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Alzheimer disease in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/215\">",
"     215",
"    </a>",
"    ]. The effect appears to be small and of uncertain clinical significance.",
"   </p>",
"   <p>",
"    A population-based cross sectional study of older women found that those with vitamin D deficiency had lower cognitive scores compared to those without deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/216\">",
"     216",
"    </a>",
"    ], while another found that women with vitamin D intake at the recommended level had higher cognitive scores compared with those with inadequate intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/217\">",
"     217",
"    </a>",
"    ]. A second cross sectional study found that patients with low vitamin D levels had higher volumes of white matter hyperintensities and infarctions as well as higher odds (2.0) of all-cause dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/218\">",
"     218",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective cohort series, however, have come to different conclusions. One prospective study that followed 1604 older men for a mean 4.6 years found no significant relationship between vitamin D status and either concurrent or incident dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/219\">",
"     219",
"    </a>",
"    ]. In contrast, low levels of vitamin D were associated with cognitive decline over a six year observation period in a cohort of 858 adults over 65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/220\">",
"     220",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Inflammatory markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of inflammation in the pathogenesis of dementia remains to be elucidated. Cohort studies examining the relationship between inflammatory markers and incident dementia have had somewhat mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One cohort study of 452 patients found that systemic markers of inflammation and hemostasis (fibrinogen, interleukin-6, and intracellular adhesion molecule-1) were associated with cognitive decline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/221\">",
"       221",
"      </a>",
"      ]. While such markers are also associated with risk of atherothrombotic vascular events, the association in this study was independent of major vascular comorbidity.",
"     </li>",
"     <li>",
"      In the Rotterdam and Leiden studies, which included more than 4000 patients, the association between inflammatory markers (C reactive protein and interleukin 6) and cognitive decline was modest overall, but was seen most strongly in APOE epsilon 4 carriers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/222\">",
"       222",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in another study, elevated C-reactive protein in association with an family history negative for dementia, was associated with a particularly low risk of incident dementia (HR = 0.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/223\">",
"       223",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 691 older participants in the Framingham study, higher production of the cytokines, interleukin 1 and tumor necrosis factor alpha by peripheral blood mononuclear cells was associated with incident AD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/224\">",
"       224",
"      </a>",
"      ]. However, there was no association seen for serum levels of C-reactive protein or interleukin-6 and risk of developing AD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical significance of these findings is unknown. These markers are not specific enough to aid in the diagnosis of individuals at risk for dementia. Treatment with nonsteroidal anti-inflammatory agents or cyclooxygenase-2 inhibitors has not been shown to be beneficial and may be harmful when used in older patients to prevent cognitive decline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of dementia\", section on 'NSAID therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Medical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A higher risk of cognitive decline and dementia has been postulated to occur in survivors of acute medical illness, particularly in older adults. Specific settings in which this has been studied include cardiac surgery (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3834?source=see_link&amp;anchor=H12#H12\">",
"     \"Neurologic complications of cardiac surgery\", section on 'Encephalopathy'",
"    </a>",
"    ) and hospitalizations complicated by delirium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28185?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention and treatment of delirium and confusional states\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Survivors of severe sepsis had a substantial increase (OR 3.3) in the prevalence of dementia compared to survivors of a nonsepsis-related hospitalization in one large prospective cohort study of older hospitalized adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/225\">",
"     225",
"    </a>",
"    ]. There was also an associated increase in new functional limitations in these patients.",
"   </p>",
"   <p>",
"    Other studies suggest that this may be of concern in a broader range of acute medical illness:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study, cognitive evaluations were performed every two years in 2929 individuals 65 years and older without baseline dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/226\">",
"       226",
"      </a>",
"      ]. A higher likelihood of cognitive decline and incident dementia were observed in those who were hospitalized. Adjusted hazard rates for dementia was 1.4 following noncritical illness hospitalization and 2.3 following critical illness hospitalization. Whether acute medical illness is a risk factor for incident dementia or hastens its presentation is not certain.",
"     </li>",
"     <li>",
"      A longitudinal, population-based cohort study of 1870 older adults followed for a mean of nine years, also found that cognitive functioning declined substantially after hospitalization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/227\">",
"       227",
"      </a>",
"      ]. More severe illness, longer hospital stay, and older age were each associated with faster cognitive decline.",
"     </li>",
"     <li>",
"      A decline in health status as measured by a fraility index (a cumulative score of 19 deficits including visual impairment, hearing loss, arthritis, others) was associated with incident dementia in another population-based study including 7239 healthy older adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/228\">",
"       228",
"      </a>",
"      ]. For each deficit recorded, the odds ratio of dementia increased by 3.2 percent, after adjusting for age, sex, education and baseline cognition.",
"     </li>",
"     <li>",
"      Self-rated health as &ldquo;poor&rdquo; or &ldquo;fair&rdquo; as compared to &ldquo;good&rdquo; was associated with a higher incidence of dementia in the Three City prospective cohort study; OR = 1.70 and 1.34, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/229\">",
"       229",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to organophosphate and organochlorine pesticides were linked to incident dementia in a population based cohort study in Utah (HR = 1.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/230\">",
"     230",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A link between oral aluminum exposure and risk of AD is controversial and not well substantiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/231-233\">",
"     231-233",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggest a possible association between occupational solvent exposure (chlorinated and aromatic solvents) and late life cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/234-236\">",
"     234-236",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benzodiazepines were associated with increased risk of dementia (HR 1.5) in a prospective population-based study in France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/237\">",
"     237",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3034867\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies suggest that a history of depression may be a risk factor for dementia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AD, with OR 1.7 to 2.4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/238-243\">",
"     238-243",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some believe that the apparent association reflects that depressive symptoms can be an early or preclinical manifestation of AD rather than a risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/238,239,241,244\">",
"     238,239,241,244",
"    </a>",
"    ]; although the findings of other studies appear to dispute this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/240,242,245\">",
"     240,242,245",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=see_link&amp;anchor=H14#H14\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Neuropsychiatric symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24476058\">",
"    <span class=\"h2\">",
"     Hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a population-based cohort that included 881 healthy older adults, a U-shaped association between hemoglobin and incident dementia was found with persons with the highest and lowest hemoglobin levels associated with a higher risk of dementia and cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/22/36202/abstract/246\">",
"     246",
"    </a>",
"    ]. Compared with patients with a normal hemoglobin levels, those with anemia had a 60 percent increased risk for developing dementia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25195276\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age remains the strongest risk factor for dementia, particularly for Alzheimer disease (AD) in which the incidence increases exponentially with each decade. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family history is a risk factor for the development of AD; patients with a first-degree relative with dementia have a 10 to 30 percent increased risk of developing the disorder. Autosomal dominant forms of inherited AD have been linked to mutations of the amyloid precursor protein (APP) gene on chromosome 21 and to genes encoding presenilin 1 (PS1) on chromosome 14 and presenilin 2 (PS2) on chromosome 1. Beyond these familial and inherited forms of AD, the strongest evidence for a genetic risk factor in late life nonfamilial AD exists for the ApoE epsilon 4 gene. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Family history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular risk factors (hypertension, hypercholesterolemia, diabetes, tobacco smoking) have been linked to all incident dementia as well as to AD and vascular dementia individually. However, associations have not been demonstrated consistently in all studies, and treatment of these conditions has not yet been clearly linked to a reduction in dementia risk in controlled trials. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Atherosclerosis risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence from observational studies suggests that lifestyle, in particular social, mental, and physical activity, are inversely associated with the risk for dementia and AD. However, methodologic issues may obscure the exact relationship between these features and dementia risk. One theory holds that higher levels of education along with cognitive activity produce a cognitive reserve that decreases the impact of AD pathology on cognitive function. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lifestyle and activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other factors that might increase the risk of dementia and AD include comorbid medical illnesses, obesity, high alcohol consumption, exposure to certain toxins, and depression. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Others'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association Diagnostic and Statistical Manual, 4th ed, APA Press, Washington DC, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/2\">",
"      Evans DA. The epidemiology of dementia and Alzheimer's disease: an evolving field. J Am Geriatr Soc 1996; 44:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/3\">",
"      Corrada MM, Brookmeyer R, Berlau D, et al. Prevalence of dementia after age 90: results from the 90+ study. Neurology 2008; 71:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/4\">",
"      Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995; 273:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/5\">",
"      Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998; 51:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/6\">",
"      Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/7\">",
"      Graves AB, Larson EB, Edland SD, et al. Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington state. The Kame Project. Am J Epidemiol 1996; 144:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/8\">",
"      Hall CB, Verghese J, Sliwinski M, et al. Dementia incidence may increase more slowly after age 90: results from the Bronx Aging Study. Neurology 2005; 65:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/9\">",
"      Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002; 59:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/10\">",
"      Corrada MM, Brookmeyer R, Paganini-Hill A, et al. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol 2010; 67:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/11\">",
"      Larson EB, Langa KM. The rising tide of dementia worldwide. Lancet 2008; 372:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/12\">",
"      Mercy L, Hodges JR, Dawson K, et al. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology 2008; 71:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/13\">",
"      Garre-Olmo J, Gen&iacute;s Batlle D, del Mar Fern&aacute;ndez M, et al. Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology 2010; 75:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/14\">",
"      Kelley BJ, Boeve BF, Josephs KA. Young-onset dementia: demographic and etiologic characteristics of 235 patients. Arch Neurol 2008; 65:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/15\">",
"      van Duijn CM, Clayton D, Chandra V, et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991; 20 Suppl 2:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/16\">",
"      Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002; 287:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/17\">",
"      Silverman JM, Smith CJ, Marin DB, et al. Familial patterns of risk in very late-onset Alzheimer disease. Arch Gen Psychiatry 2003; 60:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/18\">",
"      Bassett SS, Yousem DM, Cristinzio C, et al. Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain 2006; 129:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/19\">",
"      Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011; 77:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/20\">",
"      Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/21\">",
"      Alonso A, Mosley TH Jr, Gottesman RF, et al. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry 2009; 80:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/22\">",
"      Solomon A, K&aring;reholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 2007; 68:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/23\">",
"      Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 2011; 68:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/24\">",
"      Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999; 282:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/25\">",
"      Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004; 61:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/26\">",
"      Dufouil C, Richard F, Fi&eacute;vet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005; 64:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/27\">",
"      Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003; 163:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/28\">",
"      Reitz C, Luchsinger J, Tang MX, et al. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 2005; 64:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/29\">",
"      Li G, Shofer JB, Kukull WA, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 2005; 65:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/30\">",
"      Xiong GL, Plassman BL, Helms MJ, Steffens DC. Vascular risk factors and cognitive decline among elderly male twins. Neurology 2006; 67:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/31\">",
"      Mielke MM, Zandi PP, Shao H, et al. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 2010; 75:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/32\">",
"      Mielke MM, Zandi PP, Sj&ouml;gren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005; 64:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/33\">",
"      Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2007; 64:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/34\">",
"      Hall K, Murrell J, Ogunniyi A, et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 2006; 66:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/35\">",
"      Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000; 54:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/36\">",
"      Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999; 53:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/37\">",
"      Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/38\">",
"      Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000; 160:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/39\">",
"      Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/40\">",
"      Yaffe K, Blackwell T, Kanaya AM, et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/41\">",
"      Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004; 63:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/42\">",
"      Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 2004; 164:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/43\">",
"      Xu WL, Qiu CX, Wahlin A, et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/44\">",
"      Verdelho A, Madureira S, Ferro JM, et al. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 2007; 78:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/45\">",
"      Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/46\">",
"      Verdelho A, Madureira S, Moleiro C, et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010; 75:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/47\">",
"      Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010; 75:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/48\">",
"      Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 2011; 77:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/49\">",
"      Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/50\">",
"      Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006; 67:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/51\">",
"      Sonnen JA, Larson EB, Brickell K, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009; 66:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/52\">",
"      Cherbuin N, Sachdev P, Anstey KJ. Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. Neurology 2012; 79:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/53\">",
"      Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/54\">",
"      Munshi M, Grande L, Hayes M, et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 2006; 29:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/55\">",
"      Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/56\">",
"      Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011; 10:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/57\">",
"      Lovestone S. Diabetes and dementia: is the brain another site of end-organ damage? Neurology 1999; 53:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/58\">",
"      Biessels GJ, De Leeuw FE, Lindeboom J, et al. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 2006; 77:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/59\">",
"      Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 2004; 63:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/60\">",
"      Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/61\">",
"      Geroldi C, Frisoni GB, Paolisso G, et al. Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol 2005; 62:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/62\">",
"      Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 2005; 62:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/63\">",
"      Kulstad JJ, Green PS, Cook DG, et al. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 2006; 66:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/64\">",
"      R&ouml;nnemaa E, Zethelius B, Sundel&ouml;f J, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008; 71:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/65\">",
"      Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010; 75:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/66\">",
"      Schrijvers EM, Witteman JC, Sijbrands EJ, et al. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 2010; 75:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/67\">",
"      Burns JM, Donnelly JE, Anderson HS, et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007; 69:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/68\">",
"      Yaffe K, Lindquist K, Schwartz AV, et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 2011; 77:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/69\">",
"      Elias MF, Wolf PA, D'Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993; 138:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/70\">",
"      Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/71\">",
"      Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/72\">",
"      Tzourio C, Dufouil C, Ducimeti&egrave;re P, Alp&eacute;rovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 1999; 53:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/73\">",
"      Freitag MH, Peila R, Masaki K, et al. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study. Stroke 2006; 37:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/74\">",
"      Obisesan TO, Obisesan OA, Martins S, et al. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2008; 56:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/75\">",
"      Tsivgoulis G, Alexandrov AV, Wadley VG, et al. Association of higher diastolic blood pressure levels with cognitive impairment. Neurology 2009; 73:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/76\">",
"      Guo Z, Fratiglioni L, Winblad B, Viitanen M. Blood pressure and performance on the Mini-Mental State Examination in the very old. Cross-sectional and longitudinal data from the Kungsholmen Project. Am J Epidemiol 1997; 145:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/77\">",
"      Verghese J, Lipton RB, Hall CB, et al. Low blood pressure and the risk of dementia in very old individuals. Neurology 2003; 61:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/78\">",
"      Hebert LE, Scherr PA, Bennett DA, et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology 2004; 62:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/79\">",
"      Johnson KC, Margolis KL, Espeland MA, et al. A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study. J Am Geriatr Soc 2008; 56:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/80\">",
"      Elkins JS, Yaffe K, Cauley JA, et al. Pre-existing hypertension and the impact of stroke on cognitive function. Ann Neurol 2005; 58:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/81\">",
"      Glynn RJ, Beckett LA, Hebert LE, et al. Current and remote blood pressure and cognitive decline. JAMA 1999; 281:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/82\">",
"      Joas E, B&auml;ckman K, Gustafson D, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012; 59:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/83\">",
"      Li G, Rhew IC, Shofer JB, et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am Geriatr Soc 2007; 55:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/84\">",
"      den Heijer T, Launer LJ, Prins ND, et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005; 64:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/85\">",
"      Elias PK, Elias MF, Robbins MA, Budge MM. Blood pressure-related cognitive decline: does age make a difference? Hypertension 2004; 44:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/86\">",
"      Staessen JA, Birkenh&auml;ger WH. Cognitive impairment and blood pressure: quo usque tandem abutere patientia nostra? Hypertension 2004; 44:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/87\">",
"      Wang LY, Larson EB, Sonnen JA, et al. Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc 2009; 57:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/88\">",
"      Beason-Held LL, Moghekar A, Zonderman AB, et al. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke 2007; 38:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/89\">",
"      Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002; 97:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/90\">",
"      Tyas SL, White LR, Petrovitch H, et al. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2003; 24:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/91\">",
"      Sabia S, Marmot M, Dufouil C, Singh-Manoux A. Smoking history and cognitive function in middle age from the Whitehall II study. Arch Intern Med 2008; 168:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/92\">",
"      Rusanen M, Kivipelto M, Quesenberry CP Jr, et al. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 2011; 171:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/93\">",
"      Yamada M, Kasagi F, Sasaki H, et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 2003; 51:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/94\">",
"      Ulrich J, Johannson-Locher G, Seiler WO, St&auml;helin HB. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol 1997; 94:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/95\">",
"      Sonnen JA, Larson EB, Gray SL, et al. Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol 2009; 65:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/96\">",
"      Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 2007; 166:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/97\">",
"      Reitz C, Luchsinger J, Tang MX, Mayeux R. Effect of smoking and time on cognitive function in the elderly without dementia. Neurology 2005; 65:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/98\">",
"      Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998; 351:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/99\">",
"      Reitz C, den Heijer T, van Duijn C, et al. Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology 2007; 69:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/100\">",
"      Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92:12260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/101\">",
"      Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/102\">",
"      Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000; 20:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/103\">",
"      Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 2009; 66:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/104\">",
"      Solfrizzi V, Scafato E, Capurso C, et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J Neurol Neurosurg Psychiatry 2010; 81:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/105\">",
"      Vanhanen M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/106\">",
"      Raffaitin C, F&eacute;art C, Le Goff M, et al. Metabolic syndrome and cognitive decline in French elders: the Three-City Study. Neurology 2011; 76:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/107\">",
"      Singh-Manoux A, Czernichow S, Elbaz A, et al. Obesity phenotypes in midlife and cognition in early old age: the Whitehall II cohort study. Neurology 2012; 79:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/108\">",
"      Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/109\">",
"      van den Berg E, Biessels GJ, de Craen AJ, et al. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007; 69:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/110\">",
"      Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/111\">",
"      Unverzagt FW, McClure LA, Wadley VG, et al. Vascular risk factors and cognitive impairment in a stroke-free cohort. Neurology 2011; 77:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/112\">",
"      Santangeli P, Di Biase L, Bai R, et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. Heart Rhythm 2012; 9:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/113\">",
"      Marzona I, O'Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ 2012; 184:E329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/114\">",
"      Dublin S, Anderson ML, Haneuse SJ, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc 2011; 59:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/115\">",
"      van Oijen M, de Jong FJ, Witteman JC, et al. Atherosclerosis and risk for dementia. Ann Neurol 2007; 61:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/116\">",
"      Wendell CR, Zonderman AB, Metter EJ, et al. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 2009; 40:3180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/117\">",
"      Wendell CR, Waldstein SR, Ferrucci L, et al. Carotid atherosclerosis and prospective risk of dementia. Stroke 2012; 43:3319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/118\">",
"      Baker ML, Marino Larsen EK, Kuller LH, et al. Retinal microvascular signs, cognitive function, and dementia in older persons: the Cardiovascular Health Study. Stroke 2007; 38:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/119\">",
"      Lesage SR, Mosley TH, Wong TY, et al. Retinal microvascular abnormalities and cognitive decline: the ARIC 14-year follow-up study. Neurology 2009; 73:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/120\">",
"      de Jong FJ, Schrijvers EM, Ikram MK, et al. Retinal vascular caliber and risk of dementia: the Rotterdam study. Neurology 2011; 76:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/121\">",
"      Haan M, Espeland MA, Klein BE, et al. Cognitive function and retinal and ischemic brain changes: the Women's Health Initiative. Neurology 2012; 78:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/122\">",
"      Schrijvers EM, Buitendijk GH, Ikram MK, et al. Retinopathy and risk of dementia: the Rotterdam Study. Neurology 2012; 79:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/123\">",
"      Dolan H, Crain B, Troncoso J, et al. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 2010; 68:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/124\">",
"      Simonsick EM. Fitness and cognition: encouraging findings and methodological considerations for future work. J Am Geriatr Soc 2003; 51:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/125\">",
"      Coyle JT. Use it or lose it--do effortful mental activities protect against dementia? N Engl J Med 2003; 348:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/126\">",
"      Alexander GE, Furey ML, Grady CL, et al. Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Am J Psychiatry 1997; 154:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/127\">",
"      Sturman MT, Morris MC, Mendes de Leon CF, et al. Physical activity, cognitive activity, and cognitive decline in a biracial community population. Arch Neurol 2005; 62:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/128\">",
"      Potter GG, Plassman BL, Helms MJ, et al. Occupational characteristics and cognitive performance among elderly male twins. Neurology 2006; 67:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/129\">",
"      Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/130\">",
"      Abbott RD, White LR, Ross GW, et al. Walking and dementia in physically capable elderly men. JAMA 2004; 292:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/131\">",
"      Weuve J, Kang JH, Manson JE, et al. Physical activity, including walking, and cognitive function in older women. JAMA 2004; 292:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/132\">",
"      Barnes LL, Mendes de Leon CF, Wilson RS, et al. Social resources and cognitive decline in a population of older African Americans and whites. Neurology 2004; 63:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/133\">",
"      Barnes DE, Yaffe K, Satariano WA, Tager IB. A longitudinal study of cardiorespiratory fitness and cognitive function in healthy older adults. J Am Geriatr Soc 2003; 51:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/134\">",
"      Rovio S, K&aring;reholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 2005; 4:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/135\">",
"      Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006; 144:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/136\">",
"      Verghese J, LeValley A, Derby C, et al. Leisure activities and the risk of amnestic mild cognitive impairment in the elderly. Neurology 2006; 66:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/137\">",
"      Bennett DA, Schneider JA, Tang Y, et al. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol 2006; 5:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/138\">",
"      Deary IJ, Whalley LJ, Batty GD, Starr JM. Physical fitness and lifetime cognitive change. Neurology 2006; 67:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/139\">",
"      Wilson RS, Scherr PA, Schneider JA, et al. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology 2007; 69:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/140\">",
"      Ravaglia G, Forti P, Lucicesare A, et al. Physical activity and dementia risk in the elderly: findings from a prospective Italian study. Neurology 2008; 70:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/141\">",
"      Burns JM, Cronk BB, Anderson HS, et al. Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology 2008; 71:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/142\">",
"      Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009; 302:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/143\">",
"      Akbaraly TN, Portet F, Fustinoni S, et al. Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology 2009; 73:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/144\">",
"      Vercambre MN, Grodstein F, Manson JE, et al. Physical activity and cognition in women with vascular conditions. Arch Intern Med 2011; 171:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/145\">",
"      Middleton LE, Manini TM, Simonsick EM, et al. Activity energy expenditure and incident cognitive impairment in older adults. Arch Intern Med 2011; 171:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/146\">",
"      Buchman AS, Boyle PA, Yu L, et al. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 2012; 78:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/147\">",
"      Wilson RS, Segawa E, Boyle PA, Bennett DA. Influence of late-life cognitive activity on cognitive health. Neurology 2012; 78:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/148\">",
"      Verdelho A, Madureira S, Ferro JM, et al. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke 2012; 43:3331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/149\">",
"      Liang KY, Mintun MA, Fagan AM, et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 2010; 68:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/150\">",
"      Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002; 8:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/151\">",
"      Stern Y, Gurland B, Tatemichi TK, et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994; 271:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/152\">",
"      Evans DA, Hebert LE, Beckett LA, et al. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol 1997; 54:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/153\">",
"      Prince M, Acosta D, Ferri CP, et al. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. Lancet 2012; 380:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/154\">",
"      Ngandu T, von Strauss E, Helkala EL, et al. Education and dementia: what lies behind the association? Neurology 2007; 69:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/155\">",
"      Fotenos AF, Mintun MA, Snyder AZ, et al. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol 2008; 65:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/156\">",
"      Yaffe K, Weston A, Graff-Radford NR, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011; 305:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/157\">",
"      Bennett DA, Wilson RS, Schneider JA, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003; 60:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/158\">",
"      Boyle PA, Wilson RS, Schneider JA, et al. Processing resources reduce the effect of Alzheimer pathology on other cognitive systems. Neurology 2008; 70:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/159\">",
"      Roe CM, Xiong C, Miller JP, Morris JC. Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 2007; 68:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/160\">",
"      Perneczky R, Drzezga A, Diehl-Schmid J, et al. Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose-positron emission tomography. J Neurol Neurosurg Psychiatry 2006; 77:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/161\">",
"      Garibotto V, Borroni B, Kalbe E, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 2008; 71:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/162\">",
"      Roe CM, Mintun MA, D'Angelo G, et al. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 2008; 65:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/163\">",
"      Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010; 67:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/164\">",
"      Perneczky R, Wagenpfeil S, Lunetta KL, et al. Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease. Neurology 2010; 75:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/165\">",
"      Hall CB, Lipton RB, Sliwinski M, et al. Cognitive activities delay onset of memory decline in persons who develop dementia. Neurology 2009; 73:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/166\">",
"      Wilson RS, Barnes LL, Aggarwal NT, et al. Cognitive activity and the cognitive morbidity of Alzheimer disease. Neurology 2010; 75:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/167\">",
"      Iacono D, Markesbery WR, Gross M, et al. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 2009; 73:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/168\">",
"      Iacono D, O'Brien R, Resnick SM, et al. Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol 2008; 67:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/169\">",
"      Wilson RS, Li Y, Aggarwal NT, et al. Education and the course of cognitive decline in Alzheimer disease. Neurology 2004; 63:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/170\">",
"      Hall CB, Derby C, LeValley A, et al. Education delays accelerated decline on a memory test in persons who develop dementia. Neurology 2007; 69:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/171\">",
"      Singh-Manoux A, Marmot MG, Glymour M, et al. Does cognitive reserve shape cognitive decline? Ann Neurol 2011; 70:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/172\">",
"      Plassman BL, Havlik RJ, Steffens DC, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000; 55:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/173\">",
"      Fleminger S, Oliver DL, Lovestone S, et al. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 2003; 74:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/174\">",
"      Fratiglioni L, Grut M, Forsell Y, et al. Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology 1991; 41:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/175\">",
"      Seliger SL, Siscovick DS, Stehman-Breen CO, et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol 2004; 15:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/176\">",
"      Buchman AS, Tanne D, Boyle PA, et al. Kidney function is associated with the rate of cognitive decline in the elderly. Neurology 2009; 73:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/177\">",
"      Helmer C, Stengel B, Metzger M, et al. Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. Neurology 2011; 77:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/178\">",
"      Luchsinger JA, Patel B, Tang MX, et al. Measures of adiposity and dementia risk in elderly persons. Arch Neurol 2007; 64:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/179\">",
"      Sturman MT, de Leon CF, Bienias JL, et al. Body mass index and cognitive decline in a biracial community population. Neurology 2008; 70:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/180\">",
"      Fitzpatrick AL, Kuller LH, Lopez OL, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/181\">",
"      Whitmer RA, Gunderson EP, Barrett-Connor E, et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005; 330:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/182\">",
"      Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/183\">",
"      Rosengren A, Skoog I, Gustafson D, Wilhelmsen L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 2005; 165:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/184\">",
"      Gustafson D, Rothenberg E, Blennow K, et al. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003; 163:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/185\">",
"      Whitmer RA, Gustafson DR, Barrett-Connor E, et al. Central obesity and increased risk of dementia more than three decades later. Neurology 2008; 71:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/186\">",
"      Gustafson DR, B&auml;ckman K, Waern M, et al. Adiposity indicators and dementia over 32 years in Sweden. Neurology 2009; 73:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/187\">",
"      Xu WL, Atti AR, Gatz M, et al. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011; 76:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/188\">",
"      Cournot M, Marqui&eacute; JC, Ansiau D, et al. Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology 2006; 67:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/189\">",
"      Stewart R, Masaki K, Xue QL, et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2005; 62:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/190\">",
"      Buchman AS, Wilson RS, Bienias JL, et al. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005; 65:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/191\">",
"      Nourhash&eacute;mi F, Deschamps V, Larrieu S, et al. Body mass index and incidence of dementia: the PAQUID study. Neurology 2003; 60:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/192\">",
"      Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol 2006; 63:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/193\">",
"      Knopman DS, Edland SD, Cha RH, et al. Incident dementia in women is preceded by weight loss by at least a decade. Neurology 2007; 69:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/194\">",
"      Hughes TF, Borenstein AR, Schofield E, et al. Association between late-life body mass index and dementia: The Kame Project. Neurology 2009; 72:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/195\">",
"      Vidoni ED, Townley RA, Honea RA, et al. Alzheimer disease biomarkers are associated with body mass index. Neurology 2011; 77:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/196\">",
"      Buchman AS, Schneider JA, Wilson RS, et al. Body mass index in older persons is associated with Alzheimer disease pathology. Neurology 2006; 67:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/197\">",
"      Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ. Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol 2008; 63:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/198\">",
"      Burns JM, Johnson DK, Watts A, et al. Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol 2010; 67:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/199\">",
"      Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/200\">",
"      Kalmijn S, Launer LJ, Lindemans J, et al. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999; 150:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/201\">",
"      Wright CB, Lee HS, Paik MC, et al. Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study. Neurology 2004; 63:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/202\">",
"      Garcia A, Zanibbi K. Homocysteine and cognitive function in elderly people. CMAJ 2004; 171:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/203\">",
"      Kado DM, Karlamangla AS, Huang MH, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 2005; 118:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/204\">",
"      Irizarry MC, Gurol ME, Raju S, et al. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 2005; 65:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/205\">",
"      Nurk E, Refsum H, Tell GS, et al. Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Ann Neurol 2005; 58:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/206\">",
"      Elkins JS, Johnston SC, Ziv E, et al. Methylenetetrahydrofolate reductase C677T polymorphism and cognitive function in older women. Am J Epidemiol 2007; 166:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/207\">",
"      Hooshmand B, Solomon A, K&aring;reholt I, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 2010; 75:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/208\">",
"      Ford AH, Flicker L, Alfonso H, et al. Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia. J Neurol Neurosurg Psychiatry 2012; 83:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/209\">",
"      Selhub J, Jacques PF, Bostom AG, et al. Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in the Framingham Study population. J Nutr 1996; 126:1258S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/210\">",
"      Hassan A, Hunt BJ, O'Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004; 127:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/211\">",
"      Kim JM, Stewart R, Kim SW, et al. Changes in folate, vitamin B12 and homocysteine associated with incident dementia. J Neurol Neurosurg Psychiatry 2008; 79:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/212\">",
"      Verghese J, Lipton RB, Hall CB, et al. Abnormality of gait as a predictor of non-Alzheimer's dementia. N Engl J Med 2002; 347:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/213\">",
"      Lin FR, Metter EJ, O'Brien RJ, et al. Hearing loss and incident dementia. Arch Neurol 2011; 68:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/214\">",
"      Gates GA, Anderson ML, McCurry SM, et al. Central auditory dysfunction as a harbinger of Alzheimer dementia. Arch Otolaryngol Head Neck Surg 2011; 137:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/215\">",
"      Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology 2012; 79:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/216\">",
"      Buell JS, Dawson-Hughes B, Scott TM, et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010; 74:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/217\">",
"      Annweiler C, Schott AM, Rolland Y, et al. Dietary intake of vitamin D and cognition in older women: a large population-based study. Neurology 2010; 75:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/218\">",
"      Annweiler C, Schott AM, Allali G, et al. Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study. Neurology 2010; 74:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/219\">",
"      Slinin Y, Paudel ML, Taylor BC, et al. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology 2010; 74:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/220\">",
"      Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 2010; 170:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/221\">",
"      Rafnsson SB, Deary IJ, Smith FB, et al. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc 2007; 55:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/222\">",
"      Schram MT, Euser SM, de Craen AJ, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007; 55:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/223\">",
"      Silverman JM, Schmeidler J, Beeri MS, et al. C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging. Neurology 2012; 79:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/224\">",
"      Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007; 68:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/225\">",
"      Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010; 304:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/226\">",
"      Ehlenbach WJ, Hough CL, Crane PK, et al. Association between acute care and critical illness hospitalization and cognitive function in older adults. JAMA 2010; 303:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/227\">",
"      Wilson RS, Hebert LE, Scherr PA, et al. Cognitive decline after hospitalization in a community population of older persons. Neurology 2012; 78:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/228\">",
"      Song X, Mitnitski A, Rockwood K. Nontraditional risk factors combine to predict Alzheimer disease and dementia. Neurology 2011; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/229\">",
"      Montlahuc C, Soumar&eacute; A, Dufouil C, et al. Self-rated health and risk of incident dementia: a community-based elderly cohort, the 3C study. Neurology 2011; 77:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/230\">",
"      Hayden KM, Norton MC, Darcey D, et al. Occupational exposure to pesticides increases the risk of incident AD: the Cache County study. Neurology 2010; 74:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/231\">",
"      Munoz DG. Is exposure to aluminum a risk factor for the development of Alzheimer disease?--No. Arch Neurol 1998; 55:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/232\">",
"      Forbes WF, Hill GB. Is exposure to aluminum a risk factor for the development of Alzheimer disease?--Yes. Arch Neurol 1998; 55:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/233\">",
"      Rondeau V, Jacqmin-Gadda H, Commenges D, et al. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol 2009; 169:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/234\">",
"      Sabbath EL, Glymour MM, Berr C, et al. Occupational solvent exposure and cognition: does the association vary by level of education? Neurology 2012; 78:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/235\">",
"      Daniell WE, Claypoole KH, Checkoway H, et al. Neuropsychological function in retired workers with previous long-term occupational exposure to solvents. Occup Environ Med 1999; 56:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/236\">",
"      Kukull WA, Larson EB, Bowen JD, et al. Solvent exposure as a risk factor for Alzheimer's disease: a case-control study. Am J Epidemiol 1995; 141:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/237\">",
"      Billioti de Gage S, B&eacute;gaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012; 345:e6231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/238\">",
"      Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 2003; 60:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/239\">",
"      Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/240\">",
"      Geerlings MI, den Heijer T, Koudstaal PJ, et al. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008; 70:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/241\">",
"      K&ouml;hler S, van Boxtel MP, van Os J, et al. Depressive symptoms and cognitive decline in community-dwelling older adults. J Am Geriatr Soc 2010; 58:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/242\">",
"      Saczynski JS, Beiser A, Seshadri S, et al. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology 2010; 75:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/243\">",
"      Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010; 75:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/244\">",
"      Wilson RS, Mendes De Leon CF, Bennett DA, et al. Depressive symptoms and cognitive decline in a community population of older persons. J Neurol Neurosurg Psychiatry 2004; 75:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/245\">",
"      Wilson RS, Hoganson GM, Rajan KB, et al. Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology 2010; 75:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/22/36202/abstract/246\">",
"      Shah RC, Buchman AS, Wilson RS, et al. Hemoglobin level in older persons and incident Alzheimer disease: prospective cohort analysis. Neurology 2011; 77:219.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5079 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36202=[""].join("\n");
var outline_f35_22_36202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25195276\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FAMILY HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MILD COGNITIVE IMPAIRMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ATHEROSCLEROSIS RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11254288\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LIFESTYLE AND ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Potential mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Role of education and cognitive reserve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Obesity and body mass index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H417059\">",
"      Homocysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H416938\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Estrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Gait and other functional impairments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H418326\">",
"      Vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Inflammatory markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Medical illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3034867\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24476058\">",
"      Hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25195276\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5079|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/38/29294\" title=\"figure 1\">",
"      Risk of dementia by ethnicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=related_link\">",
"      Estrogen and cognitive function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42153?source=related_link\">",
"      Genetic factors in the amyloid diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32089?source=related_link\">",
"      Genetics of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=related_link\">",
"      Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26138?source=related_link\">",
"      Mild cognitive impairment: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3834?source=related_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40328?source=related_link\">",
"      Overview of the chronic neurologic complications of alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10104?source=related_link\">",
"      Treatment and prevention of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_22_36203="ART recommendations for eligible HIV-infected women";
var content_f35_22_36203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiretroviral treatment options recommended for HIV-infected pregnant women who are eligible for treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maternal ART and infant ARV prophylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Mother",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Maternal antepartum daily ART, starting as soon as possible irrespective of gestational age, and continued during pregnancy, delivery and thereafter. Recommended regimens include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        AZT + 3TC + NVP or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        AZT + 3TC + EFV* or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        TDF + 3TC (or FTC) + NVP or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        TDF + 3TC (or FTC) + EFV*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Infant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daily NVP or twice-daily AZT from birth until 4 to 6 weeks of age (irrespective of the mode of infant feeding).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AZT: zidovudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; TDF: tenofovir; FTC: emtricitabine.",
"     <br>",
"      * Avoid use of EFV in the first trimester and use NVP instead.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: Recommendations for a public health approach (2010 version). World Health Organization, Geneva 2010. Copyright &copy; 2010 WHO. Available at:",
"     <a href=\"file://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf\">",
"      file://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36203=[""].join("\n");
var outline_f35_22_36203=null;
var title_f35_22_36204="Features of photoaged skin";
var content_f35_22_36204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of photoaged skin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dryness (roughness)",
"       </td>",
"       <td>",
"        Increased compaction of stratum corneum, increased thickness of granular cell layer, reduced epidermal thickness, reduced epidermal mucin content",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Actinic keratoses",
"       </td>",
"       <td>",
"        Nuclear atypia, loss of orderly, progressive keratinocyte maturation; irregular epidermal hyperplasia and/or hypoplasia; occasional dermal inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Irregular pigmentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Freckling",
"       </td>",
"       <td class=\"sublist_other\">",
"        Reduced or increased number of hypertrophic, strongly DOPA-positive melanocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lentigines",
"       </td>",
"       <td class=\"sublist_other\">",
"        Elongation of epidermal rete ridges; increases in number and melanization of melanocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Guttate hypomelanosis",
"       </td>",
"       <td class=\"sublist_other\">",
"        Reduced number of atypical melanocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diffuse irreversible hyperpigmentation (bronzing)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increased number of DOPA-positive melanocytes and increased melanin content per unit area and increased number of dermal melanophages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Wrinkling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fine surface lines",
"       </td>",
"       <td class=\"sublist_other\">",
"        None detected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Deep furrows",
"       </td>",
"       <td class=\"sublist_other\">",
"        Contraction of septae in the subcutaneous fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stellate pseudoscars",
"       </td>",
"       <td>",
"        Absence of epidermal pigmentation, altered fragmented dermal collagen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elastosis (fine nodularity and/or coarseness)",
"       </td>",
"       <td>",
"        Nodular aggregations of fibrous to amorphous material in the papillary dermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inelasticity",
"       </td>",
"       <td>",
"        Elastotic dermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telanglectasia",
"       </td>",
"       <td>",
"        Ectatic vessels often with atrophic walls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venous lakes",
"       </td>",
"       <td>",
"        Ectatic vessels often with atrophic walls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purpura (easy bruising)",
"       </td>",
"       <td>",
"        Extravasated erythrocytes and increased perivascular inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comedones (maladie de Favre et Racouchot)",
"       </td>",
"       <td>",
"        Ectasia of the pilosebaceous follicular orifice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sebaceous hyperplasia",
"       </td>",
"       <td>",
"        Concentric hyperplasia of sebaceous glands",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yaar M, Gilchrest BA. Aging of skin. In: Fitzpatrick's Dermatology in General Medicine, 7th ed. Wolff K, Goldsmith L, Katz S, et al (Eds), McGraw-Hill Medical 2008. Copyright &copy; 2008 The McGraw-Hill Companies, Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36204=[""].join("\n");
var outline_f35_22_36204=null;
var title_f35_22_36205="Precipitating factors DKA and HHS";
var content_f35_22_36205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predisposing or precipitating factors for diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            DKA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Inadequate insulin treatment or noncompliance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            New onset diabetes (20 to 25 percent)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Acute illness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infection (30 to 40 percent)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cerebral vascular accident",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acute pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Clozapine or olanzapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Terbutaline",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            HHS",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Inadequate insulin treatment or noncompliance (21 to 41 percent)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Acute illness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Infection (32 to 60 percent)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Urinary tract infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Sepsis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cerebral vascular accident",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acute pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acute pulmonary embolus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intestinal obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dialysis, peritoneal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mesenteric thrombosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Renal failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Heat stroke",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypothermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Subdural hematoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Severe burns",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Endocrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acromegaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thyrotoxicosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cushing's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drugs/therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Beta-Adrenergic blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Calcium-channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chlorpromazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chlorthalidone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cimetidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Clozepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diazoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ethacrynic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Immunosuppressive agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            L-asparaginase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Loxapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Olanzapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Propranolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Steroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thiazide diuretics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Total parenteral nutrition",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Previously undiagnosed diabetes",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes mellitus (Technical Review). Diabetes Care 2001; 24:131.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36205=[""].join("\n");
var outline_f35_22_36205=null;
var title_f35_22_36206="DDx Foot ankle pain athlete A";
var content_f35_22_36206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68769%7EPEDS%2F82706%7EPEDS%2F58865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68769%7EPEDS%2F82706%7EPEDS%2F58865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of foot and ankle pain in the young athlete",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location of pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Talar",
"pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCD talus, posteromedial",
"       </td>",
"       <td>",
"        Inversion with plantarflexion",
"       </td>",
"       <td>",
"        Postermedial talus in dorsiflexion",
"       </td>",
"       <td>",
"        AP view of ankle, maximal plantar flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCD talus, anterolateral",
"       </td>",
"       <td>",
"        Inversion with dorsiflexion",
"       </td>",
"       <td>",
"        Anterolateral talus in plantarflexion",
"       </td>",
"       <td>",
"        Mortise view in ankle dorsiflexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stress fracture, talus",
"       </td>",
"       <td>",
"        Chronic stress (running, dancing)",
"       </td>",
"       <td>",
"        Rearfoot pain with activity",
"       </td>",
"       <td>",
"        AP, lateral, and mortise views of ankle; may be better",
"seen with MRI or CT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Lateral",
"ankle pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ankle sprain (lateral ligaments)",
"       </td>",
"       <td>",
"        Inversion of ankle",
"       </td>",
"       <td>",
"        ATFL, PTFL, CFL",
"       </td>",
"       <td>",
"        AP, lateral, and mortise views of ankle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sinus tarsi syndrome",
"       </td>",
"       <td>",
"        Severe, recurrent ankle inversion sprain",
"       </td>",
"       <td>",
"        Lateral ankle (posterior and inferior to ATFL)",
"       </td>",
"       <td>",
"        Stress radiographs of the ankle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Peroneal tendon injuries",
"       </td>",
"       <td>",
"        Acute ankle sprain",
"       </td>",
"       <td rowspan=\"4\">",
"        Peroneal tendons (superior to lateral malleolus)",
"       </td>",
"       <td rowspan=\"4\">",
"        AP, lateral, and mortise views of the ankle (to exclude",
"bony injury); Consider MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic ankle instability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peroneal",
"subluxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Os peroneum",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Lateral plantar cuboid",
"       </td>",
"       <td rowspan=\"2\">",
"        AP, lateral, and mortise views of the ankle; AP,",
"oblique views of the foot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcaneocuboid articulartion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L4 radiculopathy",
"       </td>",
"       <td>",
"        Disc herniation",
"       </td>",
"       <td>",
"        Quadriceps",
"       </td>",
"       <td>",
"        Consider MRI spine (after EMG/NCS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OCD: osteochondritis dissecans; AP: anteroposterior; MRI: magnetic resonance imaging; CT: computed tomography; ATFL: anterior talofibular ligament; PTFL: posterior talofibular ligament; CFL: calcaneofibular ligament; EMG: electromyography; NCS: nerve conduction studies.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of foot and ankle pain in the young athlete (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location of pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Medial",
"ankle pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexor hallucis longus injuries",
"       </td>",
"       <td>",
"        Extreme plantar flexion",
"       </td>",
"       <td>",
"        FHL tendon (behind the medial malleolus); may radiate",
"to the medial arch",
"       </td>",
"       <td>",
"        AP, lateral, and mortise views of the ankle; lateral",
"ankle in full equinus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Flexor digitorum longus injuries",
"       </td>",
"       <td>",
"        Excessive pronation",
"       </td>",
"       <td rowspan=\"2\">",
"        Medial plantar surface of FDL tendon",
"       </td>",
"       <td rowspan=\"2\">",
"        Not necessary for diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased effort of plantar flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Os tibiale externum",
"       </td>",
"       <td>",
"        Direct pressure",
"       </td>",
"       <td rowspan=\"3\">",
"        Navicular tuberosity",
"       </td>",
"       <td rowspan=\"3\">",
"        AP, lateral, and oblique views of the foot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direct trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eversion ankle injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tibialis posterior tendon dysfunction",
"       </td>",
"       <td>",
"        Increased stress along TPT (eg, dancers, skaters,",
"running sports)",
"       </td>",
"       <td>",
"        Along TPT, usually distal to the medial malleolus",
"       </td>",
"       <td>",
"        AP, lateral foot; MRI depending upon stage of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        S1 radiculopathy",
"       </td>",
"       <td>",
"        Disc herniation",
"       </td>",
"       <td>",
"        Posterior leg and foot",
"       </td>",
"       <td>",
"        Consider MRI spine (after EMG/NCS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tarsal tunnel syndrome",
"       </td>",
"       <td>",
"        S/P fracture or dislocation of talus, calcaneus, or",
"medial malleolus",
"       </td>",
"       <td>",
"        Plantar foot; distal foot toes; heel",
"       </td>",
"       <td>",
"        Consider MRI ankle (after EMG/NCS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FHL: flexor hallucis longus; AP: anteroposterior; FDL: flexor digitorum longus; TPT: tibialis posterior tendon; MRI: magnetic resonance imaging; EMG: electomyography; NCS: nerve conduction studies.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of foot and ankle pain in the young athlete (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location of pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Anterior ankle pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Anterior tibialis injuries",
"       </td>",
"       <td>",
"        Direct pressure",
"       </td>",
"       <td rowspan=\"4\">",
"        Anterior tibialis tendon (anteromedial ankle)",
"       </td>",
"       <td rowspan=\"4\">",
"        Not necessary for diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Running on hard surface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overstriding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive pronation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        High ankle sprain",
"       </td>",
"       <td>",
"        Hyperplantar flexion",
"       </td>",
"       <td rowspan=\"2\">",
"        Distally between the tibia and fibula",
"       </td>",
"       <td rowspan=\"2\">",
"        Plain radiographs of the ankle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forced external rotation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Posterior ankle pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Achilles tendinitis",
"       </td>",
"       <td>",
"        Repetitive microtrauma",
"       </td>",
"       <td rowspan=\"3\">",
"        Achilles tendon",
"       </td>",
"       <td rowspan=\"3\">",
"        Lateral weight bearing heel (to exclude bony abnormalities) MRI; ultrasonography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improper footwear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Errors in training technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Achilles tendon rupture",
"       </td>",
"       <td>",
"        Sports activity",
"       </td>",
"       <td rowspan=\"2\">",
"        Calf",
"       </td>",
"       <td rowspan=\"2\">",
"        Ultrasonography in dorsiflexion and plantarflexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Os trigonum",
"       </td>",
"       <td>",
"        Hyperplantarflexion",
"       </td>",
"       <td>",
"        Posterolateral talus",
"       </td>",
"       <td>",
"        Lateral ankle; lateral ankle in plantar flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Heel pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Calcaneal apophysitis (Sever disease)",
"       </td>",
"       <td>",
"        Footwear",
"       </td>",
"       <td rowspan=\"2\">",
"        Calcaneal apophysis (posterior heel)",
"       </td>",
"       <td rowspan=\"2\">",
"        Not necessary for diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Plantar fasciitis",
"       </td>",
"       <td>",
"        Footwear",
"       </td>",
"       <td rowspan=\"4\">",
"        Medial calcaneal tubercle; arch",
"       </td>",
"       <td rowspan=\"4\">",
"        Not necessary for diagnosis; may be indicated to exclude other problems (lateral and axial views)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pes planus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pes cavus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Foot pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rigid flat foot",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Consider CT scan to look for tarsal coalition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexible flat foot",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Obtain radiographs if the feet are painful, have restricted motion, or surgery is being considered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tibialis posterior tendon dysfunction",
"       </td>",
"       <td>",
"        Increased stress along TPT (eg, dancers, skaters, running sports)",
"       </td>",
"       <td>",
"        Along TPT, usually distal to the medial malleolus",
"       </td>",
"       <td>",
"        AP, lateral foot; MRI depending upon stage of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High arched foot",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Weight-bearing radiographs of the foot and ankle; consider radiographs or MRI of the spine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance imaging; CT: computed tomography; TPT: tibialis posterior tendon; AP: anteroposterior.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36206=[""].join("\n");
var outline_f35_22_36206=null;
var title_f35_22_36207="Thoracic aorta dilation";
var content_f35_22_36207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mildly dilated thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 246px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD2AToDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD56+I95b3/AIyv7mzu0vIXEWJlXaGIiQHj2II/CuZrsvi/HLH8Q9VS4hggmAh3xwY2KfJTpiuNoEtgooooGFFFFABRRRQA5vWjtSYooAUdKSjNKuA3zdO9AEkadM5znipVKhg2SvoVFJ86xbRyD3+noe1Km3flgDjp2oIbNe3urlG3zXUsijsHOK39N8SNYSKbNJIh15lJH/1q5IMHPbP+cc1NGxBBOMHjA71NhWufR3grxO2Ube5u1QM2ZVZMV6XB4huTGkzNbvGVywXOVr4yj1CVMBXkwg+6T/WlTWLyEkQ3EwU9RvPNNMEj6q8T+OtNikRo2mE8YPK8qPWvKNa8T6zeTz3+nmOaN/lzIoK49h2NeVxancLMJVlO8Hq7Z4+netUar5yuiyvbHGcKSAxNKzEyrq0z3F60tzcpuwSyqp5rKkRXYAPhSeCB1qYsPtEnm7pJT/GP6021kVLmJpVd4VYM6nuPSmtAOo8L+AdV8S6Fe6rp5DQ2zmNlKnLYHJFcje2b287QzriRT1zXfXvjD7BpU1n4bLWlpOcyoOAW7n2rg7kyXUjySAbzyxbgn8KL3Ay2jA/E84NRkbWGQMVdaHPYKw6ioMEbQRls8YFMpMi5DcZOeDxj8KCmGxtJz05qcowORuwONo7GmtESpAX7vANAXIDyBg4HenkBBxtLYxxzS+VtY5257DrTwrBx+gx0NA20W9A0a613VILC0wZpASvfGKbrekXOkXj210v7xDg4Heu1+EFo0etvqEikQx/ucg4Ic8iqPxTeU+JJd6OjKeNwwfr/APXovqSm7nDY96KU889SaSg0Fx0opQCRx+VIFO3I6HigQnegdeealMRA6jPpUbAjrmgL3Hz/AHgOwHFatvc2awRh7SNmCgEl+pxWQ+MLg9uma04dOjeGNzcYLKDj0poTV0O8W6wNf8QXOp+W0ZnCZVjnBCKp/UGseiikUFFLQPpQAlFLxS9+g+lADaKflc/d4pD24xQAlX9D046rqUVosiRFz99ugqiR26n2qezkltrmOaIlZEO5SBmgTehs+IPDcuiTbJn8xD0dVrGAIHG5gOnNemaf4g07xIYtP122ZJHwFmV8c/lWpr3weu4dPN9o86XcRGdo649OtCM+bueQEYbHOe9OQKVB3jcDgrjPFWtRsJ7CZ4riFoZE4KsKqx54IwOfTk0XHuS58wkDar9AQMYHvU6MS5bLHA7VAO+c8/l+da0EFjJab5HlSfHc8H9KQrlBZXIJOQg6YOKjc4UkMB0wewpzDaxA5XOBUyRW7QndIEcdVNMexAHAXG1Fb8TzT2LjnzHJ/uirtjaLdRS7bqKORcYVlA3fjU7xQW9sfPtLgzjgvnAPv0pCuZigsByQPTOKlVvkK7AR2DN0oTy5ZF8/bGmRkjrt7n61KiI7bINrEHqx4FAMZax+YzfPEp7eYdorc8H2tjP4t0y11dkWwkl2zEEgAY4O7rWXLvx8ywhuxUcmokEbqCS7yvwFA60COu+KWhaDo2p7dB1Dz4+6BcjP+9XDSQKSJA68YJVRgirv2aXIicNGGOTIeQF+narF1o7w26yKkkluRxIAdrfjQgudP8PvCOj38Ik8Vy3dhBcfPaTIV2Mo65PrXbz/AAf8NXdq0WjeJ4JL6TLQo8q7CM9zjrXhbzTR7EErLGvAVmJA+g6UkdySWKA8cgYo1C3U9nX4D3AuFaXW9PFlGv76ZJFJQjrgdxUNx8I9P1CEr4S8T2mr3y4EluvylAerZ9q8f/tCchljeTBHPzkD+dPGoTQsr200kL44aNyhHtwaNQPVdd0VvBA8O6NJLC1wbsPK0ZyWPvXFfEoM3iK5LqQ7NyG7Vg2+ozzarp9zcPJdSLOpxI5JJBH417YLDQrO1fXPEtg2pxzv8sLP5XljHQEdfxoS7jPCo7ZgGZl3sRgY65PT8a1rbwX4hupUji0e8ywyCYiAR9a9WufHvgDTLSWbw/4YdNUK7EW5Ikh/HP8AMYrEi+OXicGOKKa3jUOMkpwV/uc5wO2ad10HqeanQtQ/tOLTpLSX7a7eUkQHzM3YV6bovwkgtbaC/wDGWsWumWjD97EjAzRHsGBrXb4yaHcsbm+8G2zagF+W4SYht3qDivHde1y41i+nuLiWVmkckb23bQegyfShvsDTZ7FefBuz1ezS78Aa7DqVquRL5zhduB0HqfauNi+FmvT6e9ysKgiQr5X8Rx3+lcTput3+myo9ldzQSKcho3I57cdK9Jb4063stntIba2njQLI45MuO5BpXYkmecavoWpafctDdWVxHIvVTGfz+lUAs4AHT2Ir2wfHSaTT3/tbSILvUWypuFwo29hgg1UX4oeEmUNN4SUykZc7xye/andFnitFFFBQpx2pKXHAOR9KSgAp1IBk8UUAK3XsfpQeaQ05V3H/AAFAjsvh9rdhpMrJqlqk9vMeWKglfzqz4u0m2mma90aNntHOcKPuiuKKZCckduP61saFq11YShIWUoeSsnINLzIZSAaJxgEOO27GK9S+HnxMutG22d9IZoCAqnrj2Oa5W4t9O1iJrmKRLaYffj9fpXN3MS2zlAwfaMhk6CluTudp8TL+PVdQN3HLEVOTtVMH8eK4lLZ5N0ixsy+qjpWnHq93cxR2ksoeNhgB1H8xS6dbCy1SE3UMskAOSqZ5HtQhsyFyBtKtzx8xroWs7RdPiZZf3hHzKZMg/wCFbevW/ha6RGsJp4JscrJGQM46ZIrmbizWLhSm0njn+lO9xFc2c00rR28ZOOxINQ3USqB5zfvB1Qj/AAq/YyXFuCI7oQL0KkZyPy60/UI4JyrpJK5PXeBzRsFyvZWNxKTPbqp2D+MdfoK6WXWLHUNL8q/fyrhBsCrnr+H0rP0m1LlEFpchGGC4zitObRba1V5InjCkZ+bn60BoZFvY6clnvuJC+Txt4IrKkEZmYWu8p/DuqxdqGdghyoPO0cD8Ks6HZRTXA+0FGQ/wYOcUAhmlW0cqzGWKSaUDg9AKhMJa52QW7xSEnq+M/j2rvNI8LRTtNLb3U0JUfdjUH+dc1LZ3MWseWlvLdyKeBtP50Bcy76D7MpDsA5BBVpdx59xXeaf8RNOsvhvY+Hn0xZLqEENMwBU89RzmodRtdMjgWK7ijM7jO1UywPvjOOfWuG1ezMNwvlReXG3TPXNG4LUzLmQSTSSkbA5JAVc4z7elVSdqnnqfT9a6LT/DOranFdvZW0lybbBmCD7gPrWVe2kkTGOaN45weh4/Snawyi6hvUd/qfamdUcEY245JomUrk9DnBzUR+XjIIPpQUkSRzOrB0fa6EFSOuc9a9m8c+KNDl8H6dYWc4muRADcAcrvxXi4Q+QZNy43Bdu4bunXHp71Hg0mrj5UyaSXdnPzComOWye9HSkPWmNKw/JcEs33RxTO3WiigBep7k0A8jI/+vQBS8s57sT+dACyMWPPGOgo8tvVf++x/jTWOceuOeabQNBRRRQAtFFGKAAUUUoGSegoAOTVu3yMAY4GMkVFCNuGVjk9RT48gMQDjHY4oIk76Cup7AtnJpVUEBgBjOME/wAqQAg4Uc4yB/ShTtIVlC47EZoJL1ldm2YuiRODwRIuQaJpPOdnRfL5zhR0quCmchlA9CK0dJSO71C2t7mRYo3YIXVeB70DKoDODu3HA3c12GheGHn0kX9vq9uk2MmKZuRXZt8F757NLvS9SiuhtDbQMEjrjrVWB59MQ6drmiRfLld6sd386T0Jv0OevdZYwRWV5Y2suzgyRty5/pWvpGkaTqskcTadc2e7GZGYstbGheEQLg3Nvf28CSHhXVX498g16foWnafbWojupLZ89ZI2B5+lNK+4tzyzxD8M5rO2FzZ3BnhK52huR+dcLNpLpKsZimDZxk9jmvsrRfD2hT2X7qNLhW5LHmqGrfC3w/fkv5TxPnO5COKrlXcrlZ876H4C1e7h3xXdvAjdTIcVleIfBOr2N2kTzxXMbsfmt23AfUCvaPFHh630nZa297vj6FXfDj8q4O91OXTi9s08QjY7V3Abh+NZuyYtThYfDd9b3aQpBNIzfxIdua6LT/h74qCmS3tZ1UjJ2ON3416F4b1iGwhjlmMV+cZ4AVh+NaNr8Tlsp2jewuZYWbAy4JFO8VuFjhfC2g60kVxFLd2tqMkSefkMv9Ks3fhcW0O+PUVnd2wJVCjB+or2qz0jStfT7feWsaNIoON/P41k+KNJ8PafF5kkhijXqqtnNU4qwcrPOLbwTDdWwe0nE9+v8WMDPuawNc8CvYzPf63fQxuB8qr82Pyq/qvxT0/RjNBoqbl/hbGAa8x8Q+NdR12cu7Hcw6KORWbfZD5bbm5oXi+98EDU/wCzp7eePUcbxKpymOMj1ridf1ybWrwz3EESHGMqTzUN3bSxWomnIO8/dOSaq2UbXVxBCibPNlWMsT0BOMmqQIoy7WJ24HPUHmqu7a+V4r0j4kfD+PwmIpItYtbxZeQqsCw+uK87eMEbgwz3FMqLIj1OOaByetIKKCwo6UUvXNAAf50lFJQAoo6GjtSnAPBzQAlJS0lAC0lFFABRS0DGRngUAKBk1MgKrjP9KaqrkEcqOpqb5dudxLnk+lBLY0YKk5yTk4p20c7gQAOnqfrTeBuxyB24pfm4HOOmM4zQSK+CNoTBPoaRM7QvBPUHFOY7GX5AO/XNOTqSCD1ySO1AhGk2uAWxjqAMj6ipoWAb+I8elQMV2rtbPPPrUkQLY3M3HbFIDrNJ8Zaxp8Cw2t7MiKMKhOQo9q9T8E+PtCa1VPFEEF3Ljl1XJH1rwQvkYPSpI3C5BJ59O9K1tUNo+nb3xX4HaPCQlEYYDqOB+tXfDGv+C7q6W3uW8ts4BJIVvxzXzFBM4XaCdvfvV6K9kiVQWGB6DkGj3l1Fofd2l3ejx26LYXdoEI4Cyr/jWm08Ij3NNGFx97cMV8RaPrdzHtSGQYY9/wDHtXSXmt+IIrMJ5oW3wB/rgf0zQ5N7lKS2PXfiFceFLq5Kz3UfmjndGxxmvMLfQTql7s02ztpY8/I9xMw/xrz+91OaWdzNOSmefLI4/Op7eZmjH2PVH848bWkZSPypXfUlneeL/BUujWQuhqsMMwTmKOXgfTpXnNnqk1hO4vFnuVPJbzMqf0qxqtlqhj82/wB15EVwD5rcfmK503Bt0EaLtTPKtzT3DR6I61/Gt95Wywnulj7Kzf4CoLnWGu4Ha51WYynjygxOT6c1zsLTzOIrYhWPPHH61oLoWteUZ47Vdo53GRCfwyaOULliHw1dX1qLiWJoUOSCRncPWufewvbWSVIAcL/Gpxx9aSW6vFfZNcXCopP3ZD/IGp7CWS5SVJbuUL6KucimBlGdkXYV5J6+v1qAyMJfMUANnI9/pVu6MJl2QISCcAscc1W3lFcSIpJwAwYfLQAy5upbjcZZ2kyf4mJP61DtUg9SNvUL39KXKM2Cqjnr2r0rwnp/guX4dzT63P5euCVggX7xHYYyOKeiC7PLWiYMdoLd8imZ5zV258sXMoidlXJC/TpVNl2kg9qC0+4maSiloKDPFJRR3oAO1KxLEkkk+9FJmgAJzSUtJQAtJTlBY4HU1I1tMgBaKQA9CVODQFyKpY0PUj6c0CPnBwPfNPVQoHTFBLYkfAGSMD2qxDCJriONXChzgNgnmoV5PJA98VZgdVXld6+mOlBDZpap4Y1Gwh854WMR53KpPFZGwqjZGRkcCvRfDGr3h0t4kzewAYMLfeWuYvAh1F1NsYUZ+Vl4A/H86SYanPH7p4GOwPOKlRiwwzDOP0rfufD80k4+wReaX5AjO4VXudCv7RgLy1nh7gupp76iuZDLxgDOP1/xp0nzJgljz1qWWFkA3Entk00QkDLJu59efpQMYCxOJF5PQnpUkIw2BgEjjJpSrNksOPfvTYsZOAF+vakx9S2oZVVgAB0/+tTvMwRjJHcDoKbbhSfnAbPIyO9TsiMucqPYDk0CuXkNoLQBGuPPPONvGfao557mSNY2MpA7MeoqKKLKFVD7s8GkO5gAilSOrFjkUWFsA83zEjZVXP8AEy8mo5reaI7yo4PBQ5rRhe02E3MjyOv8POKyrhclmjDRx5+6aAJhczhMmWRuwAY0ilnMgeBnYqMY6rUCRBydzYTruxV+2nntcx28iuCM/dyaBsqRO6XA2h4TkBl71euLu/dEhfUG2E42k4xVa9WZsySRlTnrjBxVUGSQqcFjnK98mi1wuOngliV8ElOdxH/16r3FndQxiUpIqkZyKkuPNdCJJXUjjB5p02oySIITtUYAznqKAMkZL8dPQnP4UrEbQQoHbrVuwkit2dprdZz0ALEYNNnlje4DRQIn+znI/WncGVmUqASUOc55zj8qT7zEZOSOtLJgM2AMHsDnFI2VwCODj/61AGhZaZLqPlQ6XFcXN3sZ5YlThQMYI5yR1qhc28sExiuInjl9G4wa6PwP4uufCGtNqdnbxTXBiMQVzwvuPyqj4l1251/UZLy9CCVzu+UcUDRglcdevpQfbpVkJ5iBQrbhzx0qB02qDkHJ49aCk7kdLSUUFBRRRQAUUUUAet/Cz4eXN5Nb6rqURFoGykfdj6kV7D4u8AWGuaKVtYxBIBwV6V3yaKiwRiyCIFGCpXqKsx20ttFjaWHdTVvsZcrerPi7xN4Yu9CuylzCdnZj39652QFl6jI7Yya+mPi7ob6hEXigLHnC45r561LTpLeVo5YmjI7OMEVncDGU5yDnOOMCrAZjGg6elI8bkAKFz7cYqVbWa5LFW3Hk4HamNjrOdrWUPbzNG3Ygcg10Wm6lcagVjvfLmjJwQwwfqDXLCMo7b1cYPJYfrUkb7CGTAI+6wJyKQtz1zSdEgtWjeJWWPPEkTncp+ma9i0TUdIOkJD4git7yDbgTeWCw+or5c0jxJqFpdoRcjaONp6VvSeMtQYmIbcvkYTjP5UrtbCseqeNPhv4W1SAXvhrVIoXkziBjncfTHavJ9f8AAes6aGaSxkkiU/fQZBFZ92dUgmF5JBPCeoYr1+hrufC3xW1SxC2+pIbyzJCsMHKj3pp/zBbseVXMMsJw0TIQeQw/SkitnlQsgUjsua+mnt/h940tstPHb3JGSudpB98ivLvHfgmx0HfLp2r2syD+AP8AMP0obQ02cDaI6SAEjBHQjNdXofhC+1Z2WwSUk8/d6mneCtT0W0KrrlkZ+ciRSScV7P4V+JHh7RiVtn3QMMJ+42un/Au9NNdRWbMLwr8JJCpfVYruKT+8v3fyrI8V/D86a07Q25nQc7gDxX0No3jzQNUjDw6gEbHKOcVpS61pFxmBbu3ldhjZ1zTbix8h8MX1s0U2ww+Xxx1quIfkOfnODgZxivp/xJ8JDrVy8tvcWkKuSQuDgZ//AF1z03wNv7RcxXEMx6EDjNJJku54VY6bLeXCrCjsB1Ga1JNEv7IkBJI1AyN3Ir3fw58GruKTN9cCAdQYuc13+kfDbSrCMi4H21ickzDii1twSb6HyjpnhfUdQbA095snocgfpWhrHhHxNpdlhtI8mADIIjBOPrX1zDoVlYDNrCsQH8KAYx+Nc544vXt9LYRmORCuNrAEiqaikVys+Kbq1ljYvKwyTna/UVWW3nnZmijdgTjODxXsWpjTdQkdbqC3jcZOQB/hXNarpkiRSHT2kAHQRNsWouhXPPrrTrmBt00LKMZHPWqzuxYKQB9AM1tXtzcqrJ5SkZ5cnJP4is+C0a4cuzKnPJLU0wM9WKnPIxSB1Zto3BSeq1NexRxfLE5ds85HB+lV+VUlx7YAxQWtR2eMgkj9DUkaAsBIBg8Z6Y7DPtUAfLnOCvtSxAkZCs3PUc0A0eofED4dWHhjSLW7stct7kzIHMbOpYcegHSvL5iCuAV69qnkmklUI7u3ZRuJxVeXIUAgZHXAo16gkiGiiigsKKKKACiiigD9HUUN93HNPaFky2c44xWXZX5QASg4/vdiK2Y5VnUtHjd7GtLkaGfPbW12hiniRgeMEV5x48+HdpeQvJb2izIQc7R8y/SvUHVd2JVHpx2+lOWJ/wDlmwZOeDwQaGrg1ofEvi7wg2ns72srGPJyrjDLXJbHhcjccY5ZDX2N8QfBcGqrJNDAqyEEtgdT6182+MvCE+lTsUjlKdzt4FZtPqTtucVJI0xBzlhx/k0pij8pduBITnDHNNFr5MrB92GHOeoPvT/K+XOenUntQw3IUgleTciOR6qpP8quWlxLZTCaM4kU5+Zc/oavaNqt3pEqT2f3R95X+ZH5/QV2t74z0DVrApqGg28d0RjzIV7+tLYC/wCG/itFDarZa9pkN7BgLkADH6GtK5n+HOqobiKWawmxkxAkZPscV41MYjcMYkxHuyi56j1qV/szIChlD91IB/WjVdQsjd8Qvo0czto09yWB6Fjj+QrnpLieSTczli3Ukk5qPBC4QkE9s9acsjRqEXAxxjNFurAsCYodseADWhp8srOEjSWZQctt5/Cs2N+G3HLdelW7K+mtGzC22TpSBrsdba6hdWkLtDY3Kg8fMCRj8q09O8Wy2somMGJIz2bH6E5riP7QvGjdzcSHBzjfgVVSQswMrEt97JbJJ/wpWA920X4uSi6i85pSo7cYIr1PRviloF9ApZ7iF+Ad8eBnvzmvkTS9X+x3YlNtbTezjpXd3PxBtrrTlt/sHkSKAMxKKLtDTPp618c6LcSLHHO+4nAynB/GugEouE+TO09wa+TfAHiqHRNT8y9heaNzuBkOMfhX0X4e8babqiIsBAJA4BH8vSnFr5lKVzV1WxnuIHiglZNwxvfmuG1bwNfPav8A8TWV8g/JkYP5ivUkYOoYdDVPUbEXibWbA9AKpSTeqBxPl3WfhpcwNJdLqEe7JxHknPtVjRdCtDaNHqc0/wAp+6FwPz/+tXqWreG743zA2jvb7shoyMEe+Tn/APXReeHdIa0MdwFiIHTcc07Gdrnzv4otfC/29hbzTRhTho0BIP4gVx19KAGg063XyAd29s7j+eP5V7B4y0a00qeSW0tJJsZ42fKfxryXxFcXM8gmFkbePbgkKSPzqARzc58tiuxQD69vxqs2CuMg+o/wqedkZlATbt6nOSaikZQPlJAxxnBIqikRSfKSM5yPSlSV0XbGSM9cHrTQN5yc9ewpvQcgg9RQWTRkOcYGe/8ASurePRJvhnHHAF/4SRdSDS7jgm32OOM8ddnHWuOBwOnPrUiPhSV6j1NGorDCjAkcZHoc03FbnhzQ9Q8RalDp+lRebdygsEUgHaOtVNZ0q80a7ltNQt5IZ0fBDe1O2lwUtbGdigc0rde+PekHNIoCMUlPdSrFTjIODTKAPvfR7uC7g+z3D7pQMZzRCt5o13tihMtm5zkEnbXjs2vXtkUW4UvLEflmiOMivQPBPxBs9UiFve5WTgENxSUkZpnpkNzDdR/OOSOhFFtIkcvlnvyB0zVKIQyoDA6Op5GD0qKaOQMMMRz64rS+gzfeJHjPr6Ada82+IPhuW78x7GMMccoRnPv9K9E065jmh+8M98np2q1IiyD94owPXrihg1c+KvE3gjVhcPMmmTeVnJ2jIq14K0iGx0nxHqosorvUNOt42gguUDrHuZg0pU/e24H519Zz6BbvM8iMw39VNcN4l8BmK6/tLRXazvY1I82JypweqnHUdMips7aEtNHk/hq8kNyus6h4fS2RtOlZ76ygU8iRVW6WHpkbihx1zntXL/FSEyro+ph7C6gvoHCX1pA0L3WxgCZYyBtYbh0616lqvhjWL3RdP1eyup7fxHYTNb3FzHMcywtypA7KCCNvTmuN8TeBPFOrXaXurXhvdqhRIGJMa+gHYewpWbFojznwvoyalPslDSL6oPmHtXfTfC+zlsjPbXzW8/3hFPhR9BXSeAfDOn2135d1dSW9wDkuPkH4g/zr2ZdJtbnTNlxDBeoV+6hy3SmrCSbPinWdIm0mdornYXzwyHqKzHBJ3ZCkHqD1r2b4v+E7KwlaSxtLqAcnbKOAfrXjrxlUOcZzwGHWpsUmNjl9eCPQVMkoGN+5gBkjNMYlW44bHIHFMBJHTnHUdaLBuWGuFKjYh5525qJnZmZ9mFHQdM0wqSpZg2M9PX2pjAFQFOOcAdj70AizC5XnIAzye9advHbuM/2jGD3UxkVhhiGIkwSOpByKc77JQpwV74NAbnTRxowUJqULnPAOQT+ddt4H1e70jUY2dlFuWAbecY/GvKYpjjlmK9ua3NISW7mjjjSRhnBKnmpA+5fDerW2pWMUkM6ynaCdpzitrI614L4D1DUdHsYI0Q+Xxktjge9eo2+v2z2264uoEAHOX2/hVNJ6suMrmrrVxbpayedOqLjB5zn2rzm/8XW2nyMgtf8ARs/K68Z/OpdcvtP1SZktNQsEk7uZAx/xrlNU8LadcwN/aOqi7JO7gcClzdEyW/I5T4h+O7S/DwaXbmW4wfu/w/hXiOsXt7csyTPtAP3QNo/Gu28caZpGl3A8mczt/cVsV51dSJJNiONUB4wSTRHURU3bDuxk46Y6VG6g4yQnGcU456DPr1xUedhVgQSO1UWkNUkHg496OPfNBBBGcgHnmpopfKIwSff+79KBsiI2jlSCfWkA+lK7s5yxJNNoA3vBviW88Ka5b6tp2w3UGQocZBB65qfxj4r1HxTqL32q7TNJzlR2z/8AWrnM/IRx1pB+PtRbW4WFJ3EkDrTa9V8Y+DvCmm+DNMvtN1vzNTmgV5IM7gWIyfpzXlWOeKSaewou4GkooplHRWut3txcpvvZ1BOAS5wK9B0CLW0nimMaXtvnPmBvmAryGF2SQbT14I9a7nw5rc+ixBrS93RkAlD0H61L0M3E+jPDdwxAxcywSjB2N/nFdrZ6i5VY7qSHB4BzmvEfDHjS3vsQ3jRHcBg7u/pXS3V3LaqJIzDLB124Y4/KhS7CWh6/YRiKTeTuQ916VuRyBwAevrjrXmPg7xrZXUQhaRFZeAD2/Ou/sbzz+UwVI4I6VakpFI0+uKzr2/tLcHc+1jn5Txn8DWgCep49qSa2gugPPhSQAcblzijbcpq5xyapp9rdNJc20tvHJ8rSSD5GA9s4qG+sljvDBFq8cLNiRFKDJVuR+ddRqWhWN7bNDPAoVhjj/CuN1DwPNFP9pguTcbQFVZWOQo6DPpRvsSynq/g6S8kWa7kt7hRyX8rBxWh4f0u00tybSV3UA5VGxj8Kiju54k+yzmSCX7o3cqfxqa18K3ruLmIojEYzHJjP6UybGtrWkaZ4j0mSC8JdR134BBr5Q+IfhWTRNVmRIdsAchHBBDCvq9/D13cQ7Lm4i39PnUt+oIrifGXwvvNTty0EttIy87VVgT+ZpNOQM+T5U2udm0uCCc8ioFAZucgdeBXo3iXwBqmkO6XFq8Y6g9c/lXHXVhPajEkUgY/xFeP0pNNCuZIXJACt8vc/zpsq4ByykdQfWtQafcOnmJG7kjOM4zVJ0aIkSQjIP8Y5+lAymQwRjkY6HNNXa3AHz9BjvUrjcWK7I1PUDpTY49rElhknPFIdxoAGAcsR0PTNXrW7lt5FMbMlwDwwquEDN82QD6HvTQpV/m3HHQ+n1pgdlbeLb+CFhM6SsflILMNv5Gug0vxQtxbuJBHCfVpGP44JNebZYcmIfN1z1NaFjf20CDNqjOvQtnn/ABqOVbiO1ggE96JrSaOSQncdkCsv8hWzeXsFlAft17K/rAkPl/1rh9L8WaqsqxWJiRM5+6vH6Va1m/1WRfMutSsm3clVXLY/KkKxg+J7+2uLndaWZiA/ifnP5Yrm3KqT8m4EdSelbL2F1qDSSws8igZG8bc/QVl3MDQFg4PHBHTmrQyi+eMkdBj3pmCwbpx/dHerJUKuCm49gx4GaaI23KqKd55wDTGmJGsTwHKsz+oGAKrtxuQDv171fdWgh2vJHGT1QZLA/wAqoHOchiWPXFA0N4A7mkpzDHHcdeaaaCxc8UmeKO1L2FACoT25Hp60gznKjGOeKFIBznpXoPw78T+HdE0XVrbXtHTULi4cNAzcbBjHWi6W4ndbHn+MqT0plW9Qlhnu5ZLaLyoicqnXFdfZeFvDs9lbzS67dRySRq7ILQnaSMkZ70xOSW5yl1YzW8atuV4j3U1WSeRTlW/+vTobqaD/AFUjKMYIzwfwqYy2ssLGVJFm6grjFSFu50+giZIg0ltNGT8yt5R2n8a2h4s1WwCxwvJtz8yn5lP4VheC/El1o1yvkSRzQE5a3nAx+B7V60zeFvFUCSSslnckclD8v+c0rIjVB8Or+31O5WSWDyJ1PLp0J9/evfNEMZLxW96VnjAMgxnAPTNfPXhoTaJqDwWri9sSSNyRbWH+NeuaDqrIgkiYsgAyANpGPUHmnF2BHpH21oY1NyhYY5Zeahk1+zjBLyBRnGTxXLS+KRAgL27zDp+76ivO/HPjyJHRYrOcRZ53KRj396JNdC7nuttqtrdrmG4hc+iuM/zqzHKHbgfiD1r5csfE7yMJNOkVZQfvBttdPZ+N/EtlGGKrOmOruCKSl5C5tdT3DUNFsdSINzCS2eoOKs2Onx2Mfl24IXsCx4rzHw78T3uSsd7bqHxyYx/Su2stfivXXyJkORyvc1SbY1Y6bAIwRSbVAxiq8F0jgc5zU4dR04H0qGmitDH8SaBaa1amK6j3ehHBFeQeKvh+FjaKz1CSNcnCyJkD9K9561DPbRTrtkQMp7VSktmS4JnyRceB1sVLX0xmxwDbsSfyrlNW06ztUkVEuWfPWVDx+NfY9x4P0SdZTJYod/J9a8/8b/C3SH0yee0u5Ld05VWwR696dk9UzNxaPkOSNfNcEBB7jrUgtpg6uqryOAGGCPXrXW69p62M8sLCJyD1wOaybbS5LqUrBAys3Ay2KS1AxpgTkHJPdQvANTRQiTH31dOTgbs13Vn8OtVntzJtRSBkA/PkfhWjZ+Atxjjmn2SdMNEwH507MVzz+K2ExDySbVHGeCw/Cql7bok+AyyA/dxxg17xovwevruRcoyqRkTP/qyP51o6l8DrxLeV4ZtP3AZJZjinysEz5tk3BeU2Z67ePxq9Y6a8si+eXKt3DAk/nXZy+GV0nUfI1C2G9SdrRybwfoKluvDTXwRoLK5AJwflKn9akLnD3t1KhWGBpEWMYKseg/Cs+UR8u2WOMkMf1rvJvAWrBCwtJY4v77zK2B9M1PonhYecIMRSXJ+Xdg4p7DuecPZMY/MwgTruz/OmWlrc3E4jtc4Y43Dp+de13eg2mixETW4aYLkk8/jivLb3UUttWLxyReWGyUQDaeaVwQW3hXULlgPK3DP3i4xit3UPDOk6VpKvcXEct0AcEA9ff1qaXxnBDYItkrCRsbgYiBj61xup6hLqE0pG5VzlRIcmldhZ9TLv0jNw3kvvHYAVXeNlUFlYZ9uKkcGHIVmVu46VCzFupJ/GqNEJ7mij86MUFB2xSsckk9aAPzpBQBqeHNIuNe1qy0qyI8+7kEa56Z969Mb4a+PbRjbxS2/lwny1w64wOB2ryewvbiwu4rqzlaG4ibckinBU+1asni/xBJIztq11uYkn56Tv0FbUogWt0mS4t5sc8Hax/pVBhgnnNFFMErFvT7ee4kCQQtL7L1rp9M0C9mlKQLdW7FR/rOBmuVs7uazmEttI0cg7qa7jwz4v1q4mWCOGC6f/AKacE/kRSZEkztfCWm+KNNdMCCVV9SDkf416XFqcn2fGp6e9pc4wJ4MH88Vyuh3esxIWvNMlh+XIMADj9TWu3jcWEeL62k8nHOF+YfUUtiUWPtMlwzLdyR3CH7sjgg/jXN3x8RaNfm50jyZLeQqsgVA+V3DqDn1NQa94x0PVrd4rCdlnI5DcDNcPZa3rOkahGIB9ogeVcRxtuZ/mHy4yeTSTuDPUtQ117r4w2/h6WGzFhDdLIMQqDxblvmIGSMkkiuM124+zeH59Z8O6/e3UEN8bS4iuY/LCs+9g0fqvyEYPtRd+M7ceN7nWbyzexvo2mX7LcHDR7ojHgnHbOa5KPxDBp/haTRHgS836il956ycFVR124x1y+evY02+bcZe0zWnadHn1MwS56oDxXZWXj7UtORw14mpw4Axkgge9ec3+o+H7iBStvIkmOUC7cfiKwJJInldrWOUITgJnJH1pWA+j9C8aWl06OZI4XP8ACJCK9P0PxIHij3RylTxlTuP8/wDOK+NLE6jYSJLHFIM8nAyDXqHgfxUYZ411DSi27GJAZFx+tNXQXPp9dQtmVXaS5XsOoFW4NQt5R+5nEjfqa5jw/Na31okkabQecF2OB+JrZW1h8wrGACTkYQDNa2uWmaE2opCCZEYKOS3pXNa34r0Z4THKzyKTg7VzVzUrYtEyJePB16Ngj3rgdV8PfvS8N9dNc5yG4ZT+GKhxtsDZr2/hLQdfUSqC6dcPGB/Spn+F+nLIGtphAAenlKx/lWPolv4whQiBoZlB4BXaa6Sw/wCEnlYLeCWEdMhFIq7t6WJsnubGkeH49LiwJVcAcERBT+lP+2zvdG3WwnYA/fbgVPaW2pwsDJeLKv8AdaMZFacLF1+ZWHqDSbZSQy3jKjLKBketSyxKw5GR6U5tg+vakZlKnJx+NRdt3KsrHC618OdL1O++1AmJ85+U96y774fBFC2l3qDvnotw0aj9cV6D9usln8n7Qhm/u81NMW8r5ZViH94gH+dVdPdEOKPMbb4XkDdrOtXMkP8AzyeUn8MnrT/ETaJ4a0wpp9ik8oGMge3ciu4GnW91n7TdG7JPA3cZ+gqOTRLaMHyoUdscBhnn+lPpZaC5ex8t6w1z4guGDyvZwknA2nn8TXGeJvDemWZONShlnIzgnv8ASvpLx9ol68DvNPCkQ4EcK7SfzJryDS/Clm+vLdXBubo7v9Xt/wDrVFrOxOx5haaFrl7D5lrbM0Q4zjANMfS0sQw1SfZID8yRjJz746V9S6nNpllpW65CQRon3D1NfPnjvxKkl3JHpVlHFCclpGUEt9M5ob1shq5wuoSQyznyFbHQFutV5YXiALjAPTmgzPknIyetMZixySSaZokB5pB0PrS9DyKQAnOO1AxVJDZGMjpSUDiigBc8880h5PPWjPNGfp+VADkUucDrjNSuqArjhv4lPT86gp5lYrgmgTTGHGeAR9a67wroiahCJIb5I5icbW9e3cf5FZGiz2BmSHUIysZODIvOPwr2jwt8M9E16x83Tb4+YQCNr4/OgiT6DdH1vxL4YiWO5ia/tAPvLgkfSunk8V6Br9kwnRUuAOjLtOayf+EU8WeG5mW4Mt9p3bo+B9Bz0pLmC1aI7ZPKn7RvFtBP4jNTtoSeTeMDC+pSi1gIhDfKQOPw4rpPgrpU1zr99qsSxs+lWrzwiWRY0Nw2ViBZuB/EefQVjeI2eO4Zb7TG4bG6NyFP6Vmf25cw6BdaHDtTTrm4W5lyvzsyjCgt/dHPHvTTsPc7v4y6ReNquhalcxRPe6vaxx3BWVZM3SYjb5lJHIKH/gVNn8DeHZNRu/DlpqN6PE1tC7PKyL9mlkSPzGjA+8OM4bue1cTH4qvl8LxaLsiMNre/bbeYj97E+ACAfThTj1FdbJ48triTUNesfDcieJp7YxXWoJMWgh3r5bShMfKxBxycZNLoO19zzy6s5rcb+GjHBIzVaKRlfMcjg/XHFRo0ryBUZy7HhQSd2fb1pJEMbmORWV1OGUjkH6Hv7VXqJo1tN1PUIZ1WC4dT2ywx+te4/D6fxHPbRM+mw3UGM8Sx5x9C1eDWl0yOrPDCwB5Drk/zr3T4Y6poJWMXOjzqzYBZAxX9DxSEz0q2822xJcabd2q8N8rKR+jV0+keJdDkQK915bg4xI+P61khvB0iIZ40iPbzC49qoa1Z6JPEq6RNZb92cF6q9titT0FINNv1WSMicdjncDToXWKfybaAJjuy4/WvP9FvTp0PlMisw/55S/0rqNPe/wBYjJMzRQdsH5j+NUncdzr03lRux/wGglgCV61z/wDZdzFHldTv+OcJIB/MVxnjDVtU0tJBBea0eOqmJgP1FQ9NWF7I6rxBrep2cxWzt2b/AIDkf41yHiPxbr8drudLW2wOSt1tb8QVrw3X/E+v3V7LJFcX8ygYbedhH/fJNcLqOq3c7ss9xKWPZ5ST+tRdvYXMz3iD4mauLkwW7iSUtgDfvH5iui03xj4jRWuNZt4jDnhFYDI/Fq+XrS/eCdXt5miwR84fb/OvQrXW/OtYIr+7luA2DuQ7v5dKeqFdn0f4Z8Y2msP5aW4tpCOr4J/MV0E2mtcyeYb2XB524GPyr5i0o38d2G0XULuJTyQxwP1FexeGdWNvaRyeJb6ZwQMNMwwD9Vq1K+4Jno8TwWURVVDED+ECsy81y4AYQ2cpB4zinaZ4j0i+TFhLHcKMcpyB7Zqvr+vw2NuzMqjH8Lnbk021uUcX4t1PURC0t1YwtHyQS4BryHWfiLdK7W9lblAMjKkYB9j0qT4i/Ee/1HULjT7CGHycEDdg/lXl8WkX107CS4VFOS0SsMj8Kzvclk+s+KdVvGkjlLMXPI3BsfiK5tbK7u5dqKzk/hzXZaL4da3Zpgu4hesqlefbNZuv6silkt5PLYHawiGM0Ky2Gn2ObutPktMC6ZI3xnZnJqm2AeDkVJcyLJKWXcc9S3Wo85Xnt04qi0DEtyxJ7ZNNpc5ooGJS0lFACjryM0lLSUAFLSU4ISu4KcetAEtrF50m3ci/75ABr1L4aeKb3w7cKklqr2wPLxEZH4968oUZIA6muj0jTtXC+ZC00cf94cihkSPtXwj4jstZsQ8Fwr54KlcEH05ra1PRdO1q1MF7bRup7lRn6ivkLT9S13TYY3N4I1/56xgh1/Kvefhr44jvLZYZb03bKPvtw2fempX0Yk11MPxX8FnnkeXQr0quSDDOOCR1A9q8S8Y+CdY0MhrqxeIE435JBr7XjvVmjzGwdSMccmue8UaMur2zRuoKtxhkBoaVtAtrofD9vps8jzWzAxssMshLdP3cbSED6hCPxrCr6h8afDR5rSVIJBA7KVDxQ5IyCMcdsHH514frvgO/0nJeQSgHHyoQfypX7ji7bnHVcsJIoxJ50HnIcZ+Yrt981LNpc8XBSbd7x8fzqH7NJHkOjjpgFcZoG2rHSaFFZz3SOtvCFRslZbgcn0wa9i0LW7TTYcmzktVQAhobpHUj6A14DYLIshZ7VpBnnPSvSvBt34ZuQI9ThjgnxjmEYxUu5mz1FfHcN4BC0kNxC/GGjOT+OKlaz0SYfazeSWT+pwAPzrKDx6WUl068aa2ABCo4/QV0VhfWGtwLuvFjPQxz00ISz8VR2DrBbOmoZO0DYOn1FejaHqMV1aKwVLWUjJBkFcTHpWm2UTSsGlK94VDYrC1Dx1ounT+T5Uwm/uNGd3H+zTvYpaHrE/8Aa5z5E8EiE56gVy3jTTFuLMve6e8zMOdrjIP51y1j8TracIlvdpHn+FoNpFM1zxVc3lq4s9TYP0xE2P0zQ5KwXR4t4rv5NMvpBaLPbjcQTKARXK3WozXAJnuI23nnaorufEeiXGoh7jUtSk8o872YEVxd/pmk20ReLUo7hl6gMN1Sg0Y201k6fIpsoIHJGMyANu+oNXJdd1PUNkUUMEBHINvGEx+Nc46xRpvt5gSDyHHP4UQX80BAikMWfvMvOadh27HZrd+JYEQy3MhQjj94K6jRx4gvgqQaqm4AZ3EnHtXnSahbyxgXuo3ki4/1ZZjn9adp17Itwf7NZ0TO3Ltkj1pWFY+j9GguNNtk/tvX2h44UAAH8a5L4j3cV5amLS9RnvWP3dhz+Bx0rnfDOgaZqA8zXNZcsTu8qMtlfbJrodUbw1pNgDb2d7Oo6sFB/OkxXPKVspUn3X7SCRTzGPv1tQa7FpETC30KZZSPlmuCcZ/GtF9c0y5jkcWHkp2aTIxXnut37T3zeTO7xnoGwFH4f1p+Q9zR13xJql/F/pV6sY6eVbrtDfiK5ZiWbJJJPc1Mk/lnOxWcHvyKZJM0nXaB6KoH8qpItIjoHJoooKDGOtJS0lAC0HGTjOPekooAKKKKAFAzT45HjztYgHqPWmAkHIODS5JPrQA5n3H7qr9K19G8Q3umyII5C8XdHIwfxxWMfTFLGVDAuMr3FAmkegp4utJoVW7sGV2PyyRXA6+4xVnSLTW/tBudKikMTNuxnO72964C1lhWUAQFs9/vY/CvXfhlqbxTRpLJLER0Ep2qfpmpaM2rHrPw01vWQBHq9kYY93HBII/E17BAYpoVKhSGHTvXE6FqcRjUOY2PrjOfxxXQjUoF4bK9844rSNkho1J7QOpEL+Wx74yB9RWRdeHIbkN51vZyZ6/uhzVh9RieM+VMrN6FsUtibmQZdwMnIAbdn8aYzz/xJ4CmiVpNJ228g5VQoKfiK4XVtD1TyY49USyDL0mMeAT+VfRE00kXlq0LShjhimMIPU57fTNYHiWC2nt33rEWAzhxUuPYXKfNt/o7W8jL5GlXCN6XOz/2Wq2l2gtpW/4p2CdT0C3Ak/IleldF4whtlmcXGnhUY48y3G7j9MU7wvpU7R+Zp+pl2HASSILtHpwahEl7TtPhviiweE4UlQfMweMY/wDHRTrvwx4kilMljpl7CnXCSo2PzFb66Tr6FSqWYXjLFgh/nWlZ2usMu17wxuR90TIwqrPqI8Z8Ran4m0Yumpi+tY+xKIR+lc9q99Z6japKju18RtDxSMWBx3Ga9v8AF2garNAWW0s7s+rk5/wryPVPBWvW08k1lp1tauxJDLIePYAily2Hexwvk6upzF9vfng4Y/1qK8e7t4yJhLE7HktGVJ/Gu2jsvHkMDbbOUqvTEedw9RXG6/ba/Gw/tiK9UHkCUHHP1osNbmVNcvKoy7nHqf6VAoyeoHfmk6cGk4pmlhy7Q/J49QM06QqAdjMQeuRioz14p6HDD5N/+yc8/lQAsULynCDJq1Yzm1ly0CSnsD0/GiEFF2sBG2cAlsH8KmNxDbRsFQNKe7c0E3udjpPiPWIoPKiuLTTYW6MoOAPXGaxNTu47q8U6jq7XK5+Z4lxx9MVzLCWUlyrN3zilijZwSu3HqTilYFE2dQvrGEFdPeeYg53TD+grDkcu5Y4BPpRIu1yMg+4oVyucYIIwcjtTKStsIqlugJpDx1q3JekptjjWId9tVGJJyTk0ArgKSiigYUtJSgbiAOpoASilxQOCCRn2oASiirp0y9Bx9negV7FKiiigZPBO0ZxgMndWHBps7rJITGiovoKKKBdS5Y6bPPB9oidFUE9SQePwr1n4d+Io9PjS11SwhvEX+I8n9aKKUtiZrQ+gfDVzp17aqbW0a3Xso6Cti60y2njO+PJHqaKKqGsbsmJkW+nWv2rCIybTjIYn9K6m0hSKJSmQSKKKqKGTXF81pA0si+Yo7Z5rmNZ1myv7OVJraVQRncpGQfaiipk9QZ4r8SfBsAsp7i2vrstHlv3jY4H0rx/RdcvdMv1+zzybRzyxooqQPaPCviibW1Ed6hJ2jGGwK6eO200r5oiukcY5WXvniiipvqStwv8Ax0+hRkBJZ41HAfBrmNR+KX9oRmN4ZkVl3ZCL0/OiiocmJsx4/HyodkUl9hgB8yr/APFVw3jbxrqWpI9vI8TRBsDMWG/PNFFVF33CLuzgHYuxZup602iitDcKWiigAyc5zzTwzFNueOtFFAFy0tJ7pQiygIozgk1uW/hRXtBO9yeRnAHaiik2ZybWxi6zZLZTqqH5SKzaKKaLjsFKRjFFFMY4ISAeOTim/WiigCzdWskRVnKfvE80BfQ1X2niiikIVkI25xyM0m05IoooAu6I1pFqtrLqcLz2KOGmiRsM6A8gGvbf+E7+Gh5Hg69x7uv/AMVRRWdSTRlU3P/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis precordial view shows slight dilation of the thoracic aorta (Th Ao).",
"    <div class=\"footnotes\">",
"     CS: coronary sinus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_22_36207=[""].join("\n");
var outline_f35_22_36207=null;
